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Abstract
Antigen presentation is the “sine qua non” of the mammalian adaptive immune 
system. The assembly o f MHC class I/peptide complexes in the endoplasmic 
reticulum (ER) relies on the orchestrated interplay between different chaperonins, 
which assist MHC class I folding, and the peptide loading complex (PLC). Mutant 
lymphoblastoid cell lines with defective MHC class I surface expression have 
greatly helped the functional analysis of the PLC. The TAP transporter associated 
with antigen processing translocates MHC class I peptide ligands from the cytosol 
into the ER and is critical for successful MHC class I assembly and maturation. In 
the first two results chapters of this thesis I will describe the identification, clinical 
description and molecular and genetic analysis of a new clinical syndrome in a 
group of patients with dramatically reduced MHC class I surface expression. The 
disease in these patients could be identified as primary TAP-deficiency.
Mycobacterial infections were conspicuously absent in these TAP-deficient patients 
whereas TAP-deficient mice are known to be highly susceptible to mycobacteria. 
The focus of the third and fourth chapter of this thesis lies on lipid antigen 
presentation via CD1 molecules, which are known to present mycobacterial lipids to 
T lymphocytes. The first objective of this thesis was to generate recombinant 
mycobacterial lipid loaded CD1 molecules as tools to measure mycobacterial lipid 
specific T cell responses in the TAP-deficient patients. Chapters three and four 
describe novel protocols for the generation of recombinant human CD lb and CD Id 
molecules with loaded single lipid species.
Preface
Both an insufficient and an inappropriately strong immune response can cause serious 
diseases in humans. My personal interest in clinical immunology was sparked by my first 
patient with an inflammatory disease of small vessels back in 1994 in Switzerland. At that 
time, clinical immunology was still mainly about making the diagnosis and correctly classify 
immune-mediated diseases, and to develop a long-term treatment strategy for the patients in 
order to get the best therapeutic effect with the least side effects. While these principles are 
still valid today, recent advances in targeted immune therapies underline the need for 
clinicians to understand the basic mechanisms in immunology. However, today, knowledge 
in immunology is growing exponentially and keeping up to date with all the different areas of 
immunology is hardly possible.
Primary immune deficiency (PID) syndromes are rare diseases, which offer the 
clinical immunologist a unique opportunity to get insight into the links between clinical and 
basic immunology. In my case, an encounter in 1996 with an extraordinary patient, “AK”, 
who was suffering of a then unknown PID with severe mutilation of the face, completely 
changed my career path and was the “sine qua non” of this thesis. However, after all those 
years since “AK’s” death I do not remember her because of her clinical phenotype or the 
fascinating research I was allowed to do with her tissues and cells. Like all the other patients 
with the same disease who I met over the years I remember “AK” for the exceptional bravery 
with which she endured her illness, and for the feeling of powerlessness her disease evoked 
in me.
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Outline of the thesis
The central theme of this thesis is antigen presentation. The first two results chapters 
(i.e. chapters 3 and 4) will describe the MHC class I antigen presentation pathway in 
patients with a very rare PID, TAP-deficiency.
The clinical observation that TAP-deficient humans do not exhibit increased 
susceptibility to mycobacterial infections, while TAP-deficient mice are highly 
susceptible to mycobacteria, stimulated my interest in another class of antigen 
presenting molecules, namely the non-polymorphic lipid presenting CD1 molecules.
The third results chapter describes the development and application of new tools to 
study human CD ld-restricted lipid-specific T lymphocytes.
Finally, the fourth and last result chapter describes how human CD lb molecules 
bind and present lipid antigens and offers an explanation of how human CD lb can 
bind mycobacterial mycolates that have very long alkyl chains.
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1. Background
1.1. Antigen presentation by MHC class I molecules
1.1.1. The concept of Innate and adaptive immune receptors in higher vertebrates 
The immune system of higher vertebrates comprises two principal mechanisms to 
differentiate “self’ from both “non-self’ and “altered self’, namely the innate and the 
adaptive immune systems. As the name indicates, the innate immune system relies on 
a repertoire of germline encoded, and therefore limited set of receptors, which 
recognize pathogen associated molecular patterns (PAMPs). Innate receptors are 
therefore also referred to as pattern recognition receptors (PRRs). PRRs have evolved 
to ensure highly reliable recognition of pathogen associated structural elements, that 
can’t be easily mutated by the pathogens, such as bacterial carboydrates, 
peptidoglycan, glycolipids, or bacterial and viral nucleotides. Prototypical PRRs 
include the toll-like receptors (TLRs) which can bind to PAMPs either at the cell 
surface or intracellularly, and the cytosolic NOD-like receptors \  Activation of the 
innate immune system by PAMPS via innate receptors is of key importance for 
effective activation of adaptive host defense responses. Consistently, PRRs are 
preferentially expressed on such immune cells which arrive very early, within a few 
hours, at the site of inflammation, e.g. neutrophilic granulocytes, macrophages, and 
dendritic cells. Inherited mutations in genes encoding TLRs or NODs are associated 
with both susceptibility to infectious disease 2 and autoinflammatory bowel syndromes
3
An important limitation of the innate immune system is the limited diversity of 
the repertoire of canonical receptors, and the limited ability to recognise “altered self’.
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Importantly, the innate immune system is not sufficient to ensure full protection 
against pathogens. This is illustrated in children with defined primary immune 
deficiencies of the innate immune system’s counterpart, i.e. the adaptive immune 
system. These children suffer from very severe bacterial, fungal, parasitic, and viral 
infections 4.
The appearance of the adaptive (synonym: acquired) immune system coincides 
with the emergence of jawed vertebrates (Gnathostomata), which were first to use 
Recombination Activating Genes (RAG) 1 and 2 to generate random T- and B-cell 
receptors (TCRs and BCRs) by way of somatic recombination of a limited set of 
germline encoded variable (V), diversity (D), joining (J), and constant (C) gene 
segments 5. The main function of jaws, i.e. chewing food, bears considerable risks 
since the delicate mucosal barrier of the mouth can be easily wounded by mechanical 
stress, allowing a wide range of pathogens to enter the blood circulation. The greater 
diversity of antigens that can be “seen” by an immune system employing random 
receptors might therefore be an essential requirement to defend the host from the broad 
range of pathogens entering the blood circulation of jawed vertebrates.
However, there are other valuable hypotheses why random T- and B-cell 
receptors have been added to the immune system’s armory. Invasive tumors, like the 
adaptive immune system, are also limited to jawed vertebrates 6. Some invasive 
tumors in animals, such as the facial tumors that can afflict the Tasmanian devil or the . 
invasive venereal tumors affecting dogs are transmissible 6’ 7. Thus, the adaptive 
immune system might have evolved to better protect the host from tumors.
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1.1.2. Immune receptors of adaptive cellular immunity
In contrast to the innate immune system the adaptive immune system employs a 
virtually unlimited diversity of antigen receptors, i.e. TCRs and BCRs, which are the 
hallmarks of T-lymphocytes and B-lymphocytes, respectively. The specific functions 
of T- and B-lymphocytes are crucial ly dependent on the ability of their T- and B-cell 
receptors (TCRs, BCRs) to recognise antigen.
The protein structure of both TCRs and BCRs is dominated by immunoglobulin 
(Ig-) like domains, i.e. antiparallel beta-sheets arranged in a “greek key” pattern, and both 
types of receptors share many highly conserved framework residues 8. However, while 
BCRs can be secreted by B-lymphocytes and are able to bind free antigens in the blood or 
tissues, TCRs require the antigen to be presented by specialised endogenous antigen 
presenting molecules on the surface of other cells 9.
The first and still best known class of antigen presenting molecules are the 
histocompatibility leukocyte antigen (HLA) class I and class II molecules, which are 
encoded within the major histocompatibility complex (MHC) on the short arm of 
chromosome 6. They are therefore also called MHC class I and class II molecules.
MHC class I molecules have a quaternary structure with an HLA class I heavy chain 
(HC) and a beta-2 microglobulin light chain ((32m), whereas MHC class II molecules 
are heterodimers of one a  and one (3 HLA class II heavy chain I0. Despite these 
differences MHC class I and class II molecules share a highly similar three 
dimensional protein structure, the key feature of which is an antigen binding domain 
built from two alpha-helices overlaying beta-pleated sheets.
3
Furthermore, both MHC class I and MHC class II molecules present short 
peptides to T-lymphocytes n , albeit of slightly different length. However, MHC class I 
and class II molecules differ in their ability to interact with CD4, CD 8aa and CD8a(3 
co-receptors of CD4+ and CD8+ T-lymphocytes, respectively 12. The co-receptor of 
CD4+ T-lymphocyte binds to the extracellular portion of the a  heavy chain (more 
precisely the a3 domain) of HLA class II molecules, while CD8 co-receptors bind to 
the extracellular a3 domain of the heavy chain of HLA class I molecules 13,14. 
Although both types of co-receptors do participate in the encounter between T- 
lymphocytes and an MHC molecule expressing antigen presenting cells, their 
contribution to the overall binding avidity of this interaction is very low compared to 
the avidity provided by the binding of the TCRs to the antigen presenting 
MHC/peptide complexes 15. In fact, the binding kinetics of a T-lymphocyte’s TCR to 
its cognate MHC/peptide complex(es) determines both the T-lymphocytes selection in 
the thymus and its functional activation in the periphery.
In the following sections I shall focus on antigen presentation by MHC class I 
molecules.
1.2. Introduction to MHC class I molecules
The function of MHC class I molecules as antigen presenting molecules is 
underpinned by the three-dimensional structure of their extracellular domains. These 
domains are formed by a single heavy chain and consist of a membrane proximal a3 
domain, which is non-covalently associated with f32m, and two membrane distal alpha 
domains (a l and a2) which form the peptide binding groove. The peptide binding
4
groove comprises six defined pockets, A ’, B \  C \  D’, E’ and F \  designed for specific 
interaction with certain amino acid side chains 10.
Different isoforms of MHC class I molecules, namely HLA-A, -B, -C, -E, -F, -  
G, and -H  (HLA-H is a pseudogene), are encoded within the HLA locus on human 
chromosome 6. HLA-A, -B, and -C  are highly polymorphic, whereas the other 
isoforms exhibit limited allelic polymorphism
(http://www.anthonynolan.org.uk/HIG/lists/classllist.html). HLA-A, -B-, and -C  are 
commonly referred to as “classical” MHC class I molecules, and HLA-E, -F, and -G  
are called “non-classical” MHC class I molecules. The very prominent polymorphism 
of classical MHC-class I molecules is thought to reflect their ongoing exposure to 
significant evolutionary pressure exerted by frequent mutations, i.e. counter­
adaptations, of viruses. Conversely, the limited polymorphism of non-classical MHC 
class I molecules suggests they are involved in immunoregulatory processes, via 
interaction with NK receptors, rather than host defence to viruses.
As every person has inherited one set of HLA class I alleles from the mother 
and one from the father the HLA class I haplotype of an individual comprises 3 to 6 
different HLA-A, -B, and -C  alleles. The statistical likelihood of having 2 identical 
sets of parental HLA class 1 alleles is extremely low, unless the parents are first degree 
relatives.
Importantly, the polymorphic residues in MHC class 1-molecules significantly 
contribute to the structure of the peptide binding groove and therefore the peptide 
selection o f different MHC class I alleles.
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The N- and C-termini of MHC class I bound peptides are anchored within the 
A’ and F’ pockets, respectively via specific peptide residues. These “anchor residues” 
of the peptides are typically located at positions P2-P5 for the N-terminal anchor and 
the peptide’s C-terminal position, e.g. P9 of a nonamer peptide, for the C-terminal 
anchor 16.
MHC class I molecules typically bind short peptides of 8-11 amino acids, but 
longer peptides, up to 14 amino acids long, can be presented by some MHC class I 
molecules to CD8+ T cells. Longer peptides such as the HLA-B*3501 bound 11-mer 
peptide “EPLPQGQLTAY” are anchored via the same positions and the more central 
parts of such long peptides bulge out of the groove 11. Interestingly, the conformation 
of bulged peptide is flexible and the peptide can be flattened upon T cell receptor 
binding 18.
The peptide anchor residues vary according to the specific MHC class I 
molecule. For example, HLA-A2 prefers hydrophobic anchor residues, while others 
use proline anchors (HLA-B7 and 11LA-B35) or basic amino acid anchors (e.g. HLA- 
A3).
Different MHC class I molecules also exhibit significant differences in their 
dependency on the proteasome, the peptide loading complex and N-glycosylation, as 
well as in the speed with which they traffic from the ER to the cell surface.
1.3. The role of MHC class I molecules for immune surveillance
While their role in antigen presentation is widely known recent studies have 
demonstrated that MHC class I molecules are also involved in non-immunological
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areas o f vertebral biology, namely mating selection 19 and inter-neuronal signalling20. 
In the following I shall keep the focus on their role in host immunity.
Classical MHC class I molecules can present “normal self’ as well as tumour- 
and pathogen-derived peptides to specific cytotoxic CD8+ T-lymphocytes. Specific 
HLA class I haplotypes are associated with auto-inflammatory diseases, cancer 
susceptibility and protection against viruses 21'26, supporting the notion that MHC class 
I molecules are involved in immune surveillance. Furthermore, an indirect yet very 
persuasive indication for the importance of MHC class I molecules in host defense is 
the variety of highly sophisticated mechanisms employed by different viruses to 
subvert presentation of viral peptides by MHC class I molecules (reviewed in 27). 
Similarly, MHC class I/peptide presentation is severely suppressed in many malignant 
tumor cell lines strongly suggesting a role for MHC class I molecules in tumor
'•y O
immune surveillance .
While cell surface expressed MHC class I molecules actively report to T- 
lymphocytes on the presence of intracellular peptides of viral or tumor cell origin, the 
absence of MHC class I molecules from the cell surface, i.e. “missing self’, can trigger 
innate immune responses by unleashing Natural Killer (NK) cell activation 29. NK 
cells are innate-type lymphocytes which can exert strong cytokine secretion and 
cytolytic activity. They specifically express different sets of germline encoded 
receptors that bind to MHC class I molecules, namely Killer Inhibitory Receptors 
(KIRs) and C-type lectin receptors. Both inhibitory KIRs and inhibitory C-type lectin 
receptors, such as CD94/NKG2A, contain Immunoreceptor Tyrosine-based Inhibitory 
Motifs (ITMs) in their cytoplasmic domains 30’31. Binding of MHC class I molecules
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to these receptors delivers a negative signal that inhibit killing by NK cells and certain 
T cells, e.g. y5 T lymphoctes. The classical MHC class I molecules HLA-A, -B, and - 
C, in particular HLA-C alleles, bind to inhibitory KIRs. Conversely, the non-classical 
MHC class molecule HLA-E is a ligand for the inhibitory C-type lectin NK receptors 
CD94/NKG2A, CD94/NKGK2B and CD94/NKG2C, but not for K IRs32, and HLA-G 
can interact with both KIRs and C-type lectins. A third group of germline encoded 
inhibitory receptors, widely expressed on leukocytes comprises the Immunoglobulin- 
like transcript (ILT) receptors ILT-2 and ILT-4, which have been demonstrated to bind 
to the classical MHC class I molecules HLA-A and -B , as well as to HLA-G, -E, and 
-F  33. ILT-2 is the only ILT expressed on NK cells. Similar to KIRs and 
CD94/NKG2A ILT-2 and ILT-4 deliver negative signals to ILT-2 and ILT-4 
expressing NK cells and cytotoxic T cells 34 which prevent them from killing MHC 
class I expressing cells.
1.4. Molecular interaction of MHC/peptide complexes with NK receptors
The available crystal structures of peptide-loaded MHC molecules in complex with 
either KIRs or C-type lectins show different modes of binding (Figure 1). The crystal 
structure of the complex formed by KIR2DL2 and HLA-Cw3 (PDB entry lefx) shows 
some similarities with TCR-MHC/peptide structures. KIR2DL2 docks onto the C- 
terminal part of the MHC/peptide groove in an almost orthogonal orientation across 
the alpha 1 and alpha2 helices of HLA class I molecules 35. Interestingly, the germline 
encoded KIR makes contacts with residues at position P7 and P8 of the MHC bound 
peptides. Earlier functional studies had suggested that the bound peptide can influence
the lysis of target cells by NK cell clones 36. In contrast to KIR binding, the murine C- 
type lectin receptor Ly49c binds to the alpha3 domain of the mouse MHC class I
l  <^7
molecule H2K , away from the binding site of either KIRs or TCRs . Atomic 
structures of ILT:MHC/peptide
Figure 1. MHC class I molecules are ligands for different types of immune receptors
TCRab:HLA-A2 KIR2DL2: HLA-C w3 Ly49C:H2Kb
PDB lao7 PDB lefx PDB lplz
MHC I 
+ b2m
Vrs
MHC I 
+ b2m
Ribbon diagrams o f  three atomic structures o f MHC class I  molecules (in grey colour) 
and bound immune receptors (in orange and yellow colour). The first solved structure 
o f a human HLA-A2/peptide complex with bound afTC R38 (only variable domains are 
shown) is shown on the left-hand side. Human HLA-Cw3 in complex with a killer 
inhibitory receptor3:> (KIR2DL2) is shown in the middle, and the mouse MHC class I  
molecule H2Kb in complex with a C-type lectin receptor37 is shown on the right-hand 
side. The figure was created using the indicated PDB files using PyMol software.
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complexes have not yet been solved, but functional data have shown that both ILT-2 
and ILT-4 effectively compete with CD8 for MHC class I binding, indicating that they 
both bind to the alpha3-domain and/or (32m 39.
1.5. TCR structure and molecular interaction of TCRs with MHC/peptide complex
TCRs are heterodimers of two heavy chains, each of which is constructed from two 
immunoglobulin-like domains. The main classes of TCR heterodimers in humans are 
TCRap and TCRyb. The membrane distal Immunoglobulin-like domains in both 
classes are encoded by rearranged V-, J-, and D- gene segments. These “variable” 
domains make direct contact with the antigenic surface and are highly polymorphic 
(Figure 1 and 2) 38>40. in contrast, the membrane proximal “constant” domains, the 
transmembranous and the cytosolic domains, all of which are encoded by C-gene 
segments, are nonpolymorphic. The antiparallel beta-strands of the variable TCR 
domains are connected via highly polymorphic flexible loop structures. These loops 
determine the shape complementarity between the TCR and the MHC/peptide 
complex and are hence called complementarity determining region (CDR) loops.
Three CDR loops (CDR1, 2, and 3) of each TCR heavy chain are involved in direct 
antigen contact. The CDR3 loops exhibit by far the highest structural diversity. They 
are encoded by randomly rearranged V-, J-, and D- gene segments, while the less 
diverse CDRl and CDR2 loops are encoded by V-gene segments only. On the other 
hand, the diversity of the CDR3 loops can be increased by at least ten-fold through 
random template independent nucleotide insertions and deletions at the V-, J-, and D- 
gene segment junctions via a terminal deoxynucleotidyl transferase (TdT) 41.
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Figure 2. CDR loops of a human apTC R  contacting the MHC/peptide complex
CDR3a
Close-up view o f the first solved structure o f a complex between human T-cell
38receptor, a viral peptide and HLA-A2 (PDB accession code 1A07). The a l/a2  
antigen binding domain o f  HLA-A2 is shown as a ribbon diagram in green colour and 
the HLA-A2 bound viral peptide is represented as sticks with carbon atoms in yellow, 
nitrogens in blue and oxygens in red. The T-cell receptor alpha chain is coloured 
salmon and the beta chain is coloured in blue. The CDR loops are represented as 
sticks. The figure was generated using PyMol software.
Crystal structures of mouse and human TCRs and MHC/peptide complexes, 
both free and in complex with each other have yielded important insights into the 
molecular basis of antigen recognition by the adaptive immune system42. Typically the 
TCR docks in a diagonal way onto the MHC/peptide complex surface, thereby
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allowing contacts between the TCR and both the MHC molecule and the bound 
peptide antigen. Still unexplained is the fact that the variable alpha chain of the TCR is 
located more over the N-terminal part of the peptide, while the variable beta chain is 
situated more over the C-terminal part of the peptide. The hypervariable CDR loops 
mediate all TCR contacts with the MHC/peptide accessible molecular surface area. In 
most TCR-MHC/peptide structures to date the CDR3 loops make most contacts with 
the peptide, while the CDR1 and CDR2 loops make more contacts with the MHC 
protein surface. Of note, neither the CDR loops nor the MHC/peptide surface are rigid 
surfaces and both can undergo significant conformational changes upon ligation. Still, 
the shape complementarity (i.e. geometric fit) of the TCR-MHC/peptide interface, 
even in “higher affinity” TCR-MHC/peptide complexes, is generally low compared to 
known molecular interfaces of enzymes and their substrates. This is reflected by the 
relatively low affinity (KD dissociation constant for most TCRs in the range of 1-100 
pM) that characterises the binding between TCRs and their MHC/peptide 
counterparts. An obvious advantage of a low compared to a high avidity is the higher 
degree of freedom of movement for the T-lymphocyte while it scans the surface of 
antigen presenting cells. Importantly, in almost all documented cases the MHC bound 
peptide has a significant impact on both space complementarity and affinity between 
the TCR and its cognate MHC/peptide complex, as best illustrated in the differential 
binding of the “2C” TCR to either H-2Kbm3 or H-2Kb 43.
Interestingly, some human TCRs make hardly any contacts with the MHC 
bound peptide44. However, in any case the peptide serves an essential role by 
stabilising the MHC class I molecule. In fact, without any bound peptide MHC class I
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molecules do not reach the cell surface but are retained in the endoplasmic reticulum 
(ER).
1.6. MHC class I processing and presentation pathway
1.6.1. Origins of peptide supply to MHC class I molecules
The seminal work by Alan Townsend and colleagues in Oxford has revealed that the 
antigens recognised by T lymphocytes are not whole proteins bound to MHC 
molecules but rather small peptide fragments11, 45.
All proteins have a limited half-life and recycling of amino acids and small 
peptides via cytosolic proteolysis is a vital housekeeping mechanism for every cell 
which is adjusted constantly to the cell’s metabolic rate. Accordingly, genes encoding 
for the components of the proteolytic machinery of cells are both ancient and highly 
conserved between all domains of life.
1.6.2. Routes of protein degradation in the cytosol
Most proteins are very rapidly digested in a sequential way by different proteases. In 
fact the cytosol digests most proteins completely before they have a chance to reach 
the ER. At least 10,000 copies of a given protein must be expressed in the cell to 
create a realistic statistical chance for its peptide fragments to reach the ER and be 
presented by MHC class I on the cell surface. The speed with which proteins are 
degraded after their synthesis is of different importance for different challenges, e.g. 
tumors versus acute viral infections. During acute virus infections viral proteins must 
be processed and their peptides presented on surface MHC class I molecules before the
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virus completes its replication cycle -  otherwise the whole exercise is futile. This 
means, that a proportion of freshly made viral proteins must immediately be directed 
towards proteolysis. It has been recently proposed that a proportion of all newly made 
self and foreign proteins are led straightaway into a degradation pathway while 
ribosomal translation is still running. In fact, ca. 30% of newly synthesized proteins 
are immediately degraded46. Two different routes could be taken by such proteins:
The first route is rather time consuming and involves the covalent attachment 
of polyubiquitin to the doomed protein. This pathway is thought to be taken by 
incorrectly folded proteins, and these failed attempts of mRNA translation have been 
called “defective ribosomal products (DRiPs). One problem of this model is that it 
predicts a bias towards epitopes from proteins with a higher inherent tendency to 
misfold, while no such bias has ever been discovered in peptide-elution studies. 
Another problem of the model is that even misfolded viral proteins “survive” at least 
several hours before they are digested, since they are cared for by heat-shock proteins 
(HSP) and chaperonins. Still, ubiquitin-tagged proteins are efficiently captured by the 
19S cap of the 26S proteasome, unfolded, and digested into 3-10 amino acid long 
peptides.
An alternative model to the above first route is simpler and more consistent 
with the time constraints discussed above. According to the alternative model a certain 
proportion of proteins is translated by ribosomes that are not occupied by ribosome- 
associated HSP RAC and NAC (RAC: HSP70-associated ribosome associated 
complex; NAC: Nascent polypeptide associated complex). The polypeptides released 
from such ribosomes have a very high chance to misfold. The misfolded polypeptide
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could be captured by the HSP-like structural components of the 20S proteasome and 
immediately digested. This stochastic model does not predict a bias in the peptide 
repertoire presented by MHC class I. molecules and is compatible with the narrow 
time window for epitope generation during acute viral infection47.
1.6.3. Cytosol ic proteases
The major protease in the cytosol and the nucleus and the only cytosolic 
carboxypeptidase is the proteasome (Figure 3). Peptide release by cytosolic 
proteasomes is essential for surface expression of most MHC class I molecules 48. A 
few MHC class I molecules, e.g. HLA-A2 can be stabilised by signal peptides in the 
ER and their surface expression is therefore not totally dependent on the proteasome.
The proteasome can exist in different forms. The basic catalytic core unit is the 
20S proteasome, a cylindrical barrel structure made from two identical a7-[37 units. 
The alpha units contain members of the ATPase family and form a narrow pore, i.e. 
the entrance to the inner structure, of 13.A diameter. The beta-1, beta-2, and beta-5 
subunits have chymotrypsin-like (cleavage behind hydrophobic and aromatic amino 
acids), trypsin-like (cleavage behind basic amino acids) and peptidylglutamyl peptide 
activity (cleavage behind acidic amino acids), respectively 49. As will be discussed 
below, both TAP and MHC class I molecules prefer peptides with hydrophobic, basic 
or aromatic C-termini, but not acidic C-terminal amino acids). The beta-1, beta-2, and 
beta-5 subunits are exchanged by beta-li (LMP2), beta-2i and beta-5i (LMP7) upon 
exposure to IFNy, and this alternative composition is called the immunoproteasome as 
opposed to the constitutive proteasome. Interestingly, the immunoproteasome exhibits
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enhanced chymotryptic and tryptic activity but decreased peptidylglutamyl activity, 
which should increase the release of TAP- and MHC class I compatible peptides. Most 
non-hemato-poetic cells contain copies of the constitutive proteasome, while most 
hematopoetic cells contain a mixture of immunoproteasome and constitutive 
proteasome.
The “basic” 20S proteasome structure (Figure 3) can accommodate one or two 
19S caps, which are dynamically attached to one or both sides of the 20S proteasome. 
The combined 20S proteasome and 19S cap form the 26S proteasome, which is 
specialised in the degradation of polyubiquitinated proteins. Ubiquitin efficiently 
targets proteins to the 26S proteasome but the proteasome can cleave proteins also 
independently of ubiquitin 50. The 19S cap unfolds proteins and directs them through 
the 13A pore into the catalytic centre.
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Figure 3. The mammalian 20S proteasome structure
Crystal structure o f  the bovine 2 OS proteasome51 (PDB ID liru) shown as molecular 
surface (a) and ribbon diagram (b). The outer alpha rings are coloured blue and the 
inner beta rings in orange and red. (a) The panel on the right shows a crossection 
through the catalytic center, (b) Each ring is made up o f seven subunits (right-hand 
panel). The figure was created from the original PDB file (liru) using PyMol 
software.
In vitro and in vivo studies of proteasome cleavage have given different results with 
regard to the length of released peptides. In vitro studies found the released peptides to 
be of 3-20 amino acid length, whereas in vivo studies found mainly peptides of more 
than 15 amino acids length. The latter indicates that peptides released from the 
proteasome need to be digested further in order to be suitable for MHC class I loading.
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Several cytosolic proteases can be involved in this process: Tripeptidyl 
peptidase II (TPPII) is an aminopeptidase which digests peptides of 6-30, but mainly 
longer than 15 amino acids length. Although TPPII is the major peptidase involved in 
the trimming of long antigenic precursors it is not essentially required for all MHC 
class I antigen presentation. Knockdown of TPPII with gene silencing small hairpin 
(sh) RNAs leads to a markedly decreased surface expression of many, but not all 
MHC class I surface52,53.
Other cytosolic aminopeptidases include leucine aminopeptidase (LAP), 
Thymet oligopeptidase (TOP), and neurolysin. All of these are able to generate 9-mer 
peptides, but could also destroy potential MHC class I ligands. In fact, TOP inhibition 
with small inhibitory (si)RNA gene silencing markedly increases surface MHC class I 
expression 54.
1.6.4. Peptide trimming in the ER
Although all cytosolic proteins undergo extensive proteolytic cleavage in the cytosol, 
many of the resulting peptides reaching the ER are still slightly too long for MHC 
class I molecules or have suboptimal N-termini. These peptides can be cut to perfect 
size by the ER resident amino peptidase ERAAP (in humans: ERAP1)55. ERAP1 has a 
broad specificity but prefers 9-16 amino acid long peptide substrates with hydrophobic 
C-termini56. Interestingly, similar to TAP and the immunoproteasome components 
LMP2 and LMP7, ERAP1 is upregulated by IFNy. Recent studies have indicated that 
ERAP1 has an inbuilt “molecular ruler” to suit MHC class I as peptides shorter than 
10 amino acids are very poor substrates57,58. In the absence of ERAAP MHC class I
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molecules are loaded with unique long peptides of suboptimal affinity. ERAAP might 
therefore fulfil an important role in editing of the MHC class I bound peptide 
repertoire. Consistent with this notion, in the absence of ERAAP MHC class I 
molecules present many highly immunogenic but unstable peptides59.
Intriguingly, a recent genotype scan of more than 10,000 single nucleotide 
polymorphisms (SNP) in four different human autoimmune patient groups has found a 
statistically significant association of two markers residing in the gene encoding 
ERAAP/ERAPl (ARTS1) with ankylosing spondylitis, a disease well known for its 
association with HLA-B2760.
1.7. The MHC class I biosynthetic pathway (Figure 4)
MHC class 1 molecules are co-translationally integrated into the bilayer of the 
endoplasmic reticulum (ER). The folding of the MHC class I proteins, including their 
assembly with p2-microglobulin and acquisition of peptide ligands are assisted by a 
chaperonin-based refolding and quality control system. Correctly folded MHC class 
I/(32m/peptide complexes (pMHC) molecules bind to cargo receptors, such as BAP31, 
and accumulate at ER exit sites 61. They leave the ER in coatomer protein complex 11 
(COPII-) coated membrane vesicles and traffic via the ER/Golgi intermediate
A 9compartment (ERG1C) and the Golgi apparatus to the plasma membrane .
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Figure 4. MHC class I assembly (Overview)
TC’R ap  
CD8+
apTCR
GOLGI
ERp57
ERAAP
ERp57
TAPI/2
Peptides +  Proteasome « Protein
MHC class I  assembly in the endoplasmic reticulum (ER). Abbreviations: Cnx, 
calnexin; ERp57, ER-residedprotein 57; Tpn, tapasin; -S-S- symbolizes the disulfide 
bond between tapasin and ERp57; ERAAP, ER-associated aminopeptidase; Crt, 
calreticulin; TAP, transporter associated with antigen processing. Negative (-) and 
positive (+) symbols indicate the inhibitory and activating effects o f  MHC class I  on 
cell functions on NK cells and CD8+ T cells, respectively.
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Improperly folded MHC class I molecules are retained within the ER or are 
retro-translocated out of the ER to the cytosol via interaction with EDEM/1 Itml/Mnl 1 
and/or Derlin-163. In the cytosol they are degraded by proteasomes. This type of fate of 
misfolded MHC class I molecules is known as ER-associated degradation (ERAD).
In contrast, proteins that are either incorrectly folded but have escaped the ER, 
or proteins with incorrect subunit assembly can still be transported back from the 
ERGIC or Golgi apparatus to the ER by coatomer protein complex I (COPI-) coated 
vesicles. COPI -  coated vesicles are recruited by proteins containing C-terminal di- 
Lysine motifs, such as tapasin62,64.
Similar to other proteins, which are co-translationally integrated into the ER 
bilayer, the correct folding of MHC class I molecules within the ER is assisted at 
d ifferent stages of the folding process by chaperone proteins, including BiP, calnexin, 
calreticulin, ERp57 and protein disulfide isomerase (PDI). In addition, assembly of the 
pMHC is supported by transporter associated by antigen processing (TAP) and by 
tapasin.
1.7.1. Early folding stages of MHC class I molecules in the ER 
Nascent MHC class I polypeptides are first chaperoned and retained in the ER by the 
immunoglobulin binding protein BiP via BiP’s “K-D-E-L” ER retention motif. They 
undergo post-translational modification by addition of an N-linked glycan to 
asparagine 89 (N89), which is contained in the consensus sequence “N-X-S/T of the 
MHC class I heavy chains. The lipid-linked precursor dolichol-PP-GlcNAc2Man9Glc3 
is used by most eukaryotes as oligosaccharide-donor molecule. After removal of some
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glucose and mannose residues by glucosidases I and II the N-linked glycan generally 
consists of GlciMan7-9 GlcNAc2 65. The protein-linked monoglucosylated 
oligosaccharide recruits calnexin, a lectin-type, ER-resident membrane bound protein, 
which replaces BiP as a chaperonin.
Calnexin is known to help the refolding of many different proteins and it can 
bind to nascent MHC class I molecules before they associate with (32m. However, 
calnexin plays other roles in physiology, such as Ca2+ storage in the ER. The luminal 
domain of calnexin consists of a lectin-like N-domain and a stalk-like proline-rich (P-) 
domain. The C-terminus of calnexin contains an ER-retention signal (“R-K-P-R-R-E”) 
66, while the P-domain of calnexin is important for binding of another chaperonin to 
calnexin, i.e. the thiol oxidoreductase ERp57.
Early during the refolding process, before peptides bind to and after (32m 
associates with the MHC class I heavy chain calnexin is exchanged for calreticulin67, 
6S. Calnexin and calreticulin are homologous proteins and share ca. 40% sequence 
identity. Like calnexin, calreticulin contains an N- and a P-domain, but it lacks the 
transmembrane domain and cytoplasmic tail of calnexin. Like BiP the sequence of 
calreticulin contains a C-terminal “K-D-E-L” ER retention m otif69.
Calreticulin knockout mice show severe failure of cardiac development and all
70mice die prenatally . However, calreticulin-deficient cell lines are viable and have 
allowed to assess calreticulin’s contribution to peptide loading of MHC class I 
molecules71. The calreticulin deficient mouse fibroblast line K42 exhibits both 
quantitative and qualitative defects in pMHC surface expression: pMHC clomplexes in 
K42 are less stable at the cell surface, causing an approximately threefold reduction of
22
MHC class I surface expression. Interestingly MHC class I molecules in K42 
fibroblasts still associate with the transporter associated with antigen processing (TAP) 
but they are obviously released into the secretory pathway before reaching optimum 
stability. Calreticulin deficiency cannot be compensated for by calnexin, as 
overexpression of the latter in K42 is unable to restore a normal phenotype. The 
different physiological function of the two proteins is also illustrated by the fact that 
calnexin deficient mice survive up to three month after birth and suffer mainly from 
the consequences of large myelinated nerve fiber degeneration 12.
The P-domains of calnexin and calreticulin recruit ERp57 to the folding 
complex (Figure 4)73,74. ERp57 is expressed in many cell compartments, including the 
ER, the cytosol, the nucleus, and also on the cell surface. On the other hand it serves 
many cellular functions, e.g. in protein folding, cell metabolism, signaling, and even 
acts as a cell surface hormone receptor75"78. Not surprisingly, ERp57 deficiency 
(studied in mice) is not compatible with life. An obvious way by which ERp57 could 
help the folding of pMHC and other proteins is via its capacity to act as both a thiol- 
dependent reductase and cysteine protease79,80. However, the precise role of ERp57 in 
the folding of pMHC is still unclear.
ERp57 depletion by RNA interference has only subtle consequences for MHC 
class I processing and presentation, including slightly delayed heavy chain disulfide 
bond formation and slowed folding of the heavy chain a3 domain as well as slightly
delayed egress of MHC class I molecules from the endoplasmic reticulum to the Golgi
81. However, the oxidation state of MHC class I molecules is unchanged in ERp57-
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deficient cells. It has been suggested that another ER-resident oxidoreductase, ERp72, 
might support MHC class I folding in the absence of ERp57 82.
Intriguingly, ERp57 is covalently linked to the ER resident protein tapasin via 
a stable disulfide bond of its cysteine 57 with tapasin’s cysteine 9 5 83. Moreover, IFNy 
promotes the association of ERp57 with tapasin 74, suggesting a possible link between 
immune activation and functional activity of ERp57 in antigen presentation. Of note, 
ERp57, when bound to other proteins, uses an (oxidoreductase) escape pathway which 
ensures that the association is short-lived. However, the covalent link of ERp57 with 
tapasin is stable because of non-covalent links between the two proteins 84.
It has been hypothesized that the firm interaction between ERp57 and tapasin 
supports the stability of the peptide loading complex (PLC), ensuring longer 
interaction time between the MHC class I molecule and the PLC, and thereby 
optimising the loading of peptides onto MHC class I molecules 83. Consistent with 
this, one study reported that the assembly of MHC class 1 into the PLC was strongly 
reduced in ERp57 deficient primary B cells and immortalized fibroblasts 85. However, 
others found that, upon depletion of ERp57 by RNA interference, the peptide loading 
complex assembled properly, and peptide loading onto MHC class I was apparently 
normal 81.
Possibly, the unusually stable link between ERp57 and tapasin could serve a 
rather different purpose: tapasin might actually keep ERp57 in check in order to 
restrain ERp57 from reducing fully oxidized, peptide-receptive MHC class I/(32m 
complexes. Full oxidation of the MHC class I heavy chain is a known prerequisite for
O/T
efficient peptide loading . Conversely, the peptide receptive state of MHC class I
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molecules, induced after full oxidation of the heavy chain and association with (32m, is 
rather unstable. ERp57’s thiol-dependent reductase activity might therefore get in the 
way of efficient peptide loading, unless it is physically separated from peptide- 
receptive HC by tapasin.
While ERp57, ERp72 and (32m 87 all can independently promote disulfide bond 
formation in MHC class I, full oxidation of the MHC class I heavy chain, and in 
particular correct disulfide bond formation in the a2 domain is dependent on protein
o o
disulfide isomerase, PDI . Besides a catalytic domain PDI has a functional peptide- 
binding domain and has been demonstrated to bind peptides and deliver them to MHC 
class I molecules. In the absence of PDI maturation of MHC class I molecules is 
clearly delayed and pMHC surface expression is reduced by 40% 88.
1.7.2. The peptide loading complex (PLC)
To exert their role in adaptive immunity MHC class I molecules must assemble with 
(32m, capture suitable peptide ligands in the ER, achieve a stable quaternary 
conformation and reach the cell surface. This task is considerably more complex than 
the refolding of glycoproteins of simple tertiary structure.
The “bottleneck” in the MHC class I antigen presentation pathway is the 
supply and successful loading of suitable peptides onto MHC class I molecules in the 
ER. In fact, even an up to 50-fold increase in MHC class I molecule expression has not 
influence on either the extent of peptide loading or the rate of MHC class Epeptide
OQ
complex maturation . On the other hand, in the absence of suitable peptide ligands
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MHC class I molecules are not able to reach a stable conformation and are retained 
within the ER.
The peptide loading complex (PLC) is a very large multimolecular complex of 
proteins 90 which act in concert to ensure peptide supply, peptide selection and peptide 
loading onto MHC class I molecules. TAP, the transporter with antigen processing, 
and tapasin (TAP associated protein) are the key elements of the PLC, and defective 
function of either TAP or tapasin leads to allele-dependent reduction in MHC class I 
surface presentation.
1.7.3. The Transporter associated with Antigen Processing/Presentation: TAP 
The discovery that TAP was critical for MHC class I antigen presentation was greatly 
helped by previous analyses and selection of gamma-irradiated B-lymphoblasts that 
had lost MHC class I surface expression 91. Deletion mapping and chromosome 
walking techniques of two such B-lymphoblast lines led to the identification of a 
“peptide supply factor (PSF) gene” in the HLA class II region, now called TAPI, 
controlling the cell surface expression of MHC class I molecules 92
Sequence analysis of TAPI revealed that TAP belongs to the ancient 
superfamily of ATP-binding cassette (ABC) proteins, specialised in the transport of a 
wide variety of substrates across extra- and intracellular membranes. Prominent 
members of the ABC transporter families include the mammalian multidrug resistance 
(MDR) proteins and the cystic fibrosis transmembrane conductance regulator (CFTR).
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1.7.3.1 .TAP function
The importance of a functional TAP transporter for MHC class I antigen presentation 
is illustrated by the fact that MHC class I surface expression is severely reduced in 
TAP-deficient cell lines, such as the human B lymphoblastoid cell line (LCL) 721.174
92
TAP translocates 8 to 40 amino acid long peptide substrates with free N- and 
C-termini from the cytosol into the ER 93,94. To fulfill this task TAP must first capture 
suitable peptides in the cytosol and then undergo significant conformational changes 
that allow the peptides to reach the ER. TAP also generates the energy required for the 
conformational changes by carrying out ATP hydrolysis. Phosphorylated or 
glycosylated peptides with side chains of up to 70A  can be transported by TAP. 
Interestingly, the preferred peptide size for TAP transport is 9-12 amino acids, which 
corresponds to the typical length of MHC class I bound peptides. Furthermore, human 
TAP preferentially binds and translocates peptides with hydrophobic, aromatic or 
basic amino acids at the C-terminus, while it fails to translocate peptides with acidic 
C-termini and is inefficient to translocate peptides with a proline at P2 or P3 95. This 
bias in the binding motif corresponds well to the known “anchor residues” of most 
MHC class I alleles, with the exception of some HLA-B alleles (e.g. HLA-B7 and 
HLA-B35) that have proline anchors at P2. TAP has a very broad peptide binding 
specificity and TAP polymorphisms in humans or mice have not yet been directly 
shown to bias cytosol-to-ER translocation of peptide variants 96. Some studies reported 
on possible disease associations with TAP polymorphisms, but linkage disequilibrium 
between TAP alleles and the nearby HLA class II coding regions could not always be
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9 Vexcluded . On the other hand, a TAP2 splice variant widely expressed in 
lymphocytes, Tap2iso, which lacks exon 11 and the original 3’untranslated region,
QO
was shown to impact on peptide selectivity .
Most MHC class I molecules compete for binding to TAP in the ER 
However, some MHC class I molecules do not require to associate with TAP for 
efficient peptide acquisition. Such MHC classs I molecules include several members 
of the HLA-B molecule family: HLA-B13, -B*1501, -B* 1518, -B*2705, -B35, - 
B*4405, -B56, -B60, and -B62. Interestingly, HLA-B alleles are also generally less 
dependent on their association with tapasin and can traffic more quickly to the cell 
surface.
Other MHC class 1 alleles, namely HLA-A*0201 and HLA-E can mature in the 
absence of TAP. These MHC class I molecules have in common the ability to bind 
signal sequences in the ER. However, the cell surface expression of both HLA- 
A*0201 and HLA-E is clearly higher in TAP-competent compared to TAP-deficient 
cell 10°.
The significance of TAP for immunity against cancer and pathogens is not 
clear cut. Evidence for an increased occurrence or enhanced severity of viral infections 
or tumors in TAP deficient animals is conspicuously sparse 101> 102, but studies in TAP- 
/- mice have shown a clearly enhanced susceptibility to Mycobacterium tuberculosis
103,104
TAP’s role in immunity against viruses and cancer is underpinned by the fact that 
many viruses, in particular members of the herpes virus family, have invented 
ingenious ways to specifically sabotage TAP’s function as a peptide transporter. Of
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note, herpesviridae are large DNA viruses encoding many potential MHC class I 
epitopes for cytotoxic T lymphocytes. The herpesiviridae comprise Herpes simplex 
(HSV) I and II, Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Varicella 
virus (VCV), all of which can establish life-long infection with latent phases and 
recurrent acute infections. To achieve this commensal-like state these viruses need to 
be able to escape the immune system without making the host susceptible to other 
lethal infections. Table 1 shows mechanisms used by herpesviridae to target TAP 
function.
Table 1. Herpes virus proteins targeting TAP
Virus Protein Property Reference
Human CMV gpUS6 binds TAP in the ER and freezes TA P’s conformation 105, 106
H SV l/II ICP47 Outcompetes cytosolic peptides for binding to TAP 107,108
EBV vIL-10 Downregulates TAPI and LMP2 expression 109
VCV UL49.5 TAP conformation arrest and degradation by proteasomes "110 "
Murine yHSV-68 MK3 Degradation o f  TAPI and tapasin 111
Pseudorabies UL41 Degradation o f  cellular mRNAs, including TAP mRN A 112
1.7.3.2. TAP structure and function (Figure 5)
TAP is a large heterodimer consisting of one TAPI (81 kDa) and one TAP2 (76 kDa) 
ABC halftransporter. Both TAPI and TAP2 are required for peptide translocation into 
the ER 113’114. Heterodimerisation also greatly enhances the stability of TAP2, which 
otherwise has a very short half life 115. The genes encoding for TAPI and TAP2 are 
located in the HLA class II region on human chromosome 6. The TAPI gene lies 
adjacent to the gene encoding for the low molecular mass polypeptide subunit 2 
(LMP2) of the immunoproteasome, while the TAP2 gene lies adjacent to the LMP7
29
gene. Interestingly, TAPI and LMP2 share a bidirectional promoter l16, linking 
epitope generation by the immunoproteasome with peptide supply for MHC class I 
molecules in the ER.
Figure 5. TAP structure and function
ER lumen
TAPI TAP2
N  domain 6 + 6 TM translocation core N domain
600000^ oooooot id
NBD2
Tapasin binding NBDl
Peptide binding
Cytosol
Model o f TAP topology based on data obtained with cysteine-mapping117. According 
to the model TAPI has 10 transmembrane domains (TM) while TAP2 has 9 TM. The 
C-terminal 6 domains o f  each TAP subunit form the translocation core domain. The 
core domain contains the peptide binding loops and the nucleotide binding domains 
(NBD. Tapasin binding is mediated by the N-terminal domains.
Both TAPI and TAP2 contain one COOH-terminal cytosolic nucleotide binding 
domain (NBD) and one transmembrane domain (TMD).
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The NBDs of human TAPI and TAP2 are homolgous to NBDs of other known 
ABC transporters and contain several highly conserved peptide sequences, such as 
Walker A and B, and the C- and Q-loop sequences 118. Functional and structural data 
indicate that the two NBDs of TAPI and TAP2 co-operate in the binding and 
hydrolysis of two ATPs via the Walker A binding motif of one NBD and the C loop of 
the other NBD 119. While the function of the Walker B motif is less defined, the 
glutamine (Q) of the highly conserved Q-loop is thought to sense ATP binding and 
trigger dimerisation of the TAPI - and TAP2-NBDs 11S. Furthermore, based on 
structural insights from other ABC transporters, such as the vitamin B 12 importer 
BtuCD the Q-loop is believed to be critical in the cross-talk between the NBDs and the 
TMD 12°.
The membrane topology of the TMD of TAP is still a matter of debate and 
atomic structures of the TMDs of TAPI and TAP2 are not available yet. The model 
which seems to have the most solid foundation from topology algorithms, detailed 
sequence alignments and experimental studies proposes ten and nine transmembrane 
spanning helices for TAPI and TAP2, respectively (Figure 5). The six C-terminal 
transmembrane spanning segments of TAPI (residues 167-488) and TAP2 (residues 
123-454) form the essential translocation core. These domains govern TAP1/TAP2 
heterodimer assembly, peptide binding in the cytosol and the peptide translocation into
117 1 9 1 1 9 9the ER 9 5 .O n the other hand, the first N-terminal transmembrane helices of
TAPI and TAP2 are important for the recruitment of tapasin and therefore MHC class
1 9TI molecules and associated chaperonins to the PLC . Within the PLC TAP associates
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with 4 tapasin and 4 MHC class I molecules 64, but the association of TAP with 
tapasin is not required for peptide binding and translocation by TAP.
1.8. Tapasin
Similar to the discovery of TAP, the existence of tapasin was postulated based on 
studies with a y-irradiated mutant B-lymphoblast line, .220, unveiling the importance 
of a physical association of some but not all MHC class I alleles with TAP for efficient 
cell surface expression 124. Calreticulin-bound MHC class l/p2m heterodimers are 
recruited to the PLC by tapasin, which thereby constitutes a bridge between the 
peptide inflow into the ER and the peptide-receptive MHC class I molecules 125,126. As 
described above, tapasin binds to the N-terminal transmembrane segments of TAP. On 
the other hand, most MHC class I molecules associate with tapasin and TAP via their 
F’pockets, through residues 114 and 116, or via residues 122-136 and 222 within their 
alpha2 and alpha3 domains, respectively 127.
Although TAP-deficient and tapasin-deficient cell lines are both characterized 
by reduced MHC class I surface expression (with surface expression being more 
reduced in TAP- compared to tapasin-deficient cell lines) the mechanisms responsible 
for this phenotype are very different. As described above, in TAP-deficient cell lines 
MHC class I molecules are not loaded with peptide and retained within the ER. In 
contrast, in the absence of tapasin MHC class I molecules still acquire peptides and 
actually traffic to the cell surface faster than in the presence of tapasin. The reason for 
the reduced cell surface expression of some MHC class I molecules in tapasin- 
deficient cell lines is the reduced stability of the MHC class I molecules. A likely
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cause for the MHC class I molecules’ reduced stability is their loading with 
suboptimal peptide ligands.
Interestingly, some closely related MHC class I molecules are totally different 
with regard to their tapasin-dependency. This is best exemplified by the highly 
tapasin-dependent HLA-B*4402 (Aspartate 116) and the tapasin-independent HLA- 
B*4405 (tyrosine 116) which differ in only one amino acid at position 116 in the 
F’pocket. Comparative molecular dynamics simulations of these two MHC class I 
molecules have suggested that, in the absence of peptide, B*4405 more easily adopts a 
peptide receptive conformation, which would allow for tapasin-independent peptide
• 1 9 Rloading . Hence, tapasin might help stabilization of a peptide-receptive MHC class I 
conformation. Consistent with this notion it has been recently shown that tapasin 
skews the peptide repertoire loaded onto MHC class I towards such peptides with slow
190dissociation kinetics .
Tapasin is stably linked to ERp57 and the meaning of this interaction for the 
function of tapasin is not clear yet. As discussed above tapasin might restrain ERp57 
from reducing the disulfide bonds of peptide recepti ve MHC class I molecules.
Two tapasin alleles, which differ by one residue at position 240 (R/T) have been 
found, with no known implications for tapasin function or association with human 
diseases. On the other hand, tapasin independent MHC class I molecules might 
compensate for the loss of function of TAP-dependent MHC class I expression 
inflicted by viruses or tumors. To date, one case of a 54-year old woman with tapasin 
deficiency, slightly reduced MHC class I surface expression and glomerulonephritis is
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described in the literature. Interestingly, her HLA genotype was found to be 
homozygous for HLA-B*1501, which is both tapasin- and PLC-independent130.
1.9. Type 1 Bare Lymphocyte Syndrome
The primary immunodeficiency syndromes characterized by severely reduced or even 
absent MHC class I cell surface expression are called type 1 bare lymphocyte 
syndromes (type 1 BLS). Based on clinical and immunological grounds type I BLS 
can be subdivided into at least three groups 131:
Group 1 type 1 BLS includes patients with severe recurrent bacterial, fungal 
and parasitic infections starting within the first half year of life. Patients of this group 
succumb within the first three years of life from infectious complications132'134. The 
immunological defect in these patients consists of both severe reduction of MHC class 
I and [32m on the cell surface and complete lack of antibody production. The published 
patients were heterozygous for the HLA haplotype.
Group 2 type 1 BLS patients are completely asymptomatic. Only one family 
with two affected children has been described so far 135. Downregulation of MHC 
class I- and [32m - surface expression was the only observable immunological finding. 
The two siblings had different heterozygous HLA haplotypes. Northern blot analysis 
demonstrated a decrease in HLA class I and [32m mRNA, consistent with a
136transcriptional defect .
Before the work of this thesis was published, a third group of type 1 BLS had 
been characterized in a family from Morocco with 2 affected siblings. The patients‘ 
peripheral blood mononuclear cells displayed severely reduced MHC class I surface
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expression. In contrast to Group 1, the patients survived into adulthood without major 
infectious complications but recurrent respiratory infections. The patients shared an 
identical homozygous HLA haplotype. Further molecular and genetic analysis 
revealed a frameshift mutation in TAPI ,37.
Chapters 3 and 4 of this thesis will describe the molecular and genetic analysis 
of a group of patients with type 1 BLS.
The next part of this introduction will describe the biology of CD1, a MHC 
class I-Iike family of antigen presenting molecules. In contrast to MHC class I and 
MHC class II molecules all members of the CD1 protein family have been 
demonstrated to bind lipids. Some CD 1 /lipid-specific Tdymphocyte responses have 
recently been characterised in humans. It is possible that CD 1-restricted cellular 
immune responses could complement MHC class I or MHC class II specific T- 
lymphocyte functions, or even compensate for the loss of MHC class I antigen 
presentation in patients with type 1 BLS.
1.10. Antigen presentation by CD1 molecules
1.10.1. A short history of the discovery of CDl as a third line of antigen presentation 
It has been long known that a small but significant proportion of human peripheral 
blood mononuclear cells were CD4- CD8-, i.e. double negative (DN) memory a(3 T 
cells, which suggested the possibility that these lymphocytes might be restricted by
138antigen presenting molecules other than MHC class I or MHC class II .
In 1975 George Kohler and Cesar Milstein had described a novel technology to 
produce monoclonal antibodies from hybrid myeloma clones139 (in 1984 they received
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the Nobel prize for their discovery140), and in 1979, using a monoclonal antibody 
generated with this technology, Andrew McMichael and Cesar Milstein defined a 
human thymocyte antigen, which they named cluster of differentiation (CD) 1141. The 
CD1 locus on chromosome 1 was subsequently shown to contain five genes in 
humans, CD1A-CD1E142. The predicted amino acid sequence of these genes revealed 
a low but significant homology to human MHC class I molecules143. In addition, 
serological studies had shown that CD1 proteins were associated with (32m on the 
surface of antigen presenting cells143. However, in contrast to the highly polymorphic 
genes encoding MHC class I and class II, no significant polymorphism could be 
detected for any of the CD1 genes. A role for CD1 in adaptive T lymphocyte mediated 
immunity was therefore not suspected at the time.
One decade later, in 1989 Steven Porcelli and colleagues showed for the first 
time that CD1 molecules could induce MHC class I and II independent, but CD3- 
mediated activation of human DN T-lymphocyte lines144. One DN ap  T-cell line was 
shown by these authors to be restricted by CD la, while activation of a DN y5 T- 
lymphocyte line was dependent on CDlc. In 1992 Steven Porcelli and colleagues 
described a human DN a p  T-lymphocyte line restricted by CD lb 145. Using this T cell 
line they showed for the first time that CD1 could restrict the response of cytotoxic T 
lymphocytes to microbial antigens. The identification of the first antigen presented by 
CDlb to a DN ap  T-lymphocyte line followed in 1994146. It came as a major 
breakthrough in cellular immunology and as a shock to many immunologists -  the 
antigen was a Lipid! Moreover, the identified lipid antigen was mycolic acid, a
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branched, very long-chain fatty acid found in mycobacteria. How could such an 
antigen be presented by a MHC class I-like molecule to a T cell receptor?
In 1993, studies in mice had revealed a strong bias for the use of TCR Vp8 
among mature DN ap  T-lymphocytes147. The selection of these DN T cells in mice 
was shown to be dependent on hematopoetic cells rather than thymic epithelial cells, 
which suggested their restriction by non-classical MHC class I or MHC class I-like 
molecules. Similarly, in 1994 Raulet and colleagues demonstrated the existence of 
CD4+CD8- ap  T-lymphocytes which were dependent on p2m-expression by 
hematopoetic cells148, and, in the same year, Lantz and Bendelac showed that the 
major fraction of thymic mature DN ap  T-lymphocytes co-expressed the NK marker 
NK1.1 and an invariant TCR Val4-Ja281 alpha chain149. Importantly, a highly 
homologous invariant TCR alpha chain, TCR Va24-JaQ, had also been identified 
among DN ap  T-lymphocytes in several unrelated human donors in 199315°. In 1995 
the work of two research groups showed that DN and CD4+ mouse T cells using the 
invariant TCR V al4-JaQ  rearrangement were restricted by CD Id151,152.
The next important breakthrough discovery was published in 1997 by Kawano 
and colleagues, who showed that the CD Id-restricted iNKT cells could be strongly 
and specifically activated by KRN7000, an alpha-galactosylceramide glycolipid 
derived from a marine sponge153. Interestingly, KRN7000 had previously been shown 
by the Pharmaceutical Research Laboratories of Kirin Brewery (Gunma, Japan) to 
significantly prolong the lifespan of mice in a B 16 melanoma metastasis model154. 
Finally, the first atomic structure of mouse CD Id published in 1997 by Zheng and
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colleagues basically confirmed that CD1 molecules were designed to present lipid 
antigens155.
In the following sections I will give an overview on the biology of CD1.
1.10.2. Group 1 and group 2 CD1 proteins
According to their predicted amino acid sequence the five human CD 1 genes on 
human chromosome lq22-23 can be categorized into Group 1, containing CD1 A,
CD IB, CD 1C and CD I E, and Group 2, which only comprises CD ID 156. Phylogenetic 
analysis has indicated that the human CD1 gene copies were duplicated prior to the 
evolution of primates and well before the bulk of HLA class I genes157. In mammals 
the CD1 and HLA loci are on different chromosomes, but in chicken they occupy 
adjacent regions on the same chromosome. Avian CD1 can’t be classified as either 
group 1 or group 2, suggesting that it represents an ancient precursor to “modern” 
mammalian CD1 genes158. Nothing is known yet about the functional role of the 
chicken CD1.
Interestingly, the two groups of mammalian CD 1 molecules segregate with 
regard to tissue expression and T lymphocyte restriction159. Group 1 CD! molecules 
are expressed to levels similar to MHC class I on myeloid cells and are highly 
expressed on immature cortical thymocytes. In addition, CDlc is highly expressed on 
marginal zone B-lymphocytes, while CD la  is a classic phenotypic marker of 
Langerhans cells in the skin. In contrast, CD Id surfaceexpression is generally much 
lower compared to CDla, but it is more widely expressed in the body. CDld seems to 
be constitutively expressed on various epithelial cell types, including keratinocytes,
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intestinal epithelial cells and endothelial cells, but it is also expressed on antigen 
presenting cells. In general, the tissue distribution of CD Id expression resembles that 
of MHC class I molecules, while group 1 CDl expression is more similar to MHC 
class II tissue expression. Group 1 CD1 expression can be induced on epithelial cells 
under inflammatory conditions, e.g. on neurons in multiple sclerosis lesions160. 
Similarly, CD Id expression can be upregulated by inflammatory cytokines and danger 
signals, i.e. TNFa and IFNy, or IFNy and lipopeptides161. Consistent with this, the 
CD1D gene, which is controlled by dual promoters with multiple transcription 
initiations sites, contains 9 IFNy response elements (y-IRE_CS) as well as 5 putative 
nuclear factor for IL-6 expression (NF-IL-6) response elements162. However, while 
cell surface expression of CD la, CD lb and CD l e molecules is upregulated in GM- 
CSF and IL-4 treated human monocyte, CD Id is downregulated in the same cells163. 
Interestingly, the Peroxisome Proliferator-Activated Receptor-gamma (PPARy) has 
been shown to mediate opposite effects on CD Id and group 1 CD1 expression on 
immature dendritic cells, supporting the notion that group 1 and group 2 CD1 
molecules serve different physiological functions164.
Of the five human CD 1 molecules all except CDle are expressed on the 
surface. While CDla-d have all been shown to present lipid antigens to T 
lymphocytes, CDle was found to be involved in the processing of complex glycolipids 
within endocytic compartments165. Therefore, CDle should be viewed as a separate, 
i.e. third class of CD 1 molecules.
CD Id shows other interesting differences to group 1 CDl molecules. First,
CD Id is the CDl molecule with the highest degree of conservation in mammals. Mice
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have two CDld alleles, CD1D1 and CD1D2, but both rats and mice have deleted the 
group 1 CDl encoding genes for unknown reasons166. On the other hand, the reason 
why the CD I D genes have not undergone the same fate is likely to be linked to their 
specific role in the selection of a highly conserved T lymphocyte subset in mice and 
men, namely the invariant NKT cells (iNKT). These CD Id-restricted iNKT cells 
express a semi-invariant T cell receptor which is highly homologous in humans and 
mice and can recognize human and mouse CDld in a cross-species specific way167. In
contrast, group 1 CDl restricted T cells use highly diverse T cell receptors, similar to
168MHC/peptide specific T cells . For these reasons it is generally believed that iNKT 
cells have immunoregulatory functions, while group 1 CDl specific T lymphocytes 
might serve roles in host defense.
1.10.3. Classes of CDl ligands (Figure 6)
The first identified ligand for CDl, which could activate a human CD lb-restricted DN 
ap  T cell line, was mycolic acid, a class of alpha-branched p-hydroxy fatty acids with 
very long C70-90 alkyl chains 146. Mycolic acids (MA) are an essential component of 
mycobacterial cell walls and actinomyces 169. They are clearly foreign antigens and no 
similar lipid structures are synthesized in mammals.
The second identified class of CDl antigens contains mycobacterial 
phosphoglycolipids, which include phosphatidylinositol mannosides (PIMs) and
1 70lipoarabinomannan (LAM) . Similar to MA, phosphoglycolipids have two alkyl 
chains. However, LAM has a ca. 17 kDa hydrophilic headgroup, which is too large to 
be accommodated within any of the CDl binding grooves and too bulky to allow T
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cell receptor binding to both CD l b and LAM. In fact, activation of T cells by LAM- 
pulsed CD lb-expressing antigen presenting cells requires both internalization via the
171mannose receptor and endosomal acidification, i.e. processing of the head group
170
The study of another mycobacterial cell wall lipid and close relative of MA, 
glucomonomycolate (GMM), provided further important insights into the structural 
requirements for CDl mediated glycolipid recognition by the T cell receptor. GMM is 
a mycolyl glycolipid consisting of a single glucopyranoside residue esterified to 
mycolic acid. Importantly, the T cell stimulatory activity of GMM is highly dependent 
on the carbohydrate headgroup, while substantial variations of alkyl chain length have 
no significant effect172. Based on these facts a first general model of lipid antigen 
binding to CDl was proposed. According to the model, CDl ligands were anchored to 
the protein via two fatty acids that were buried within the CDl ligand binding groove, 
while the hydrophilic headgroup of these ligands could be exposed on top of the CDl 
protein surface and determine the fine specificity of T cell receptor binding. The first 
structure of a CDl molecule, mouse CDld, was fully consistent with this model, but 
could not explain how very long fatty acids such as those of MA could be buried 
within CDl 155.
The first identified antigen for CDld was KRN7000, a ceramide structure with 
aphytosphingosine chain and an alkyl chain, which underpinned the above model153 
and the crystal structure of CDld with bound KRN7000 provided further insight into
1 73CDl ligand binding : Hydroxyl groups of both the phytosphingosine chain and the 
galactose headgroup of KRN7000 were found to stabilize binding to the CDld
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molecule. These interactions are not an absolute requirement for binding to CDld as 
sphingosine containing glycysylceramides and gangliosides as well as 
phosphatidylinositol, glycosylphosphatidylinositol (GPI), and diacylated 
sulfoglycolipids all have been shown to bind to CDld molecules 174'177. Moreover, the 
sulfoglycolipid sulfatide, which is based on a common ceramide backbone, has been 
shown to bind to all group 1 CDl molecules176.
The identification of another mycobacterial cell wall derived CDl antigen, 
mannosyl-pl-phosphoisoprenoid (C35), revealed that glycolipids with only one alky] 
chain could be presented by CDle to T cells178. Interestingly, phosphoisoprenoids are 
related to dolichols in mammals, but mammalian dolichols are much larger structures 
often containing 90 and more carbon atoms. The antigens presented by CDle to 
human autoreactive T cell lines are still not defined.
Another class of antigens presented by CDl comprises lipopeptide antigens. 
Mycobacterial didehydroxymycobactin (DDM), a relative of mycobactin siderophores, 
was shown to specifically activate CD la-restricted T cell clones, which had been 
previously demonstrated to exert antibacterial effects against mycobacteria-infected
1 70macrophages . The structure of DDM shows no obvious similarities with sulfatide, 
another CD la  ligand, suggesting that the CD la  lipid binding groove can undergo 
conformational adaptation to the bound ligand.
The most recent addition to CDl bound ligand classes are synthetic small 
nonlipidic molecules with multiple aromatic rings, phenyl- 
pentamethyldihydrobenzofurans (PPBF), which were identified by serendipity as 
CD Id-restricted T cell antigens180. How these small molecules bind to CDld, inside or
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outside of the antigen binding groove, is not known, but their existence indicates that 
small molecules might become useful tools in the future to regulate lipid-specific T 
cell functions.
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Figure 6. Different classes of CDl ligands
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Chemical structures o f different classes o f ligands fo r  CDl molecules. The very long 
MA and GMM can only bind to CD lb, while Man-/3-lPip specifically binds to CDle 
and DDM to CD la. Abbreviations: MA, mycolic acid; GMM, glucomonomycolate; 
Man-ft-1 Pip, mannosyl-(3-1 -phosphoisoprenoid; PI, phosphatidylinositol; PPBV, 
phenyl-pentamethyldihydrobenzo-furan; DDM, Didehydroxymycobactin; KRN7000, 
Kirin 7000 (which is representative fo r  the class o f a-glycosylceramides).
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1.10.4. CDl protein structures
The crystal structures of mouse CDld and human CD la, CD lb and CDld have been
17^ 1f t1 1 ft Ssolved ’ " . These structures revealed that the CDl and MHC class 1 molecules
shared an identical domain organisation with an immunoglobulin-like, (32m-associated 
membrane proximal alpha3 domain, and a distal antigen-binding superdomain 
consisting of two alpha helices overlying beta-pleated sheets (Figure 7).
Figure 7. MHC class I and CDl extracellular domain organisation.
38Ribbon diagrams o f  side (a) and top views (b) o f  HLA-A2/peptide ' (left side; a l-aS
domains in dark blue, /32m in lightblue, peptide in yellow; PDB 1A07) and
181CDlb/ligand complex (right side; a l-  a3 domains in in magenta, (32m in light rose,
ligands in yellow; PDB 1GZP). The figure was created with PyMol software.
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The major structural differences between the CDl and MHC class I structures 
are found in the antigen binding groove of the two classes of proteins. The peptide 
binding groove of MHC class I molecules comprises 6 distinct hydrophilic pockets A’- 
F’, for accommodation of, and hydrogen bonding with peptide side chains. In contrast, 
the antigen binding groove of CDl consists of up to four relatively plump, voluminous 
hydrophobic channels (Figure 8). In an attempt to adopt the nomenclature used for 
MHC class I structures these hydrophobic channels in CDl molecules are designated 
A’, C’, and F \  Sequence alignement and direct structural comparison indicates that 
the A ’ channel is the most conserved lipid binding region in all CDl molecules, while
1 ft 1the F’ channel is the least conserved region . The A ’ channel runs from the entry of 
the antigen binding groove at the top of the protein surface down to the bottom of the 
a l / a  2 superdomain, where it bends around a conserved hinge region formed by 
bulky hydrophobic residues (Figure 8).
CD la  and CDld both bind two alkyl-chain containing ligands, despite 
significant differences in the architecture of their binding grooves (Figure 8).
Structures of CDl c and CDle are not available yet, but both can accommodate two- 
alkyl chain ligands.The structure of CD lb, which will be discussed in detail in chapter 
6, is special, because the antigen binding groove consists of four interconnected 
channels, including a unique tunnel T’, which runs at the bottom of the a l /  a2 
superdomain and connects channels A ’ and F’ with each other181. A continous 
superchannel formed by A ’, T’ and F’ can accommodate up to 60 carbon atoms and 
explains how the very long fatty acids of mycolic acid can be completely buried within 
CD ib181,186. Tunnel T’ is absent in CDla or CDld, where bulky amino acid residues
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block the connection between A’ and F \ Sequence analysis of all CDl proteins 
suggests that tunnel T’ is a unique feature of CD lb. Also, channel F’ is occluded in 
CDld and C D la181.
Figure 8. CDl lipid binding grooves
Cross-sections o f human C D ld with bound KRN7000173 (a), human CD lb with bound PI 
and detergent'81 (b), and human CDla with bound lipopeptide,S4 (c) or sulfatide185 (d). 
Ligands are shown as sticks with carbon atoms in yellow, nitrogen atoms in blue and 
oxygen atoms in red colour. The CDl protein surface is in pale green except for the “hinge 
region ” (magenta) o f  channel A ’ and valine 98 (red) in (a), which closes o ff channel A ’.
The position o f  the second “hinge region ” in human CD lb (b), which is formed by 
phenylalanine 44 (F44) is indicated. The figure was created using PyMol software. PDB 
files used were: 1 ZT4 (a), 1GZP (b), 1XZO (c) and ONQ (d).
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MHC class I and CDl structures also exhibit significant differences in the 
region of the CD8 binding loop, which is part of the alpha3 domain. No direct 
evidence has yet been found that CD8 co-receptors bind to any of the CDl molecules. 
However, experimental data generated in mice have strongly suggested that CD8 
expression by iNKT cells induces their negative selection in the thymus166.
Figure 9 shows a view onto the molecular surface of the structures of human 
CDld with bound alpha-galactosylceramide173, human CDlb with bound ganglioside
1 8 1 '  • 38 •GM2 and detergent and HLA-A2 with bound peptide . The figure illustrates that 
the galactosyl head group of CDld bound a-galactosylceramide makes a relatively 
small contribution to the total molecular surface which is exposed to the TCR, while 
the ligands bound to both CDlb and MHC complexes occupy a considerably larger 
area on the molecular surface.
The recently solved crystal structure of a human CDl d/a- 
galactosylceramide/iNKT receptor -  complex has disclosed that most of the TCR- 
CDId binding is mediated by protein-protein contacts187, which might explain the 
known limited structural diversity of iNKT TCRs compared to CDlb and MHC class I 
restricted TCRs.
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Figure 9. A TCR’s view onto CDl/ligand and MHC/ligand molecular surfaces
CDlb/GM2CDld/aGC
HLA-A2/peptide
Molecular surfaces o f CDld/KRN7000 (upper left), CDlb/GM2+detergent (upper 
right) and HLA-A2/peptide complexes are shown. The protein is shown as molecular 
surface with acidic groups in red, basic groups in blue, thiols in yellow and carbon 
atoms in grey. The bound ligands are shown as Van der Waals speres with carbon 
atoms in yellow, nitrogens in blue and oxygens in red. The bound detergent molecule 
in the CDlb structure is shown in orange. The figure was created with PyMol 
software. PDB codes used: CDld/a-GalCer (1ZT4), CDlb/GM2 (1GZP), A2/peptide 
(1AQ7).
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1.10.5. C D l ligand loading and intracellular trafficking
The fact that different CDl molecules can present the same ligand, e.g. sulfatide, to 
different T lymphocytes, illustrates their somewhat promiscuous ligand binding 
properties. However, the different CDl isoforms are still highly likely to present 
different lipid antigens to T lymphocytes in vivo, because they patrol different cellular 
compartments where they capture their lipid ligands. Like other glycoproteins in the 
ER nascent CDl polypeptides associate with calnexin, calreticulin and ERp57 during
188 189early refolding stages 3 . After binding to [32m and perhaps acquisition of
chaperone lipid ligands181,190,191, e.g. spacer lipids, phosphatidylcholine, 
phosphatidylinositol or GP1, CDl molecules leave the ER and reach the cell surface 
via the trans-Golgi network. A tyrosine-based cytoplasmic tail motif (YXXZ, where Y 
is tyrosine, X is any amino acid and Z is a bulky hydrophobic amino acid) present in 
CDlb, CDld and CDle mediates the association of these CDl isoforms with adaptor
1 Q9protein complex-2 (AP-2) and subsequent re-internalisation via clathrin-coated pits . 
Human CDlb and mouse (but not human) CDld can also associate with AP-3 and 
traffic from early to late endocytic compartments, including lysosomes, while CDle 
and human CDld traffic from the cell surface to early endocytic vesicles193'195. 
Interestingly, lipid ligands of different alkyl chain length target different cellular 
compartments, and the very long fatty acid containing MA and GMM are recruited 
specifically to late endosomes and lysosomes, i.e. the same compartments surveyed by 
CDlb196
In contrast to CDlb, CDle and CDld, CDla lacks a tyrosine-based motif and 
it is currently unknown how CDla is re-internalised from the cell surfaces. CDla
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shuttles between early endosomes and the cell surface via ADP-ribosylation factor 6 
(ARF6)-regulated recycling pathways197.
A proportion of CDla, CDlb and CDld molecules associate with invariant 
chain (li) in the ER. Association with li facilitates trafficking of CDla to the cell 
surface, while it enables CDlb and CDld to bypass the secretory pathway and directly 
reach late endocytic compartments198,199. It is currently not understood why CDlb and 
CDld can use two different routes to the same destination and whether they compete 
with MHC class II molecules for binding to “li”.
Some accessory mechanisms involved in the loading and the processing of 
CDl presented lipid ligands have been unravelled. Interestingly, phosphatidylinositol 
(PI) and related ligands have been eluted from mouse and human CDld and human 
CDlb molecules, and studies with ER-retained human CDld molecules have indicated 
that PI is loaded onto CDl in the ER200. An ER-resident microsomal triglyceride 
transfer protein (MTP) has recently been shown to mediate loading of 
phosphatidylethanolamine (PE) onto CDld and to be required for efficient expression
901 909of CDld on the cell surface 5 . However, PI merely serves as a chaperone ligand to
stabilise CDl molecules until exchange of PI for other cargo, e.g. with foreign 
microbial lipids. This is illustrated by the facts that CDld/PI-complexes are not 
stimulatory for either mouse or human iNKT cells, but exogenous lipid antigens can 
be presented by CDl molecules to ligand-specific T cell lines. Furthermore, inhibition 
of endosomal acidification and deletion of the cytoplasmic tail of CDld can have 
deleterious effects on both CDl-restricted T cell activation and thymic selection203. 
Also, deletion of the late-endosome-resident protease cathepsin S, which for its
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function in degradation of MHC class II-associated “li”, negatively affects 
presentation of exogenous lipid antigens by CDld to iNKT cells 204.
Based on the above facts it has been proposed that Pi-loaded and/or “li”-associated 
CDlb and CDld molecules exchange their ligands in endocytic compartments. Further 
support for this model comes from our own studies in mice with lysosomal 
glycosphingolipid (GSL) storage diseases. GSL storage interferes with iNKT selection 
in mice independent of the underlying genetic defects 205.
As indicated above, some CDl-bound glycolipids require processing of their 
hydrophilic headgroups in order to be recognisable for T cell receptors. Proof of 
principle for this notion came from a study using a synthetic galactosyl-a- 
galactosylceramide precursor ligand for iNKT cells. Presentation of this ligand by 
CDld to iNKT cells was dependent on the endosomal hydrolase a-galactosidase 206.
The fifth member of the human CDl protein family, CDle, is the only CDl 
isoform which is not expressed on the surface. CDle locates to the same late endocytic 
compartments as CDld and CDlb do. Interestingly, CDle seems to exert an important 
function in the processing of CDlb presented foreign microbial lipids, such as higher 
molecular weight PIMs. Experimental data suggest that CDle might present 
glycolipids with large headgroups to endosomal enzymes, such as a-mannosidases, to 
enable efficient cleavage of the surplus carbohydrates preventing T cell recognition
165
Ligand processing can also go “the other way”; microbial lipids can acquire 
antigenic groups during the process of tissue invasion. One such example is
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mycobacterial GMM, which is generated upon tissue invasion of mycobacteria by 
esterification of MA with glucose residues provided by the host environment 207.
1.10.6. CDl restricted T cells
1.10.6.1. Group 1 CDl restricted T cell responses
Most of the current knowledge on the biological role of CDl restricted T lymphocytes 
comes from studies on a major subset of CD Id-restricted T cells, i.e. the invariant 
NKT cells (iNKT). In contrast, little is known about group 1 CDl restricted T 
lymphocyte responses. On the one hand, group 1 CDl molecules are not expressed in 
rats and mice, and on the other hand, sensitive and specific research tools to study 
group 1 CDl specific T cells ex vivo in human blood or tissue.are not yet available. In 
addition, only a small number of specific lipid antigens presented by group 1 CDl 
molecules to T lymphocytes have been identified to date. However, it is noteworthy 
that the first CDl restricted T cell lines were isolated from the DN T lymphocyte 
fraction in patients with chronic inflammatory rheumatic diseases, namely rheumatoid 
arthritis and systemic lupus erythematosus (SLE) 144. Interestingly, DN T lymphocytes 
are expanded in those diseases, and group 1 CDl restricted T lymphocyte lines have 
been shown to stimulate autoantibody production by CDl group 1 expressing B-
A O  A A Q
lymphocytes 5 . A recent study found that in vitro generated CDl group 1
restricted T lymphocytes are often autoreactive and can promote dendritic cell 
maturation207, while another study found evidence for CDla and CDle restricted 
autoreactive T cell responses in autoimmune thyroid inflammation210.
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Interestingly, CDle was also found to be the major antigen presenting 
molecule for y61 T cells in the gut, but the function of these cells is still unknown 21 
Surprising little evidence has yet been generated for a role of group 1 CDl restricted T 
cell responses to mycobacterial infection. One study could demonstrate in vivo 
expansion of a-mannosyl-p-phosphoisoprenoid specific CDlc-restricted T cells in 
patients with active tuberculosis but not in healthy controls 178, while another study 
found CDl-restricted IFNy-producing Bacillus Calmette-Guerin (BCG) specific CD8+ 
T lymphocytes in the peripheral blood of BCG-vaccinated donors212.
1.10.6.2. CDld restricted T cells
To date three different types of CD ld restricted T cells have been described in 
humans: Invariant Va24-Jotl8+/Vpl 1+ NKT cells (iNKT); Va24-independent 
CDld/a-Galactosylceramide (a-GalCer) specific T cells; and diverse CD Id-restricted 
T cells with mostly unknown ligand specificity. In the following section I will focus 
on the CDld/a-GalCer specific iNKT cells.
1.10.6.2.1. Definition and phenotype of iNKT cells
Human and mouse iNKT cells are defined by four characteristics: They are restricted 
by CDld; they recognise alpha-glycosylceramides presented by CDld; they express 
the pan-NK marker NKR-P1 (NK1.1 in mice, CD161 in humans); and they make use 
of an invariant TCR alpha-chain rearrangement (Figure 10). Human iNKT cells use 
TCR V a24-Jal8 and mouse iNKT cells use the homologous TCR V al4 -Ja l8 . The 
CDR3a loop, which is highly variable in peptide-specific T cells, is therefore invariant
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in iNKT cells and is highly homologous in human and mouse iNKT TCRs213. 
Interestingly, the same CDR3a loop is also used by a subpopulation of human 
CDld/a-GalCer specific Va24-negative T cells214.
Figure 10. Definition of the CDld-restricted invariant Natural Killer T cells (iNKT)
Mouse*: Vf58.2 
Human: V p ll
Mouse: Val4-Jocl8 
Human: V a24-Jal8
TCR
CDld
NKR-P1 *
(NK1.1; CD161) >8. 1,
Cartoon showing four criteria defining the human and mouse iNKT cell subsets:
1) Expression o f the pan-NK receptor NKR-P1 (mice: NK1.1; humans: CD 161);
2) Use o f a semi-invariant TCR (invariant TCRa chain, variant TCR/3 chain);
3) Restriction by C D ld (ribbon diagram in pink) and
4) Specific recognition o f a-GalCer bound to CD ld
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Mouse and human iNKT cells exhibit both similarities and differences in their 
usage of TCR beta chains. The dominant TCR beta chains used by mouse and human 
iNKT cells are Vp8.1/Vp8.2 and Vpi 1, respectively. Human Vpl 1 is homologous to 
mouse Vp8. However, while no other TCR p chains seem to be expressed by human 
iNKT cells, mouse iNKT cells make use of several additional Vp families, such as 
Vp2, VpiO or Vp7166.
A characteristic of all iNKT cells is their activated memory phenotype, which is 
already present before birth or bacterial colonisation of the gu t215’216. This “ready to 
go” phenotype of iNKT cells is complemented by the expression of specific 
chemokine receptors, such as CXCR2, which are usually not present on T cells but are 
expressed on granulocytes. Subsets of CXCR2+ iNKT cells migrate within 3 hours to 
the site of acute inflammation, together with neutrophilic granulocytes and long before 
any “conventional” peptide-specific T lymphocytes217. Their phenotype might 
therefore enable iNKT cells to bridge innate and adaptive immune responses, a notion 
clearly underpinned by their functional versatility.
1.10.6.2.2. Possible roles for iNKT cells in health and disease 
The discovery of the first a-galactosylceramide ligand, KRN7000, as a potent 
stimulator of all human and mouse iNKT cells153 empowered immunologists with an 
important tool to study the possible role of CD Id in health and disease.
When injected into mice, KRN7000 induces the rapid secretion of copious 
amounts of a wide range of cytokines. Such studies have revealed that iNKT cells are 
the main source of the early IL-4 cytokine burst which is observed after i.v. treatment
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of mice with anti-CD3 antibodies166. Conversely, KRN7000 stimulates strong 
secretion of IFNy by iNKT cells with subsequent transactivation of NK cells, dendritic 
cells and other immune cells218. Human iNKT cells induce IL-12 secretion by 
dendritic cells and they are also able to direct monocytes into a dendritic cell 
differentiation pathway219,220.
Several KRN7000-based studies in mice have found that iNKT cells could 
induce protection against tumours and against viral and bacterial infections213. 
Similarly, KRN7000 and related synthetic iNKT stimulatory compounds have been
701 000shown to exert strong adjuvant effects during peptide vaccination ’ . However,
first clinical trials using KRN7000 in cancer patients have been disappointing 223. 
Possible reasons for this may include the profound defect in iNKT cells which is often
224seen in cancer patients and/or possible anergy of iNKT in cancer patients. However, 
the results of KRN7000-based studies are unlikely to reflect the main physiological 
functions of iNKT cells in vivo as KRN7000 induces complete ablation of iNKT cell 
development when added to fetal thymic organ cultures225. Moreover, alpha- 
glycosylceramides cannot be synthesised in mammals, and the identification of alpha- 
anomeric glycosphingolipids in rare bacteria species cannot explain the high degree of 
iNKT conservation in mammals.
Interestingly, the synthetic alpha-galactosylceramide OCH, which features an 
identical galactosyl headgroup as KRN7000 but a considerably shorter sphingosine 
chain (C9 sphingosine) than KRN7000 (C l8 sphingosine), elicits a significant, but 
weaker and qualitatively different in vivo response in iNKT cells than KRN7000226. In 
particular, i.v. injection of OCH into mice hardly induces any IFNy, while it still
57
996induces a strong IL-4 secretion . This TH2-biasing effect of OCH has been used in 
translational studies where it could be shown that OCH treatment could prevent 
autoimmune inflammation in TH1-biased models, such as type 1 diabetes, collagen 
induced arthritis and experimental allergic encephalitis (EAE)227. Importantly, 
protection from autoimmune inflammation can also be achieved by adoptive transfer 
of iNKT cells from healthy donor mice into autoimmune-prone mice228. Interestingly, 
several autoimmune-prone mouse strains, such as NOD and SJL, which had been used 
as models for autoimmune inflammation long before anything was known about iNKT 
function, were later demonstrated to exhibit profound defects in the iNKT repertoire.
A few studies have analysed the human iNKT repertoire in autoimmune patients. 
Interestingly, iNKT cells are deficient in classic human autoimmune diseases such as 
RA, Sjogren syndrome or scleroderma 229, but the reason for this deficiency is 
completely unknown. On the other hand, the frequency of iNKT cells in humans 
shows wide variation and healthy individuals without apparent autoimmune 
inflammation may have very low INKT frequencies (own observations). In the 
absence of a known endogenous iNKT stimulatory ligand, iNKT deficient animals are 
likely to give the most relevant information about the true physiological function of 
iNKT cells in vivo. Mice with a targeted deletion of the Ja l8  gene, which encodes the 
junctional element forming the invariant CDR3a loop of the iNKT TCR, are 
completely deficient in iNKT cells, while other immune cells are not affected230. 
Interestingly, these .M8"7' mice develop a spontaneous late onset autoimmune disease 
with strong resemblance to SLE 231.
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The above facts are all consistent with a role for iNKT cells in maintaining or 
inducing immunological tolerance. In fact, this notion is supported by evidence from 
in vitro and in vivo studies. In the model of anterior chamber-associated immune 
deviation (ACAID) iNKT cells are essential for the induction of antigen-specific 
systemic tolerance 232. Both GDI'7' and J a 2 8 r7' NKT cell deficient mice do not 
develop ACAID unless reconstituted with iNKT cells. A model how iNKT cells might 
assist in the induction of ACAID can be drawn from the studies of Sonoda and 
colleagues and Faunce and colleages (Figure 11) .
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Figure 11. Role for iNKT cells in systemic tolerance via immuneprivileged sites
Cartoon o f the ACAID model: Bone marrow derived F4/80 suppressor macrophages 
reside in the anterior chamber (a.c.) o f  the eye where TGF/3is present at high 
concentrations. Upon a.c. injection o f antigen the antigen is taken up by F4/80 
macrophages, which migrate to the spleen and start to express MIP-2 and recruit 
thymic iNKT cells. iNKT cells in the spleen secrete RANTES, recruiting more F4/80 
macrophages. 7 days later, microclusters o f  F4/80 macrophages, iNKT cells, CD Id- 
expressing B-cells and CD8 T cells are found in the spleen. RANTES and IL-10 
produced by iNKT are essentially required fo r  tolerance induction in ACAID223' 224.
The model proposes that antigen-specific tolerance is imprinted on naYve T 
lymphocytes within microclusters of suppressor macrophages, iNKT cells and CD Id- 
expressing B-lymphocytes. Cell-cell contacts of the naYve T lymphocytes with both 
F4/80 macrophages and iNKT cells are important in this process, and secretion of
Antigen injected into Antigen loaded
anterior eye chamber MIP-2+ F4/80
RANTES
[arrow
Thymus
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RANTES and IL-10 by iNKT cells is an absolute requirement for induction of ACAID 
in mice.
Apart from ACAID, iNKT cells have been shown to be essentially required for 
long term acceptance of cardiac allografts and of rat pancreatic islet xenografts in 
LFA-l/ICAM-1 and CD28/CD80 monoclonal antibody blocking models236,237.
The other side of the coin of the tolerogenic effects of iNKT cells might be a 
suppressive effect on tumor immunosurveillance. Using a fibrosarcoma tumor model 
with a growth-regression-recurrence pattern, Terabe and colleagues have elegantly 
shown that IL-13 secretion by iNKT cells via activation of the 1L-4 receptor/STAT6 
pathway attenuates the initial anti-tumor cytotoxic T lymphocyte response, thereby 
interfering with complete elimination of the injected fibrosarcoma cells238.
In summary, iNKT cells are very versatile T lymphocytes that can bridge 
innate and adaptive immune response. In the absence of infection iNKT cells seem to 
be important for both the maintenance and induction of immunological tolerance.
Coreceptors are likely players regulating INKT functions. The most 
conspicuous coreceptor for iNKT cells, which is highly expressed on the majority of 
human iNKT cells, is the lectin-type NK receptor NKR-PIA (CD161). This receptor is 
also expressed on the majority of NK cells. Ligation of CD161 via its recently 
described natural ligand, lectin like transcript-1 (LLT1) evokes different responses 
from NK and NKT cells239. While NK cells are inhibited by CD161 -LLT1-binding, 
NKT cells are activated. Previous studies using monoclonal antibodies have 
demonstrated, that CD161-crossIinking is not stimulatory for iNKT cells on its own, 
but requires simultaneous TCR crosslinking, e.g. via anti-CD3 antibodies240. These
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data are consistent with the concept that different signals, coming from TCR- and 
costimulatory receptor/ligand ligation, are integrated by iNKT cells in order to shape 
one or another type of response.
1.10.6.2.3. Molecular interaction of iNKT cells with antigen presenting cells 
While iNKT cells can rapidly migrate to the site of acute inflammation in a CD Id- 
independent way, all relevant functional iNKT responses described to date require 
binding of the iNKT TCR to CDld. We and others have used recombinant human 
iNKT TCRs to measure their binding to CDld/lipid-complexes and study their atomic
241 242structure ’ . The binding studies have shown that human iNKT TCR bind with
relatively high affinity to CDld/KRN7000 complexes, with very fast ON- and OFF- 
rates241. We have analysed the structures of three different CDld/KRN7000-specific 
human TCRs, two of which were Va24-negative. Interestingly, sequencing analysis 
has revealed that these Va24-negative TCRs, like iNKT TCRs, also use the Ja l8  
junctional segment to bind to CDld/KRN7000241. In addition, Vpl 1 is the dominant 
TCR f3 chain used by these Va24-negative TCRs214. The recently solved crystal 
structure of a ternary CDld/a-galactosylceramide/iNKT TCR complex has provided 
further fascinating insights. In particular, the ternary complex structure has disclosed 
that the iNKT TCR docks virtually parallel to the CD Id-binding cleft and that the 
position of the iNKT TCR is shifted towards the COOH-terminal end of CDld (Figure
1 8712b) . In the published structure the polymorphic CDR3p loop makes no contacts
with the bound glycolipid ligand and only minimal contacts with the CDld protein 
(Figure 12c). Importantly, detailed analysis of this interaction showed that only very
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little binding energy is provided by contacts of the iNKT TCR to the glycol ipid ligand 
and that the great majority of contacts are protein-protein contacts between the 
CDR3a and CDR2P loops of the iNKT TCR with the alphal helix of CDld 243. Based 
on these facts it can be argued that the iNKT TCR behaves more like an innate 
receptor than an adaptive T cell receptor.
Figure 12. CDld recognition by iNKT TCR
Ribbon diagrams fo r  comparison o f the docking o f a peptide-specific TCR onto MHC 
class I/peptide complex244 (a) in grey colours (PDB 2VU) with docking o f a human 
iNKT TCR onto CDld/a-GalCer (b, c). NKT TCRa chain in blue, TCR/3 chain in gold, 
CD ld in green, lipid shown as Van der Waals spheres with carbon atoms in yellow, 
nitrogen in blue, oxygen in red (PDB 2P06)187. (c) Detail showing CDR3(3 loop 
position..
!>Rlra
( l ) R J a
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1.11. Objectives of the thesis
In 1996 I identified and clinically characterised a primary immunodeficiency 
syndrome in 6 patients with bronchiectasis, necrotising granulomatous skin lesions, 
and strongly reduced cell surface expression of MHC class I molecules.
The first objective of my PhD was to unravel the molecular mechanisms and 
genetic defects causing the reduction of MHC class I cell surfaceexpression in these 
patients.
Another objective of my studies was to delineate the immunological processes 
leading to the mutilating granulomatous skin lesions in these patients.
In light of the severe defect in MHC class I antigen presentation I was 
intrigued by the fact that none of my patients had ever suffered from mycobacterial 
infections. This led me to ask the question whether peptide-independent antigen 
presentation via CDl molecules could protect MHC class I deficient humans from 
tuberculosis. My PhD therefore also aimed at developing sensitive and specific tools 
to study CDl-dependent T lymphocytes.
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2. Methods
Identification o f TAP deficient Patients
The index patient (“AK”) was treated for suspected Wegener’s granulomatosis (WG), 
an autoinflammatory disease, at the time when I joined the Rheumaklinik Bad 
Bramstedt (the German national vasculitis centre) in 1996. Why 1 doubted the 
diagnosis of WG and how “AK” was diagnosed with type 1 BLS is described in the 
introduction of the first results chapter (p. 87). When studying “AK’s” clinical files 
(going back to the early eighties) I came across a handwritten letter from Capa 
University in Istanbul, describing a first-degree relative of “AK” - “FT”- with similar 
skin lesions who lived in Turkey, near Istanbul. After having found her dermatologist 
in Turkey, Dr. Cem Baykal, he kindly asked “FT” to participate in our studies and 
arranged for the patient’s peripheral venous blood to be taken and sent over to Oxford. 
By searching the Medline database I identified another potential patient with a highly 
similar clinical syndrome of unknown cause245.1 contacted the patient’s doctor in 
Brussels, Maria Willemsen, who also kindly arranged for the patient’s blood to be 
tested for Ml 1C class I expression and then be sent to Oxford after informed consent. 
This was patient “NP”. Through Edouard Grosshans, a pathologist at Strassbourg 
University, who had previously published a few patients with necrotising 
granulomatous disease of unknown origin in France I made contact with Dr. Julien 
Lambert, a dermatologist in Brussels who cared for patient “NV”. Dr. Julian Lambert 
also very kindly arranged for “NV’s” MFIC class I expression to be tested and for her 
peripheral heparinised blood to be sent to Oxford. After having studied the clinical 
files of “AK”, “FT”, “NV” and “NP”, all of whom shared a similar clinical syndrome
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with recurrent infections of the respiratory tract and mutilating necrotising 
granulomatous skin lesions, I sent letters to all Swiss Dermatology Clinics, describing 
the clinical syndrome. Prof. Stanislaw Buechner from the Dermatology Clinic at the 
University of Basel responded to my letter and he arranged an interview between the 
family of patient “GAB” and me at the University Hospital in Basel. “GAB’” s sister 
“SAB” was also present during the interview. Although “SAB” didn’t suffer from skin 
lesions, it became very clear during the interview that she also suffered from recurrent 
respiratory infections. Both “GAB” and “SAB” gave informed consent to participate 
in the study and their blood was sent to Oxford for later analysis. “GAB” and “SAB” 
are still my patients today. A year after I had come to Oxford to study the molecular 
and genetic basis of this syndrome I received a phone call from my former colleague at 
the Rheumaklinik Bad Bramstedt, Dr. Peter Lamprecht, who had just made a diagnosis 
of type 1 BLS in a patient. The patient, “BS”, had just been admitted three days before 
with a suspected diagnosis of Wegener’s granulomatosis. The same week I travelled to 
Bad Bramstedt to interview the patient and view the clinical files. “BS” very kindly 
donated a venous blood sample for my studies which I brought back to Oxford.
Flow cytometry for analysis o f  TAP patients
The following antibodies were used at 5pg/ml to detect MHC class I surface 
expression in different experiments: W6/32 (stains HLA-A,B,and -C molecules), 
MA2.1 (stains HLA-A2 and -B57), 4D12 (stains HLA-B51), and Tl 16-5-28 
(Saxon/UK; stains HLA- A32,and -B44), followed by FITC-goat-anti-mouse F’ab 
(DAKO). Staining was done on ice in FACS-buffer (phosphate buffered salline/1%
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FCS). Cells were washed twice with FACS-buffer in between and after antibody 
stainings and fixed in FACS-buffer plus 4% formaldehyde before fluorescent activated 
cell sorter (FACS) analysis (FACScalibur, Becton & Dickinson) or 
immunofluorescence microscopy (Zeiss, Germany).
The following antibodies were used to phenotype the patients’ PBMC : 
Antibody specific for CD94 (F1P3B1; IgG), and immunoglobulin-like transcript 2 (ILT 
2; 3F1) were used for both fluorescence-activated-cell-sorter (FACS) analysis and 
immunostaining of cryostat sections. y§ T cells were stained with the monoclonal 
antibody B1 (IgGl). The variable 81-chain (V51)-specific antibody A13, and variable 
52-chain (V52)-specific antibody, 4G6 (IgGl) were kindly provided by Gennaro De 
Libero (Kantonsspital Basel, Switzerland), and were used to measure the 51 to 82 ratio 
in PBMC and for immunostaining of cryostat sections.
Processing o f  lesional skin biopsies
Frozen skin biopsy sections were stained by streptavidin-biotin immunoperoxidase 
technique and counterstained with Mayer haematoxylin.
HLA typing o f  patients
HLA class I and class II typing was carried out by PCR using sequence-specific 
primers (PCR-SSP) at the Oxford Transplant Center (Churchill Hospital, Headington, 
Oxford).
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B-Lymphoblast cell lines
Immortalised B-cell lines “AK”, “FT”, “NP”, NV”, “SAB”, “GAB” and “BS” were 
generated by transformation of B-cells with Epstein Barr virus according to standard 
protocols. Lines “AK” and “FT” were generated by Helene Teisserenc before my
arrival in Oxford. Briefly, 5-10 x 10^ PBMC were suspended and incubated in 2 ml of
O
EBV-containing cell-free supernatant from B-958 marmoset cells at 37 C, 5% CO2 . 
After 2 hours, 8 ml of cell culture medium (RPMI, 20% FCS) supplemented with 1 [ag 
cyclosporin A (final concentration 0.1 pg/ml cyclosporin A) were added. The cells 
were transferred to a T-25 tissue culture flask and incubated in an upright position. 
After successful transformation the patients’ EBV B-lymphoblast lines were cultured 
in RPMI and 10% FCS, supplemented with 1% penicillin, 1% streptomycin and 1% 
glutamine ( -  R10).
721.174 is a human lymphoblastoid cell line, generated in the laboratory of 
Rob De Mars91, which lacks both TAP genes and expresses only the HLA-A2 and 
HLA-B51 class I molecules. 721.174.TAP is a stable transfectant of 721.174, 
expressing TAPI and TAP2. 721.220.B44 is a tapasin-deficient, stable transfectant 
derived from 721.220, which expresses only the HLA-Cwl- and HLA-B44 class I 
molecules.
Cell lines 721.174.TAP and 721.220.B44 were cultured in R10 
supplemented with 1 mg/ml G4'18 (Gibco). Cell lines .45 and LG2 are TAP and 
tapasin-competent positive control B-cell lines.
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Metabolic labelling o f  B-lymphoblast lines
B-cells growing in log phase, 2x107 per experiment, were cultured for lh in 
Methionine-free medium and labelled at high density (5xl07/ml) with 300pCi 35S- 
methionine for 20 minutes at 37°C. For some experiments, cells were first labelled
* * 3 5 *with 300pCi S- methionine overnight (16h), washed once in methionine-free 
medium, and labelled again with 3Q0pCi 35S-methionine for 20 minutes or used 
directly without a second labelling step. Samples were then washed twice with ice- 
cold PBS before further processing.
Isoelectrofocusing o f metabolically labelled MHC class I  molecule 
35S'methionine labeled EBV B-lymphoblasts from patient AK and from control B-cell 
lines were lysed with 1% NP-40 either immediately after the 35S'methionine pulse or 3 
hours or 15 hours after washing the cells and the addition of the chase medium. MHC 
class I molecules were immunoprecipitated as described below with the anti-MHC 
class I antibody W6/32 and protein A sepharose beads and then separated by an 
isoelectrofocusing gel and exposed to autoradiograph film.
Immunoprecipitation
Metabolically labelled B-cells were washed twice with ice-cold PBS and lysed with 
1% NP40 or 1% digitonin for immuno- and co-immuno-precipitation, respectively. 
Immunoprecipitation with protein A-Sepharose beads (Sigma) and specific antibodies 
(rabbit-anti-human TAPI antiserum AK13; mouse anti-human TAPI monoclonal 
antibody 147.3) was carried out after an overnight preclearing step at 4°C with
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formalin-fixed Staphylococcus aureus and normal rabbit serum. The beads were 
washed four times and proteins were eluted by boiling the beads for 5 minutes in 
Laemmli sample buffer. The samples were separated by 10% sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). The gel was dried and exposed to 
autoradiograph film (Kodak) or analysed with phosphoimager.
Western immunoblotting
Total 1%NP40 cell lysates of patients’ EBV B-lymphoblast lines and control lines 
were centrifuged at 10,000 rpm for 5 minutes at 4°C using a microfuge to remove
nuclei, separated by SDS-PAGE (with an equivalent of 3xl05 to 1x10^ cells per lane) 
and transferred onto a Hybond-C membrane (Amersham). The membranes were 
probed with rabbit sera to the C-terminal portion of human TAPI (AK13) and TAP2 
(AK8), or the monoclonal mouse anti-human TAPI antibody 147.3 (kindly provided 
by Robert Tampe; Max-Planck Institute, Martinsried, Germany) in blocking buffer 
(5% Marvel milk/0.1% Tween20). After several washes in PBS/0.1% the membranes 
were exposed to the secondary antibody (HRP-conjugated goat anti-rabbit or goat anti­
mouse), washed, developed with amplifier reagent (ECL; Amersham Pharmacia) and 
exposed to autoradiograph film (Kodak).
Transient fusion o f TAP-deficient and TAP-competent B-cell lines 
B-cell lines used for fusion experiments were grown to log phase, and 15xl06 cells of 
each B-cell line, i.e. each fusion partner, were used per experiment. Two fusion 
partners were thoroughly mixed, washed, and resuspended in 5ml R10 containing
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25ug/ml PHA-P (Sigma). After incubation for lhr at 37QC cells were spun at 400G. To 
the cell pellet, 400ul of 37°C warm fusion buffer (50% PEG 1300-1600 and 5%
DMSO in PBS) was added drop wise over 1 min. After incubation at 37°C for 1 min. 
15ml of 37°C warm PBS were added drop wise over 2 min., followed by gentle 
centrifugation at 250G and careful resuspension of the cells in 10ml 37°C PBS. After 
incubation for 30min. at 37°C, cells were centrifuged at 400G and resuspended at 
106/ml in R10. After 24h in culture, cell viability was checked by trypan blue staining 
and fresh R10 was added to adjust cell density to 0.6 x 106/ml. On the next day, fusion 
products were stained with HLA-specfic antibodies and analysed by 
immunofluorescence microscopy and FACS.
Restoration o f class I  expression in TAP-deficient EBV B-lymphoblast lines with a 
recombinant TAP 1/TAP2-encoding vaccinia virus (TAPs-VAC)
2-5 million immortalised EBV B-lymphocytes were infected for 1 hr at 37°C with a 
recombinant vaccinia virus (“TAPs-VAC”), encoding both human TAPI and TAP2 
proteins 246, or a recombinant control vaccinia virus (“Influenza matrix protein VAC”) 
at 5 plaque forming units/cell and stained with W6/32 and a FITC-labelled anti-mouse 
antibody, before FACS analysis. Both recombinant vaccinia viruses were kindly 
provided by Jonathan Yewdell (Bethesda, USA).
Peptide translocation assay
5 x 106 B-lymphocytes per experiment were used. Cells were washed once in 
incubation bufffer (5mM Flepes, pIT 7.30, 130mM KC1, lOmM NaCl, lmM CaCft,
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2mM MgCl2 , and 2mM EGTA) and permeabilised with 2 U/ml streptolysin 0  (Sigma) 
for 10 minutes at 37°C in 50pl incubation buffer. Then, 1 Ojul of 125iodine-labeled 
peptide RRYQNSTEL, 10pl of lOOmM ATP and 30pl of incubation buffer were 
added and the samples incubated for another 5 minutes at 37°C, followed by lysis in 
1% NP40-buffer on ice. After centrifugation to remove cell nuclei, the glycosylated 
peptide fraction was isolated using concanavalin A sepharose beads (Sigma) and the 
radioactive peptide fraction quantified with a gamma-counter.
Radiolabeling o f the peptide “RRYQNSTEL”
The peptide RRYQNSTEL is used for TAP translocation assays because it contains 
both a tyrosine (Y) which can be labelled with iodine and a “NST” glycosylation motif 
94. Stock solutions of radioiodinated peptide RRYQNSTEL were prepared at lOmM 
concentration in water after removal of free iodine by Sephadex G10 columns. Briefly, 
lOpl (ImC) of 125iodine (Amersham Pharmacia) were added to 2 washed iodobeads 
(chloramine-T beads; Pierce) and 90pl PBS in a 1.5ml Eppendorf tube and left at room
1 9 S 1 9 S
temperature for 5 minutes to transform iodine into the active form iodide, lmg of 
RRYQNSTEL peptide in 100 pi PBS was added and left at room temperature for 15 
minutes. The reaction was stopped by removing the iodobeads. Excess free iodide was 
removed from the iodinated peptide by separating the reaction mix on a Sephadex G25 
column.
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TAP 2 gene analysis in patient “A K ”
The TAP2 coding sequence was determined on both strands by DNA sequencing using 
an Applied Biosystems automated sequencer. PCR amplification of exons 5 and 6 of 
the TAP2 gene was performed using the forward primer 
S’TGGTGTTTGCTGGCCCTCS’ (position 45811) and the reverse primer 
5’GAGAGCAGGCT TGGCTTC3’ (position 46354). Restriction fragment length 
polymorphism analysis was carried out using the Hpall restriction enzyme247 (data not 
shown).
RT-PCR and sequencing o f  TAP 2 in patient “B S ”
Total RNA was prepared from “BS” B-cell line with RNAzol reagent and single­
stranded cDNA was synthesized by reverse transcription using Moloney murine 
leukemia virus reverse transcriptase and an oligo(dT) adaptor in a reaction volume of 
50pl. Genomic DNA was purified from BS B-cell line using Purogene DNA isolation 
kit. Overlapping segments of BS TAP2 cDNA were amplified using the following 
primers: 5’ACCTCAGCGCTGAAGCAGAAGTCC (FP1), 5’AGCT 
GGTCACTGTGGG CTGTTCTG (FP2), 5 ’GAGACTAAGACAGGGGAGCT GAAC 
(FP3), 5’GAACGCGC CTTGTACCTGCTCGA (FP4), 5’CCTGTGCTCAAGGG. 
GCTG ACGTTT (FP5), 5’GAT GTAGGGGAGAAGGGAAGCCAG (FP6), 
3’AGTATCCCTGGGGCCTCAG TCCAT (RP1),
3 ’AGCCGCCATCACCTTATCATCTTC (RP2), 3’GTAGGAGAAAACCTTCT 
CTGCAGC (RP3), 3’CTGATGGCGGGTGTTGTACA CCTT (RP4), 3’GTCAAAA 
TCACCTCCCAGGATGTC (RP5), 3’TAGCTTTAGCAG CCCC CACAGCCC
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(RP6). For amplification of genomic TAP2 intron 6 DNA of patient “BS” the 
following primers were used: 5,GATCTGGGGGCCTGCTGTCTTTGC (FG1), 
5’AAAAGTGTATAACAACAAAGCC ATTATC (FG2), 5’TCCAAGAGGCACACA 
ATGTC TGG (FG3), 3 ’AGCACAGGATGTATACA TGTGAG (RG1), 
S’CTCCTTAAATGCAGGCACTGTGCC (RG2), and RP3 (see above). All PCRs 
were done in a final volume of lOOpI with 200pM of each deoxynucleoside 
triphosphate, 0.4pM of each primer, 2.5 units of Expand High Fidelity polymerase 
(Boehringer Mannheim) and lOpil of the corresponding lOx reaction buffer. After an 
initial denaturation step at 95°C for 2 min., amplification was carried out for 10 cycles 
of 95°C for 1 min., 55°C for Imin., and 72°C for 4min., followed by 26 cycles of 95°C 
for lmin., 60°C for lmin., and 72°C for 3min. PCR products were analyzed by 
agarose gel electrophoresis. Amplified TAP2 segments were gel purified using Qiagen 
gel purification kit and sequenced using the corresponding primers by automated 
sequencing. DNA sequences were analysed by EditVIEW, DNAstrider, and Clustal W 
prgrams.
Generation o f TAP-patients ’ NK and yS T lymphocyte clones
y§ T cells derived from patients “AK” and “FT” were sorted with the pan-y5 antibody 
B1 and cloned in 96-well plates at 1-5 cells per well. y5 clones were maintained in 
Iscove medium, containing 5% human serum supplemented with 200 U of 
recombinant IL-2. The irradiated B-lymphoblast line LG2 and peripheral-blood 
mononuclear cells from normal volunteers were used as feeder cells. Natural killer 
(NK) cell lines were obtained from patient “GAB” after two rounds of negative
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selection using antibodies to CDS and CD 14. The lines were restimulated in Iscove 
medium containing 5% human serum plus 1000 U recombinant interleukin 2. B-cell 
lines LG2 and “GAB” were irradiated and used as feeder cells for natural killer cells.
Cytotoxic activity o f  TAP deficient yS clones and NK polyclonal lines 
Chromium release assays with TAP-deficient effector and different target cell lines 
were carried out according to the standard protocol described below (“Chromium 
release assays”). In a first series of experiments three y8 T cell clones (y8 clones 1,7, 
12) from patient “FT” were tested against EBV transformed B-lymphoblasts from 
patient “AK” as well as against the MHC class I-negative and -positive control lines 
721.221 and LG2, respectively. “FT” and “AK” B-lymphoblast lines were derived 
from first degree relatives sharing an identical HLA-haplotype. Target cells, i.e. “AK” 
B-lymphoblasts were infected overnight either with recombinant TAP-vaccinia 
(“TAPs VAC”) or recombinant “Influenza matrix protein VAC” as a control. In 
further experiments the y5 clone 6G11 from patient “GAB” was tested against 
autologous “GAB” lymphoblasts after overnight infection with either “TAPs VAC” or 
“Influenza matrix protein VAC” and against 721.221 and LG2. In experiments 
analysing the cytotoxic activity of an NK line obtained from patient “GAB” the 
following target cells were used: EBV transformed B-lymphoblast lines “GAB” and 
“AK”, NK target lines 721.221 and K562 and the class I positive B cells line LG2.
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Generation o f human CD lb  and CD ld encoding plasmids fo r expression o f the 
extracellular domains in E.coli.
The extracellular alpha l-alpha3 domains of human CD lb (Swiss-Prot entry 29016) 
and human CDld (Swiss-Prot entry P I5813) were amplified by PCR and cloned into 
the prokaryotic expression vector pET23d (NOVAGEN, USA) using an Ncol 
restriction site (CCATGG) in the sense primer and a BamHI restriction site 
(GGATCC) in the antisense primer. As a template I used cDNA derived from my own 
monocyte-derived dendritic cells (see protocol for generation of Mo-DC below). The 
following oligonucleotide primers were used to amplify human CDl d: Sense primer: 
GACGCCATGGTACCA CAAAGACTTTTCCCA; Antisense primer: 
GCTGCGGATCCCGGACCCCAGTAG AGGACGATG TCCTGG. Primers used to 
amplify human CD lb: Sense primer:
G ACGCCATGGG AT CT G A AC AT G CTTT CC AG GGTCCTACC; Antisense primer: 
GCTGCGGATCCCGGACCCCAGTATTCGATTTT CTGAGC.
The PCR mix (per one 1 OOpl reaction) typically contained 0.4pM of each 
primer, 0.2mM dNTPs, 1 pi of the enzyme (Expand High Fidelity polymerase from 
Roche), lOpl of the lOx Expand High Fidelity reaction buffer (Buffer 2, Roche) and of 
lpl of the template. The PCR reactions were run on a Px2 gradient cycler (Thermo 
Hybaid). All restriction enzymes were from New England Biolabs. NcoI/BamHI - 
double digested pET23d plasmid and PCR products were gel purified before ligation 
using T4 ligase (New England Biolabs). E.coli strain DFI5a was transformed with the 
ligation product and spread onto (lOOpg/ml) ampicillin-supplemented Luria Broth 
agar plates. Bacterial colonies were screened by PCR using the original cloning
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primers and 3-5 of the positive colonies were selected for plasmid purification using 
Miniprep kits from Qiagen. Plasmid sequences were determind by the Oxford 
Biochemistry Sequencing Facility and results controlled using the software Edit View. 
The plasmid pET23d-(32m was a gift of Dr. Bent Jacobsen.
Generation o f recombinant human inclusion body proteins
All proteins used for in vitro refolding were synthesised in E. coli strains BL21 and 
Rosetta according to standard protocols 248. In brief, competent bacteria were 
transformed with expression plasmids and single colonies were grown to log phase in 
ampicillin (100qg/ml) supplemented low salt Luria broth (5gNaCl, lOg 
BactoTryptone, 5g yeast extract in 1000ml H20). When growth reached an optical 
density ODeoo of ca. 0.5 AU protein expression was induced with 0.6mM IPTG 
(Melford Laboratories). Bacterial pellets were harvested ca. 4 hours later, resuspended 
in ice-cold PBS and sonicated to break up the cells and liberate the inclusion bodies. 
The inclusion bodies were washed several times with Triton-Xl 00 containing buffer 
using a glass homogenizer before they were solubilised at 5-10mg/ml in a buffer 
containing both reducing and chaotropic agents, i.e. DTT (20mM) and either 8M urea 
or 6M guanidinium hydrochloride. Soluble inclusion body protein was separated from 
insoluble material by centrifugation and used immediately or frozen at -80°C.
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Generation o f CDld-tetramers
Oxidative refolding chromatography was applied for in vitro refolding of CDld/p2m 
complexes in the presence of either oc-galactosylceramide (a-GalCer) (Kirin Brewery), 
a-mannosylceramide (a-ManCer) (Kirin Brewery), p-galactosylceramide (p-GalCer) 
(Fluka) or ganglioside GM1 (G-7641 Sigma-Aldrich) lipid ligands, following the 
principles of a protocol previously described 249. Soluble protein fractions were 
concentrated to a volume of 3ml and directly biotinylated as previously described. 
Biotinylated monomeric CDld/(32m/glycolipid complexes were separated from 
soluble protein aggregates and free biotin by FPLC size exclusion chromatography 
using a Superdex75pg 26/60 gel filtration column (Amersham-Pharmacia, Uppsala, 
Sweden), and conjugated to Streptavidin-PE (Sigma-Aldrich).
Liver disease Patient samples
Heparinised peripheral venous blood was obtained from 7 patients (patients 1 to 7) 
with active hepatitis C virus (F1CV) infection during routine follow up visits, and also 
from 4 healthy donors. Peripheral blood mononuclear cells (PBMC) were separated on 
a Ficoll-Hypaque gradient. Human liver specimens were obtained from four patients 
with end stage liver failure due to chronic inflammatory liver disease of various 
etiologies: patient 8, Hepatitis C (HCV); patient 9, HCV; patient 10, HCV; patient 11, 
HCV plus Hepatitis B virus (HBV). Informed consent was obtained from all 
individuals. Intrahepatic mononuclear cells were separated from the liver specimens 
by cutting the tissue into small pieces using a scalpel, followed by incubation at 37 °C, 
for 4 hours in complete medium containing 0.5mg/ml type IV collagenase (Sigma-
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Aldrich) and 0.02mg/ml DNAse (Boehringer Mannheim). The digested tissue was 
passed through a 100pm metal mesh filter, washed twice with PBS, layered over 
Ficoll-Hypaque gradients, and centrifuged at 400xG at room temperature for 20 
minutes.
Mice
Wild type C57BL/6 mice, TAP'7" and (32m'7' mice (deficient for murine MHC class 1 
molecules Db'7' and transgenic for a chimeric HLA-A*0201/Db molecule covalently
250linked to human [32-microglobulin ), were used to study whether the human 
CDld/a-GalCer-tetramer could detect murine.invariant NKT cells. Splenocytes from 
these mice were obtained using the following protocol: spleens were cut into small 
pieces using a scalpel, passed through a 100pm metal mesh filter, washed twice with 
PBS, layered over Ficoll-Hypaque gradients, and centrifuged at 2000 rpm at room 
temperature for 20 minutes. Before immunostaining with CDl-tetramers the splenic 
mononuclear cells were incubated for 10 min. at room temperature with 20pg of 
unconjugated anti-FcR antibody (BD Biosciences).
Generation o f human monocyte-derived dendritic cells (Mo-DC)
PBMC were purified from healthy donors’ buffy coat by layering over Lymphoprep 
(Nycomed, Asker, Norway). Monocytes were then positively selected using magnetic 
beads coated with anti-CD 14 mAbs (MACS, Miltenyi Biotech, Germany). The 
monocyte-depleted lymphocyte fraction (CD 14-negative) was frozen in 
50%R10/10%DMSO/40%FCS in liquid nitrogen until needed. Monocytes were
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cultured in cell growth medium (RPMI 1640, Sigma, Dorset, UK; 10% FCS, 2mM L- 
glutamine, GIBCO, Paisley, UK; ImM non-essential amino acids, ImM sodium 
pyruvate, 55pM 2-mercaptoethanol, penicillin G, streptomycin, all Life Technologies, 
Paisley, UK), containing 50ng/ml GM-CSF (Novartis, Basel, Switzerland) and 1000
U/ml IL-4 251. The monocytes were plated in 6 well costar plates at 4x10^ cells/ml 
(3ml per well). After 4 days, maturation was induced in some wells by adding either 
bacterial lipopolysaccharide (final concentration lpg/ml LPS of Salmonella abortus
equi, Sigma), 50ng recombinant TNF-a (R&D Systems, Minneapolis, USA) or 4x10^ 
irradiated (6 Gy) CD40L expressing B-cells 252. Immature and matured monocyte- 
derived dendritic cells (Mo-DC) were used for phenotypic analysis and in vitro 
priming after 6 days in culture, i.e. 40 hours after induction of maturation.
T lymphocyte in vitro stimulation
Monocyte-depleted or total PBMC were plated in 24-wells at 1x10^ cells/ml in cell 
growth medium. The following culture conditions were chosen: 1) Freshly isolated or 
thawed PBMC (2x10^) from a single donor, cultured in the presence of lOOnM aGC 
(KRN7000; Kirin Brewery, Gumna, Japan); 2) Co-culture of 2x10^ monocyte- 
depleted, thawed lymphoctes and 2x10^ autologous, aGC pulsed immature or matured 
Mo-DC, respectively. For pulsing of Mo-DC with aGC, cells were cultured for 2h in 
24-wells in a volume of 200pl RPMI 1640 containing lpM aGC, followed by addition 
of 2x10 6  lymphocytes in 1.8ml of the above medium (i.e. lOOnM final aGC
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concentration). After 5 days, IL-2 was added to cultures (25 IU/ml). Thereafter, 
cultures were fed every 3-4 days with fresh medium containing IL-2 (1000 U/ml).
Flow cytometry studies using CDld-tetramers
The following antibodies and tetramers were used to stain single cell suspensions of 
Mo-DC and in vitro stimulated T cell cultures : purified anti-CD86 (Pharmingen, San 
Diego, USA), -CD83 (Immunotech, Marseille, France), -MHC-class II (mAh L243; 
ATCC), -MHC-class I (mAb W6/32; ATCC), and PE-conjugated goat-anti-mouse pan 
IgG (SBA, Alabama, USA); APC- and PE- conjugated human CDld-tetramers loaded 
with either aGC or a-mannosylceramide (aMC) were generated as previously 
described 253; F1TC- and PE- anti-hTCR Va24, FITC anti-hTCR Vpl 1 (Serotec, 
Oxford, UK), FITC-anti-CD3, -CD4, -CD8a, PE-anti-CD4 (all from DAKO, 
Kobenhavn, Denmark), FFTC-anti-CD161, PerCP-anti-CD8a, APC-anti-CD8a, -CD3 
(all from BD Pharmingen, San Diego, USA), FITC-anti-TCR V pi, -Vp9, -Vpl2, - 
Vpi6, -Vpi8, -Vp23, and PE-anti-CD8p (all from Immunotech, Marseille, France); 
Initial CD 1 d-tetramer validation experiments and tetramer staining of intrahepatic 
lymphocytes cells were carried out in the following way: Cells were first incubated 
with CDld tetramers for 20 min. at 37°C. After one wash with warm PBS/1%FCS 
samples were stained with monoclonal antibodies on ice and propidium idodide was 
added immediately before FACS analysis to gate out dead cells. For all later studies, 
cells were generally stained on ice for 30 min., washed twice in ice cold PBS/1% FCS, 
and directly analysed. In some experiments, cells were first stained with anti-TCR Vp 
antibodies, followed by CDld-tetramers. In monomer competition experiments, cells
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were first incubated with CDld-a-GalCer monomers for 20 minutes at room 
temperature before addition of CD ld-a-GalCer tetramers on ice for another 30 
minutes. Dead cells were stained with propidium iodide and excluded from the 
analysis. For monomer-binding and chase studies, cells were first incubated on ice 
with CDld/a-GalCer monomers for 30 min., washed twice in ice-cold PBS, stained 
with RPE-Extraavidin (Sigma) on ice for 30 min., and washed twice with ice-cold 
PBS. Then, cells were centrifuged and immediately fixed using 4% formaldehyde in 
PBS (Chase time “0 minutes”) or else they were incubated at 37°C 5% CO2 in a 
volume of 200pl PBS for different chase periods (15, 30, and 60 minutes) before 
fixation. Samples were analysed on a FACScalibur flow cytometer, and data were 
processed using CellQuest software (BD, San Jose, USA).
Cell sorting and generation o f Va24- CDld/a-GalCer tetramer+ cell lines 
For generation of clones and oligoclonal lines, Va24- CDld/a-GalCer-tetramer-t- and 
Va24+ CDld/a-GalCer-tetramer+ cells were sorted by a FACSVantage sorter into 
96-well plates coated with 500ng OKT3 antibody and restimulated with lpg/ml
Phytohemagglutinin (PITA; Sigma, Dorset, UK) and lx l 0^ irradiated feeder cells 
(allogenic PBMC and B-cell line LG2) in medium containing 1000 IU/ml IL-2. 
Established lines and clones were fed every 3-4 days with fresh medium. In order to
generate a polyclonal Va24- CDld/a-GalCer-tetramer+ line 3x10^ cells were sorted 
into OKT3-coated 96-wells and cultured in 200pl of IL-2 containing medium in the 
presence of feeder cells. Purity of all lines was checked after 3 weeks with anti-Va24 
antibodies and CDld/a-GalCer-tetramers. Clones and oligoclonal lines were
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restimulated once with PHA and feeder cells, while the polyclonal line was snap 
frozen in RNAzol (Biogenesis, Ltd, Poole, UK) until further use for spectratype 
analysis of TCR usage.
Chromium release assays
TCR Va24-positive and -negative lines and clones were used as effector cells in a 5h- 
51Cr release assay 14 days after restimulation. Human CD 1 d-expressing C1R cells 
(ClR-CDld, kindly provided by Cesar Milstein) were used as target cells. ClR-CDld 
were labelled for 90 minutes with 51Cr and at the same time pulsed with either 1 pM 
aGC, 1 pM aMC, or vehicle, followed by extensive washing in warm RPMI1640. In 
CD8-blocking experiments, cells were cultured in the presence of the CD8-blocking 
antibody MF8 254 or an irrelevant isotype matched control antibody at 1:100, 1:500, 
and 1:1000 dilution of ascites. Cells were cultured in triplicate in 96-well round 
bottom microtiter plates. Effector:Target (E:T) ratios were 1:1, 3:1, and 9:1. Maximum 
release was determined from supernatants of cells that were lysed by addition of 5% 
Triton-X 100, and spontaneous release was determined from target cells incubated 
without effector cells. Percent specific lysis was expressed as (cpm of sample - cpm of 
spontaneous release) / (cpm of maximum release - cpm of spontaneous release).
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Intracellular cytokine staining
2.5x10^ T lymphocytes were cultured in 48-well plates in the presence of either
glycolipid pulsed ClR-CDld (see above) or lO'^M phorbol myristate acetate (Sigma, 
Dorset, UK) and lpg/ml ionomycin (Sigma). After 90 minutes, 10pg/ml Brefeldin A 
(Sigma) was added to the cultures to block cytokine secretion. After 6h in culture, 
cells were washed twice in PBS and fixed in 2% paraformaldehyde. Intracellular 
cytokine staining was performed after permeabilisation of cells with FACS 
permeabilisation buffer (BD, San Jose, USA), using the following antibodies from 
Pharmingen (San Diego, USA): FITC-anti-IFNy, PE-anti-IL-4, PE-anti-IL-13, and 
APC-anti-IL-2. Four colour analysis was performed on a FACScalibur flow cytometer 
(BD, San Jose, USA).
Spectratyping o f TCR repertoire
Total RNA was extracted from a pure TCR Va24- CDld/a-GalCer tetramer+ 
polyclonal cell line (see above) using RNAzol reagent according to the manufacturer's 
instruction, and single-strand cDNA was synthesized by reverse transcription using 
Moloney murine leukemia virus reverse transcriptase and an oligo(dT) adaptor in a 
reaction volume of 50pl. Oligonucleotides used to analyse the 32 different TCR Va- 
and 24 different TCR Vp- families, as well as the Ca- and CP-specific primers have 
been described 255,256. Each TCR Va- and TCR Vp- PCR product was then used as a 
template for extension, or run-off, reactions using Ca- and Cp-specific nested 
fluorescent primers, respectively. The fluorescent run-off products were subjected to 
gel electrophoresis in an automated DNA sequencer (Perkin Elmer, Bucks, UK), and
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CDR3 size distribution and signal intensities were analysed with GeneScan software 
(Perkin Elmer). Analysis of Vp-joining segments (Jp) was carried out in the same way 
using previously described fluorescent Jp-specific oligonucleotide probes 256.
I  am indebted to Nicolas Dulphy, w>ho designed the spectratype experiments, carried 
out the initial experiments, and closely supervised me on all further spectratype 
experiments.
Generation o f recombinant soluble human CDlb/lipid complexes 
Initial refolding trials of human CD lb using standard refolding techniques for MHC 
class I molecules 257 were unsuccessful. Massive protein aggregation was visible 
almost immediately after addition of the denatured and reduced inclusion body 
proteins to the standard refolding buffer. Based on the assumption that the lipid 
presenting CD lb molecule was more prone to hydrophobic aggregation during early 
refolding stages (in particular during the molten globule state)258 1 designed several 
detergent assisted refolding protocols based on the principles of published protocols
259 272 • •for other proteins " . From the published detergent-assisted refolding methods it
emerged that the optimal detergent and its optimal concentration for refolding would 
be different for each new protein. For the initial refolding trials I chose 9 different 
detergents at 3 different concentrations and used these conditions for CD lb, CD I d and 
FILA-A2. The 81 refolding reactions were carried out in 1ml. To assess whether there 
were qualitative differences between the different conditions I recorded the UV 
spectrum (from 200-320nm) of these “minirefoldings”. At the time when I did these 
experiments, back in the spring of 1999 there was no printer attached to the UV
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spectrophotometer and I had to draw the curves from the machine’s monitor. Based on 
the shape of the curve in the area of expected light scattering I chose the detergent 
CTAB (hexadecyl-triammonium bromide) for further optimisation of the refolding 
protocol. Interestingly, CTAB also led to visible precipitation of HLA-A2 while it 
seemed to keep CD1 molecules in solution. The following paragraph describes the 
final protocol:
For refolding of human CD lb and human (32m the fully denatured and reduced 
inclusion body proteins were diluted into buffer 1 (1M urea, 300mM L-arginine, 
50mM Tris pH 7.5, 2mM EDTA, 5mM reduced glutathione, 0.5mM oxidized 
glutathione) containing 0.5mM hexadecyltrimethyl-ammoniumbromide and either 
phosphatidylinositol (PI; purified from soy bean; Avantlipids, USA) or synthetic 
ganglioside GM2 (kindly provided by Richard R. Schmidt). Excess detergent 
molecules were removed by methyl-(3-cyclodextrin (Fluka), and the refolding mix was 
concentrated using Amicon stir cells (Amicon, USA) and PM 10 membranes 
(Millipore). The soluble protein fractions were separated by size exclusion 
chromatography using fast liquid pressure chromatography (FPLC; Amersham 
Pharmacia) and a Superdex75 prep grade column (Pharmacia) equilibrated with buffer 
2 (Tris 20mM, pH 6.0, 30mM NaCl). Monomeric hCDlb/h(32m-ligand complexes 
were collected at ca. 150ml elution volume and purified again in the same buffer. The 
pure protein peak containing monomeric hCDlb/h(32m-ligand complexes was 
concentrated and used for sitting drop crystallisation.
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Protein Crystallisation
Crystallisation trials of CDlb/lipid-complexes, CDld/a-GalCer complexes and iNKT 
TCR/CDld complex were set up manually in microbridges (kindly provided by Karl 
Harlos) according to the sitting drop method. The proteins were at 5-10mg/ml 
concentration and for manual crystallisation I used 2pl of the protein solution and 1- 
2pl of the precipitant. The best crystals for the complexes of both human 
CDlb/(32m/GM2 and human CDl b/p2m/PI were obtained from 2p,l of protein at 
5mg/ml with lpl of Peglon screen precipitant 19 and 21 (Hampton Research). Crystals 
from both CDlb-complexes diffracted X-rays generated by the in-house beam (of the 
Wellcome Trust Centre for Human Genetics. These crystals were used for data 
acquisition at the Synchotron Facility in Grenoble (France). My crystallisation trials 
with CDld/oc-galactosylceramide complexes yielded only small needle crystals, which 
were not suitable for X-ray analysis. Later on, using another crystal screen and 
methods to dehydrate the crystals it was possible to obtain crystals for data acquisition 
(which resulted in a publication in Nature Immunology 173). My attempts to crystallise 
iNKT TCR/CDld complex (usingNaCl screen from Hampton Research) yielded 
beautiful protein crystals (Figure 13). Unfortunately they did not diffract at all. An 
atomic structure of an iNKT TCR/CDld complex was solved by others and recently
187published in Nature
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Figure 13. Protein crystals of human CDld and CDld/iNKT TCR complexes
Protein crystals o f  human CDld/a-GalCer complex (left) and human CDld/a- 
GalCer/iNKT TCR complex (right) are shown. These crystals did not diffract X-rays. 
Structure Determination
The atomic structures of human CDlb/GM2 and human CDlb/PI were determined by 
Nathan Zaccai and Yvonne Evelyne Jones at the Wellcome Trust Center for Human
1 ft 1Genetics. The detailed protocols for structure determination have been published
241
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3. Six patients with defective MHC class I cell surface expression 
due to C-terminal truncation of TAPI or TAP2 proteins
3.1. Introduction
Patients with complex chronic systemic inflammatory disease present the clinician with 
a diagnostic challenge, since diagnostic tests to establish the etiology of such 
syndromes are not available.
In this chapter I will describe the clinical syndrome and the molecular and 
genetic basis in 6 patients with type 1 Bare Lymphocyte Syndrome (BLS). How I 
identifed these patients in different European countries is briefly described in chapter 2 
(“Methods”). The index patient was “AK”, whom I first met in March 1996 on the 
“vasculitis ward” of the Rheumaklinik Bad Bramstedt. “AK” had been treated since 
1990 with various immune suppressive drugs for a suspected diagnosis of “Wegener’s 
granulomatosis” (WG)273. However, “AK” had suffered since early childhood from 
recurrent infections of the respiratory tract, and had suffered several episodes of 
bacterial lung infection before the start of immune suppressive therapies. Most 
strikingly, when I first saw “AK” her nose and cheeks were mutilated by 
granulomatous lesions (Figure 14). Intrigued by this unusual presentation I embarked 
on a complete clinical work up of this patient’s history which revealed the following 5 
facts:
1) Whereas 95% of patients with WG respond to the immunesuppressive regimens 
that had been given to “AK” from 1990 - 1996, i.e. cyclophosphamide 274, the 
disease course of “AK” seemed to have even accelerated under this treatment. A
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photograph of “AK” shortly after the start of cyclophosphamide treatment showed 
an almost intact outer nose (Figure 14a).
2) Computertomography of “AK’” s lungs revealed the presence of bronchiectasis, 
i.e. dilatation of lung bronchi caused by severe structural damage, which are not a 
feature of WG 275.
3) WG is a primary vasculitis syndrome with two different qualities, namely 
granulomatous tissue inflammation and non-immunecomplex inflammation of 
small vessels. When both are present, as was assumed to be the case in “AK” 
(because of the presence of leukocytoclastic skin vasculitis in “AK”), a disease- 
specific autoantibody directed against proteinase 3 (PR3-ANCA) can be detected in 
>98% of WG patients 276. Flowever, PR3-ANCA could never be detected in “AK” 
despite multiple testing by the German reference laboratory for ANCA-testing.
4) Analysis of the disease history revealed that her upper respiratory problems, 
which were assumed to be a typical manifestation of WG had started in early 
childhood. Childhood WG is extremely rare and children with WG suffer also 
from small vessel vasculitis and have PR3-ANCA.
5) “AK” had a first degree relative in Turkey, “FT”, who suffered from very 
similar necrotising granulomatous skin lesions on her legs (Figure 15). Familial 
WG is also extremely rare 211.
While some of these facts seemed incompatible with a diagnosis of WG, the 
combined presence of these features in one and the same patient, “AK”, made WG an 
improbable diagnosis.
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Of note, with the exception, ironically, of “AK”’s relative “FT”, a diagnosis of WG 
had been considered also in all other patients (who were treated in other countries) 
described in this thesis, and all except “FT” had received immune suppressive drugs at 
some stage during their disease. Of note, both the American College of Rheumatology
• • 978 • 97Q1990 criteria and the Chapel Hill 1992 consensus definition could be applied to 
classify the disease in 4 out of the 6 patients as WG.
The diagnosis of strongly reduced MHC class I expression in “AK”, which 
subsequently lead to the same diagnosis in all other patients, was rather incidental. It 
was the result of a very broad immunologic testing of “AK”s serum, secretions, and 
PBMC, once the diagnosis of WG was under doubt.
Once I knew that all patients with the syndrome had reduced MHC class I 
expression I revisited their family histories and found that all patients were children 
from consanguineous parents (i.e. first degree cousins). Tissue typing revealed that all 
the patients were homozygous for the HLA class I and II haplotype which suggested 
that a primary genetic defect within the HLA region could be the underlying cause for 
their granulomatous disease (Table 2).
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Table 2. HLA haplotype in patients with type 1 Bare Lymphocyte Syndrome
Patient HLA-A HLA-B HLA-C HLA-DR HLA-DQ
A K 1 A* 11 
A* 11
B*1502
B*1502
Cw*0801
Cw*0801
DR* 15 
DR* 15
DQ*0601
DQ*0601
F T 1 A* 11 
A* 11
B*1502
B*1502
Cw*0801
Cw*0801
DR* 15 
DR* 15
DQ*0601
DQ*0601
GAB2 A*2601
A*2601
B*4901
B*4901
Cw*0701
Cw*0701
DR* 1301 
DR* 1301
DQ*0604
DQ*0604
SAB2 A*2601
A*2601
B*4901
B*4901
Cw*0701
Cw*0701
DR* 1301 
DR* 1301
DQ*0604
DQ*0604
NV A* 03 
A*03
B*1501
B*1501
Cw*03
Cw*03
DR* 1301 
DR* 1301
DQ*0603
DQ*0603
NP A* 23 01 
A*2301
B*4901
B*4901
Cw*0701
Cw*0701
DR*0301 
DR* 0301
DQ*0201
DQ*0201
BS A*32
A*32
B*57
B*57
Cw*06
Cw*06
DR* 12 
DR* 12
DQ*07
DQ*07
1/2: Patients “AK” and “FT” and patients “GAB” and “SAB” were from the same 
Turkish and Italian families, respectively.
92
3.2. Results
3.2.1. Clinical data 
Patient “A K ”
A 36 year old Turkish female suffered since her childhood from recurrent purulent 
rhinitis with nasal polyps and chronic sinusitis which did not improve after several 
surgical interventions. In contrast, no severe viral infections were documented and a 
humoral immune response against Epstein-Barr virus (EBV), Adenovirus,
Toxoplasma, Candida and Aspergillus was detected (data not shown). At the age of 
10, she developed a chronic spastic bronchitis and from the age of 25, violaceous skin 
lesions appeared in the face and on the legs (Figure 14). Biopsies of the paranasal 
sinuses and skin revealed a severe granulomatous inflammation with infiltration of 
small vessels consistent with a diagnosis of Wegener granulomatosis. This diagnosis 
was later abandoned because of a clear clinical deterioration under treatment with 
immunosuppressive drugs. cANCA specific for proteinase 3 (PR3-cANCA) remained 
negative throughout her life. Multiple tissue culture and acid fast stains failed to 
demonstrate mycobacterial infection, while skin testing with PPD was positive on 
several occasions. Clinical features progressively worsened with a complete 
destruction of her nose, the development of bronchiectasis with recurrent severe 
bronchopneumonia, retinal vasculitis, chronic encephalitis, and leukocytoclastic skin 
vasculitis in the skin of arms and legs (Figure 14). Symptoms were not controlled by 
antibiotic prophylaxis, tuberculostatic drugs and chest physiotherapy. The patient 
developed antibiotic-resistant pulmonary infections and died of respiratory failure at 
the age of 36. Autopsy was declined.
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Figure 14. Clinical manifestations in patient “AK”
Progressive tissue destruction in « AK » under immunesuppressive therapy from 1990 (a) to 
1996 (b). Unusual manifestaions in “AK  ” included a retina vasculitis (c) and encephalitis 
(d). Two types o f  skin lesions in “A K p y o d e r m a  gangrenosum-like (big lesion in panel e) 
and leukocytoklastic vasculitis (small red dots in panel e).
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Patient “F T ”
A close relative of AK (FT, born 1947, sister of AK’s father), suffered since youth 
from recurrent upper respiratory tract infections with clinical and radiological signs of 
chronic sinusitis. During the third decade of her life she developed destructive 
granulomatous lesions localised around the tip of her nose (Figure 15), with 
perforation of the nasal septum, and destruction of nasal cartilage. Nodular skin 
lesions on the legs and arms appeared at the age of 30, with secondary ulcerations 
(Figure 15). As in AK, multiple biopsies demonstrated a necrotising granulomatous 
inflammation. Cultures and acid fast staining as well as PCR of the skin lesions failed 
to demonstrate M. tuberculosis and the progression of the granulomatous lesions was 
not halted by either antibacterial or tuberculostatic drugs. The patient never received 
immunosuppressive therapy and she is still alive. Tissue typing of AK and FT revealed 
that they were homozygous for the same extended MHC haplotype (Table 2).
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Figure 15. Clinical manifestations in patient “FT”
Mutilating skin lesions at the tip o f  the nose and on the legs in patient “F T ”.
Patient “N V ”
The patient NV suffered since childhood from recurrent purulent rhinitis, sinusitis and 
otitis which responded to antibiotic therapy. From age twelve she suffered from chronic 
spastic bronchitis and at age 18 bilateral bronchiectasis were diagnosed. At age 34 
complete destruction of nasal cartilage was observed, and at 35 years of age violaceous 
papules with secondary ulceration appeared on both legs appeared and in the face, with 
progressive destruction of the outer nose (Figure 16). Multiple skin biopsies showed 
severe necrotising granulomatous inflammation in dermis and hypodermis as well as 
small vessel vasculitis. At the age of 47 years leukocytoclastic skin vasculitis appeared. 
Multiple staining and cultures of skin biopsies failed to demonstrate mycobacteria, fungi 
or leishmania and extensive laboratory testing excluded ciliary dyskinesia, common 
variable immune-deficiency, defects of the phagocyte oxidase system, and SLE. A
96
diagnosis of Wegener’s granulomatosis was considered temporarily but abandoned 
because anti-neutrophil cytoplasmic antibodies (ANCA) were persistently negative and 
symptoms clearly progressed during therapy with cyclophosphamid and prednisone. 
Moreover, therapy with azathioprine and prednisone was complicated by bacterial 
meningoencephalitis.
Patient “N P “
At the age of 3 years this female patient developed violaceous plaques on the legs 
which slowly progressed and subsequently ulcerated. By the age of 27 years, 
mutilating lesions appeared in the face (Figure 16) leading to the destruction of the 
nasal cartilage. Biopsies showed a necrotising granulomatous inflammation245. Neither 
tuberculostatic nor other antibacterial therapies have influenced the disease course so 
far. Glucocorticoid monotherapy led to a temporary remission, but did not prevent 
relapse or progression of the lesions. The patient is now aged 52. Tissue typing of NP 
revealed that she was homozygous for the MHC haplotype (Table 2).
Figure 16. Mutilation of the nose in Type 1 Bare Lymphocyte Syndrome
Patients “N V ”, “N P ”, “A K ”, “FT“ are shown (From left to right).
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Patient “GAB ”
From the age of 4, recurrent purulent rhinitis, sinusitis and chronic otitis were 
documented but no severe viral infections were recorded, and measles and chicken pox 
ran an uneventful course. From the age of 10, the patient suffered from recurrent 
bronchopulmonary infections and bronchiectases (Figure 17) were diagnosed at the 
age of 16. Violaceous papulous skin lesions with secondary ulceration appeared at the 
age of 19 on the legs (Figure 17) and arms and histology demonstrated necrotising 
epithelioid granulomata containing multinucleated giant cells. Multiple cultures and 
stainings did not demonstrate Mycobacteria, Leishtnania or fungi and extensive 
laboratory testing excluded ciliary dyskinesia, cystic fibrosis, WG, common variable 
immunodeficiency, chronic granulomatous disease, systemic lupus erythematosus,
HIV infection and deficiency of alpha-1-antitrypsin. Skin lesions initially healed 
during tuberculostatic therapy but recurred despite 12 months of treatment. The
9 80patient is still alive at age 41
Figure 17. Bronchiectasis in type 1 BLS (patient “GAB”)
Computertomography o f  the lungs o f “GAB ” showing bilateral bronchiectasis
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Figure 18. Mutilating granulomatous skin lesions in patient “GAB”
Necrotisinggranulomatous lesions on the legs ofpatient “GAB”.
Patient “SAB“
At the age of 18 months SAB suffered from a measles infection with high fever. She 
had received standard vaccines in childhood, including measles (and polio, diphtheria, 
tetanus, pertussis, mumps, rubella). Since then she suffers from epilepsy, mostly focal 
but sporadically generalized, which is not totally controlled by antiepileptic drugs. 
Since the age of 5 she has suffered from recurrent febrile infections in the upper 
respiratory tract with otitis, rhinitis and chronic sinusitis, and from the age of 19 on 
she had also suffered from several episodes of pulmonary infections. Antibiotic 
treatment could control her infectious episodes. When I saw the patient first she had 
chronic sinusitis (Figure 19) and a chronic productive cough with yellow-green
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sputum. In contrast to her sister “GAB” and all other patients she did never develop 
granulomatous skin lesions.
Figure 19. Chronic sinusitis in type 1 BLS (patient “SAB”)
Magnetic resonance imaging (MRl) o f  the head in “SAB ” showing fluid accumulation 
and mucosal thickening in the paranasal sinuus. Both panels show total occlusion o f the 
right maxillary sinus (*), subtotal occlusion o f the left maxillary sinus, and near total 
occlusion o f both ethmoidal sinuus (**). Panel (b) shows increased blood flow (white 
areas) in the thickened mucosal lining o f the sinuus (more pronounced in the right 
maxillary sinus compared to the left maxillary sinus) which indicates ongoing 
inflammation.
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3.2.2. Phenotype of peripheral blood mononuclear cell subsets 
FACS analysis of patients’ PBMC demonstrated very low expression of MHC class I 
molecules compared to positive control samples (Figure 20), while the level of 
expression of MHC class II molecules was not altered (data not shown). Patients were 
not lymphopenic, with the exception of patient GAB, due to a reduction of the 
absolute numbers of CD3+CD8+ cells (0.250xl09/l). Despite the severely reduced 
MHC class I expression, significant numbers of CD3+CD8+ cells were detected in the 
PBMC of all patients (Table 1). Analysis of T cell receptor Vp usage demonstrated
that CD8+ cells in “FT” were polyclonal (data not shown). A significant expansion of 
(CD3-CD56+) NK cells and yST cells was observed in “AK” and, to a lesser extent in 
“GAB”, “NV” and “NP”, while CD3+CD56+ cells were expanded in “FT” and NP 
(Table 3).
Staining of patients’ PBMC and yS bulk cultures with V51 and V62 specific 
antibodies revealed that the proportion of yb T cells using the V61 T cell receptor, 
rather than the V52 T cell receptor, was greater than in other members of the family 
and control PBMC (data not shown). The inversion of the V81/V82 ratio was 
particular significant in “GAB” with more than 90% of yS T cells expressing the V81 
T cell receptor.
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Table 3. Lymphocyte subsets in type 1 BLS: Patients and healthy relatives
Patient/
Relative
CD3+
CD4+ CD8+ CD56+
CD3-
CD16+ CD56+
Pan-y5
HLA I 
expression
on PBCM
AK 24 19 8 32 32 23 50
FT 39 24 18 16 14.3 12 47
AK-F 47 24 13 7 6 10 1959
AK-M 47 25 8.8 10 11 5 . 2062
AK-B 47 25 6.7 8.8 8.6 4 1598
AK-S 55 23 4 6 6 7.6 1520
GAB 42 11 4 ND 14 17 10
SAB 54 10.3 5.4 0.3 13.8 13.5 ND
NV 4.8 87.8 0.2 0 1 3.6 10
NP 37.3 24 40 0.5 12 7 57
PBL 54 27 8.5 ND 4.9 4.5 1200
Values shown are percentages o f cells within the lymphocyte gate. Healthy family 
members o f  patient “A K ” were her father (AK-F), mother (AK-M), brother (AK-B) 
and sister (AK-S). Results are also shown fo r  analysis ofperipheral blood lymphocytes 
(PBL) from a random donor. Figure modified from 247.
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3.2.3. Analysis o f  the MHC class I biosynthetic pathway
The expression of MHC class I molecules on the B-lymphoblast lines from patients of 
all affected families, assessed by immunostaining with the pan-anti-MHC class I 
antibody W6/32, was strongly reduced (Figure 20). Pulse chase analysis of MHC class 
I molecules from the lymphoblast lines “AK” (Figure 21) and “GAB” (data not 
shown) as well as of control B-cell lines demonstrated that newly synthesised MHC 
class I molecules associated with p2m, but were retained in the ER.
Figure 20. MHC class I expression on B-lymphoblasts in type 1 BLS
OO  _____________________________________________________________________CO
o
TO
FL1-H
MHC class I  expression on EB V-transformed B-lymphoblast lines from patients o f  
affected type 1 BLS families, and control lines. Legend: Filled grey area: “A K ”, 
stained with secondary antibody only; all other B-cell lines were stained with both the 
pan-MHC class I  antibody W6/32 (mouse IgG2a) and the secondary PE-conjugated 
goat-anti-Mouse IgG antibody. Blue line: “SAB”; green line: “N P ”; brown line: 
“N V ”; red line: “A K ”; fd led  black area: “LG 2” (MHC class I  competent).
103
Figure 21. Pulse chase and isoelectric focusing analysis in patient "AKM
“AK” Healthy Control
H LA-Cw*08
B2M
HLA-B* 1502 
HLA-A*1101
Pulse-chase, immunoprecipitation and isoelectrofocusing o f MHC class I molecules o f  
B-lymphoblast lines “AK  ” and a healthy control line sharing identical HLA-A and 
HLA-B haplotypes.
MHC class I molecules in the healthy control line undergo maturation, i.e. they 
undergo glycosylation during the chase period, resulting in the appearance of 
additional bands for HLA-B* 1502 and HLA-A* 1101 (red arrows). In contrast, the 
bands for “AK”’s HLA-B* 1502 and HLA-A* 1101 show no qualitative changes over 
the whole chase period, indicating that MHC class I molecules in “AK” did not reach 
the Golgi apparatus during the 3 hours chase period.
Pulse Oh 1h 3h Oh 1h 3h
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Moreover, transport of a radiolabelled peptide from cytosol to ER was 
abolished in all tested patient EBV B-lymphoblast lines, implicating a defect of the 
TAP complex (Figure 22).
Figure 22. Peptide translocation in 4 patients with type 1 BLS
CS LHL721.174 A K  GAB NP NV
Peptide translocation in EBV-transformed B-lymphoblast lines from patients “A K ”,
“GAB ”, “NP ” and “N V ”. The healthy donor EBV B-lymphoblast line “C S” and the 
TAP-deficient lymphoblast line “LBL721.174 ” served as positive and negative 
controls, respectively.
Furthermore, infection of AK B cells with a recombinant vaccinia virus encoding the 
full length EBV LMP2A protein failed to sensitise them for lysis by LMP2A-specific
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A11-restricted CTL, while presentation of the same epitope, as a synthetic peptide, 
was not affected (data not shown).
Western blotting of B-Iymphocyte lysates from patients of all affected families 
demonstrated normal expression of TAPI in “AK” and “BS” (“BS” will be described 
in detail in chapter 5) and lack of TAPI in patients “NV”, “NP”, and “GAB” (Figure 
23). Conversely, using antibodies specific to carboxy terminal residues of the TAP2A 
and TAP2B alleles TAP2 could not be detected in lysates of patient “AK”, but was 
found in “NV”, “NP”, and “GAB” (Figure 23).
Figure 23. TAP and Tapasin expression in 5 patients with type 1 BLS
TAPI 
TAP2 
Tapasin
Western blot analysis fo r  TAPI, TAP2 and Tapasin expression, using cell lysates from  
patient and control lines. The TAP-deficient cell line LBL721.174 ( “.174”) was used 
as a negative control fo r  both TAPs, while the Tapasin-deficient cell line LBL721.220 
( “.220”) was used as a negative control fo r  the Tapasin western blots. Patient “B S” 
will be discussed in detail in chapter 5. The red arrow> indicates the band fo r  TAP2.
+ C 174 BS NV AK NP GAB
+ C .220 BS NV AK NP GAB
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Sequencing of “AK’s” full-length TAP2 cDNA showed a deletion of an 
adenosine (A) in codon 326, which caused a frameshift and a premature stop codon. 
The adenosine deletion in codon 326 generated a novel Hpall restriction site within 
exons 5 and 6 which allowed analysis of the distri bution of the TAP2 null allele in the 
patients and their family members. AK and FT were homozygous for the TAP2 null 
allele, while AK’s parents were heterozygous (data not shown).
Finally, MHG class I expression could be restored in all patients’ B- 
lymphoblast lines upon infection with a recombinant vaccinia virus encoding the 
human TAP1/TAP2 proteins (shown for 4 patients in Figure 24), confirming that the 
reduction in MHC class I surface expression was caused by a defective TAP complex.
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Figure 24. TAP-encoding vaccinia virus restores MHC class I surface expression
BS NV
S - i
O  J  |
FL1-H
NP
5 0
O J
' " I ,  VC A *' ■ ' " I i
1 0 '  10-  
FL1-H
10-
FL1-H
1 0 '
MHC Class I Surface Expression ►
Immunostaining o f  B-EBV lymphoblastoid lines “B S ”, “N V ”, “GAB”, and “N P ” 
with the unlabelledpan-MHC class I  antibody W6/32(lsl antibody) and FITC-labelled 
anti-mouse antibody (2nd antibody) is shown after infection o f the cells with either a 
recombinant TAPl/TAP2-encoding vaccinia virus ( “TAPs-VAC”; bold red line) or a 
recombinant control vaccinia virus (thin black line). Staining o f the “TAPs-VAC” 
infected cells with only the 2nd antibody is shown as a black dotted line.
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3.2.4. Additional studies
The results described in the following two paragraphs were mainly generated by Helen 
Moins-Teisserenc, They have been included in this part of the thesis in order to give a 
more rounded picture of the TAP-deficiency story.
3.2.4.1. Functional activity ofNK and y5 T cells
We then sought to address whether in patients with a germline down-regulation of 
MHC class I molecules, the activity of cells expressing MHC class I binding receptors 
was altered. Several y6 T cell clones were generated from FT, GAB and NV and their 
phenotype and activity analysed. All y5 T cell clones, rapidly proliferating from the y5 
T cell bulk culture, were Vgl Vy9 and they all expressed the MHC class I binding 
receptors ILT2 and CD94/NKG2A (data not shown). Cytotoxic activity of three y§ T 
cell clones was tested against the MHC class I negative cell line 721.221, the HLA- 
identical TAP2 negative “AK” B-lymphoblasts and, as control, against MHC class I 
positive B-lymphoblasts. We demonstrated that 721.221 cells were lysed by the three 
y5T cell clones, while a higher percentage of cytotoxicity was observed against “AK” 
B-lymphoblasts. These results were confirmed with autologous B-lymphoblasts. The 
finding that lysis of target cells was abolished after increasing the level of expression 
of MHC class I molecules, following infection with TAP vaccinia, suggested that y6 
T cell inhibitory receptors were capable of transducing inhibitory signals. Therefore 
the analysis of NK and y6 T cells was extended to “GAB”. It could be confirmed that 
several V81 positive y5 clones were autoreactive, and that lysis of autologous cells 
was almost abolished after expressing wild type TAPI and TAP2 genes, and restoring
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normal surface expression of MHC class I molecules. Similar experiments were then 
carried out using a polyclonal NK line. It could be demonstrated that “GAB’s” NK 
cells were autoreactive, as defined by their ability to lyse autologous B cells.
Figure 25. Activity of NK and yd T -cells in type 1 BLS (from Reference 247)
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A and B: Three yS T-cell clones (1, 7, and 12) from patient “F T ” were tested against 
the HLA-identical TAP-2-negative B cells from patient “A K ” as target cells. In the 
experiment done with clone 7, target cells were infected overnight with TAP-vaccinia 
(TV) or as a control with an irrelevant vaccinia virus (V). C: The yS clone 6G11 from  
patient “GAB”
was tested against autologous B cells as target cells. Targets were infected with 
irrelevant vaccinia (V) or with the TAP-vaccinia (TV).D: An NK cell line from patient 
2 was tested against autologous B cells and B cells from patient “A K ” as target cells. 
The class-I-negative B-cell line 721.221 and a class-I-positive B cells line (BCL) were 
used as controls. Each bar corresponds to a different effector-to-target ratio (white 
bars 18:1; speckled bars 6:1; dark grey bars 2:1).
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3.2.4.2. Immunohistochemistry o f  skin lesions
Biopsies collected from “AK’s” skin lesions revealed the presence of several foci of 
immune cells infiltrating the dermis. To define the phenotype and origin of the 
infiltrating cells, the same sections were stained with a large panel of different 
monoclonal antibodies. The results of this analysis revealed that a large proportion of 
infiltrating cells were NK (CD3-CD56+), which expressed high levels of the 
inhibitory receptors CD94 and ILT2. A small but significant proportion of cells were 
aP+CD3+ and very few cells were 61 and 62 positive. Similar results were observed 
in skin biopsies from patient “NV”. A large proportion of NK cells infiltrating the 
necrotic lesions were positive for the activation marker HLA-DR+, suggesting a direct 
role of NK cells in the pathogenesis of the skin lesions.
Figure 26. Immunohistochemistry of TAP-deficient granulomatous lesions (Ref. 247)
CD56
CD94
HLA-DR
A large proportion o f cells infiltrating the dermis were NK cells (CD3-CD56+), 
which expressed high levels o f  the inhibitory receptors CD94 and 1LT2 and were HLA 
class-II positive. A small but significant proportion o f cells were yS* CD3 positive (not 
shown).
I l l
3.3. Discussion
The patients described above with type 1 BLS exhibit a remarkable homogeneity of 
clinical symptoms and disease course, strongly suggesting a link between their 
unusual features and the low MHC class I expression. All patients except for “NP” 
suffered since their youth from recurrent bacterial infections in the upper respiratory 
tract associated with chronic bronchitis and recurrent bronchopneumonia leading to 
the progressive destruction of lung tissue and development of bronchiectases. All 
patients except “SAB” suffered from destructive granulomatous skin lesions affecting 
the extremities of the patients. A peculiar characteristic of this disease is the 
invol vement of the face, which led to total destruction of the outer nose in “AK”,
“NP” and “NV”, and to partial destruction in “FT”. Despite intense diagnostic efforts 
no clear evidence of an infectious etiology could be found. In “NP”, the 
granulomatous lesions appeared much earlier than in the other patients, i.e. during 
childhood.
A diagnosis of WG was suspected in all patients except “FT” at some stage 
during the disease course and “AK”, “NV”, “GAB”, “SAB” and “NP” were 
transiently treated with immunosuppressive therapy. In “AK”, immunosuppressive 
therapy led to chronic clinical deterioration with appearance of recurrent pneumonia, 
in “NV” it was associated with an episode of bacterial encephalitis, and in “GAB” and 
“SAB” it was clearly associated with worsening lung function tests and 
bronchiectasis. In contrast, low dose glucocorticoid treatment might have had some 
beneficial effect on the granulomatous lesions in “NP”.
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Type 1 bare lymphocyte syndrome due to frameshift mutation in TAP2 had 
been previously described in one Moroccan family with two affected children sharing 
an identical homozygous HLA haplotype 137. These patients exhibited a similar 
clinical phenotype as my TAPI-defective patient “SAB” in that they did not suffer 
from chronic granulomatous inflammation either in the upper respiratory tract or the 
skin. It is possible that chronic inflammatory lesions in MHC class I negative patients 
might require exposure to pathogens or to other triggering events. Two other 
previously published single case reports had described sinobronchial disease and skin 
lesions on the legs of patients with low MHC class I expression; the skin lesions were
• 9 81 989described as ulcers or as plaques resembling necrobiosis lipoidica
The pathogenesis of such chronic inflammatory lesions remains unclear. The 
presence of some multinucleated giant cells in the granulomatous lesions raises the 
possibility that tissue damage might have been caused by mycobacterial infections. 
However, tuberculostatic treatments did not provide any prolonged clinical benefit in 
any patients, and mycobacteria were not identified in the lesions by tissue staining, 
culture techniques or PCR analysis.
An alternative hypothesis is that the chronic inflammation was caused by 
autoreactive lymphoid cells, such as the expanded populations of NK and/or y8T cells 
found in these patients. This hypothesis is based on the fact that effector functions of 
NK and y6 T cells are negatively regulated by MHC class I-binding receptors, such as
989 9 8Akiller inhibitory receptors and ILTs ’ . Furthermore it has been shown that clonal
distribution of inhibitory receptors expressed by NK clones from healthy volunteers is 
capable of inhibiting self-reactivity. In patients with a germline loss of MHC class I
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molecule, the threshold of inhibition provided by these receptors may not be reached, 
leading to autoimmune lesions. A similar hypothesis had been previously suggested 
by Zimmer and colleagues based on the finding that NK cells from TAP2-deficient
9 9 8 Achildren were capable of lysing autologous B cells ’ . It is possible that the degree
of self reactivity of NK cells may be different for distinct clones and may be 
influenced by the level of expression of MHC class I molecules and the HLA 
haplotype of different patients. Indeed, four clones from “FT” were not autoreactive, 
although they were capable of killing K562 cells (data not shown). The 
granulomatous lesions progressed in patient “AK” under treatment with interferon 
alpha (IFNa). It is possible that IFNa triggered activation and cytotoxicity of “AK’s” 
NK cells, thereby promoting tissue damage.
The lack of severe viral infections in TAP-negative patients is intriguing and 
clearly indicates that the immune system has the capacity to react effectively to 
viruses in the absence of a functional TAP complex. The presence in sera from “AK” 
and “FT” of IgG with specificity for a variety of common pathogens (not shown) 
demonstrates an efficient antibody response. It is possible that TAP-independent viral 
peptides were capable of stimulating a protective CTT response, and selection of 
CD8+ T lymphocytes could have been driven by surface-expressed class I molecules 
loaded with TAP-independent peptides, as previously described 287. Alternatively, 
either neutralising antibodies or other cellular mechanisms, such as those mediated by 
NK and y8 cells, could have been protective against viral infections.
In summary I have here described a novel syndrome in patients with low 
levels of expression of MHC class I molecules. The underlying molecular defect in all 
patients could be localized to the TAP1/TAP2 heterodimer. Both defects of TAPI and 
TAP2 were associated with a similar clinical phenotype of otherwise unexplained 
destructive granulomatous lesions and frequent infections of the respiratory tract. A 
characteristic of TAP-deficiency which distinguishes it from other forms of type 1 
BLS is the relatively benign disease course with all patients surviving into adulthood. 
The destructive granulomatous skin lesions are infiltrated by activated NK cells and 
y6 T cells. Together with the findings that some of the patients’ NK and y5 T cell 
clones exhibit clear autoreactivity it seems possible that inappropriately controlled 
activation of these innate immune cells, e.g. during viral or bacterial infections of the 
respiratory tract, is responsible for the severe tissue distraction in TAP-deficient 
patients. Why tissue destruction is mainly localized to the skin and not other organs 
remains unclear.
Expression of different MHC class I haplotypes by different patients is likely 
to have an influence on the spectrum of their clinical symptoms and infections. It is 
interesting that none of the so far described patients with TAP-deficiency is 
homozygous for HLA-A2, which is known to present TAP-independent peptides. It 
might be that HLA-A2+ patients with TAP-deficiency do not exhibit a primary 
immunodeficiency syndrome and that levels of MHC class I surface expression in 
such patients would be sufficient to inhibit NK activation.
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3.4. Conclusions
TAP-deficiency syndrome is an autosomal recessive genetic disorder involving either 
of the TAP-subunits TAPI or TAP2. Early diagnosis and state of the art antibiotic 
treatment are essential in order to prevent development of irreversible lung damage. 
Immunosuppressive treatment for suspected skin vasculitis is contraindicated and can 
cause rapid clinical deterioration and severe infectious complications of the lungs, 
central nervous system and eyes. Reduced MHC class I surface expression is the key 
laboratory finding. Lessons learned from the clinical and molecular analysis of TAP- 
deficient patients complement studies performed on murine cell lines or using 
artificial deletion constructs of TAP, and contribute to a better understanding of the 
peptide transporter.
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4. Type 1 bare lymphocyte syndrome due to a splice donor site 
mutation in TAP2
4.1. Introduction
In this chapter I shall describe the clinical and molecular analysis of type 1 BLS in a 
family from Eastern Europe with two affected siblings. The clinical manifestations in 
the two patients described here extend the clinical spectrum of TAP-deficiency and 
illustrate the harmful consequences of immunosuppressive drug therapy in TAP- 
deficient patients. The molecular and genetic analysis of one of the two siblings, “BS” 
is described.
4.2. Results
4.2.1. Family history
Patient “BS” was diagnosed with type 1 BLS in the Rheumaklinik Bad Bramstedt 
(Germany) in March 2000. She had been admitted with a suspected diagnosis of WG. 
Family history revealed that “BS” had had an older sister, “RJ”, with a nearly identical 
clinical syndrome, who had died of her disease several years before. The parents of the 
two patients and three more siblings (one brother, two sisters) were healthy. The 
parents were first degree relatives. All molecular studies were done on PBMC and 
EBV-transformed B-lymphoblastoid lines from “BS”, the younger of the two affected 
sisters.
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4.2.2. Clinical data
Patient “R J” (9.6.1960 -  8.12.1991)
From early childhood on, the girl suffered from recurrent upper respiratory tract 
infections and herpetic fever blisters. Following smallpox vaccination she developed 
left sided acute hearing loss and transient generalised exanthema. From the age of 13, 
plaquelike and nodular skin lesions with secondary ulceration, followed by scar 
formation and hyperpigmentation developed on the left lower leg. Clinically, the 
lesions were classified as erythema induratum Bazin. Skin swab cultures grew 
Staphylococcus aureus and Pseudomonas aeruginosa, and histologic analysis revealed 
a lymphocyte rich granulomatous inflammatory infiltrate and necrosis. Multiple 
cultures and acid fast stains failed to demonstrate the presence of mycobacteria and the 
lesions did not heal under antituberculous quadruple therapy, but extended to the left 
thigh and right lower leg.
At the age of twenty-eight, immunosuppressive therapy with lOOmg 
azathioprin per day was installed for suspected panarteriitis nodosa. A clinical 
examination of the eyes before the start of the immunosuppressive therapy revealed 
postinflammatory atrophy of the right iris. Within the next year the skin lesions 
progressed further, and the patient started to suffer from frequent bronchopulmonary 
infections and a progressive atactic syndrome involving the trunk and limbs. One year 
after the start of immunosuppression cranial computed tomography scan disclosed 
diffuse cortical and subcortical atrophy of both the cerebrum and cerebellum, and a 
left frontal lesion consistent with an old lacunar cerebral infarction. Repeated eye 
examinations now also showed postinflammatory atrophy of the left iris as well as
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bilateral subcapsular cataracts. Cyclosporin A was added to the immunosuppressive 
regimen for suspected progression of the vasculitic process.
Two years later, at the age of 31, the patient died after a series of recurrent 
strokes complicated by severe bilateral bronchopneumonia.
Patient “B S ” (11.8.1962 -  8/99)
From the age of five onwards the girl suffered from recurrent purulent rhinitis and 
sinusitis, and from frequent bouts of herpetic fever blisters on lips and nostrils. 
Between the ages of five and ten she developed measles, mumps, rubella, chickenpox 
and pertussis, all of which ran an uneventful disease course with spontaneous 
remission. Vaccinations for polio, tuberculosis (bacille Calmette-Guerin), diphteria 
and tetanus were well tolerated. From the age of ten, she underwent multiple surgeries 
of the paranasal sinus with no improvement of her chronic sinusitis. At the age of 
eleven she developed recurrent spastic mucopurulent bronchitis, which responded to 
antibiotic treatment. Extensive diagnostic investigations excluded cystic fibrosis, 
alpha-1-antitrypsin deficiency, tuberculosis, common variable immunodeficiency, 
IgA-deficiency or aspergillosis as the cause of her disease.
At the age of twenty-three, a few months after she had given birth to a healthy 
boy, nodular and plaque like skin lesions with purple discoloration appeared on the left 
lower leg and were clinically classified as erythema induratum Bazin. Histologic 
analysis showed a dense inflammatory infiltrate in the dermis consisting of 
lymphocytes, histiocytes, and few polymorphnuclear granulocytes, with perivascular
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accentuation and necrosis. Treatment with antituberculous quadruple drug therapy had 
no effect on the lesions.
At the age of thirty, immunosuppressive treatment with 20mg prednisone per 
day was instigated for treatment of the skin lesions, which were now classified as 
nodular vasculitis. Extensive diagnostic tests, including an electroencephalography 
(EEG) and magnetic resonance tomography (MRI) of the cranium were normal except 
for the finding of chronic bilateral pansinusitis. Under immunosuppressive therapy, the 
skin lesions did not improve. She now also suffered from recurrent bouts of 
pneumonia and recurrent herpetic keratitis. Cultures from sputum and 
bronchioalveolar lavage grew Staphylococcus aureus and Haemophilus 
parainfluenzae. Six month after start of prednisone therapy a diagnosis of bilateral 
bronchiectasis and colonisation of the lungs with multiresistant Stenotrophomonas 
maltophiles was made. Lung function gradually decreased and she became dependent 
on continuous oxygen supply.
At the age of 36 she suffered from two transient episodes of right sided 
brachiofacial hemiparesis, the first of which appeared in close time association with a 
bout of herpetic keratitis and herpetic skin lesions on both eye lids and the right 
auricle, confirmed by virus culture and PCR. An EEG recorded four weeks later 
revealed a left temporal focus of steep alpha waves with high amplitudes, while MRI 
showed multiple bilateral hyperintense lesions in the frontal and occipital lobes, which 
were considered to be consistent with vasculitic lesions. Duplex sonography of the 
extracranial arteries and echocardiography showed no abnormalities. One year later, 
during recovery from an acute severe stroke with right sided hemiparesis she
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developed severe bilateral pneumonia refractory to antibiotic treatment. She died aged 
thirty-seven, of respiratory failure. Four months before her death, analysis of 
peripheral blood mononuclear cells (PBMC) by fluorescent activated cell sorter 
(FACS) had revealed a reduced frequency of cytotoxic CD8+/CD57+ T lymphoyctes, 
increased frequency of y§ T lymphocytes and a strongly reduced cell surface 
expression of MHC class I molecules.
The clinical syndrome in “RJ” and “BS”, together with the low MHC class I 
cell surface of PBMC in “BS” were consistent with a diagnosis of type 1 bare 
lymphocyte syndrome due to TAP-deficiency.
4.2.3. Molecular Analysis of EBV-transformed B-lymphoblasts from patient “BS”
In order to study the MHC class I processing and presentation pathway I generated an 
EBV-transformed B-cell line (“BS”) from PBMC of patient “BS”.
Tissue typing of “BS” B-lymphoblasts by PCR revealed that she carried a 
homozygous [HLA-A32, HLA-B57, HLA-Cw6 ] haplotype.
FACS analysis of “BS” B-lymphoblasts stained with MHC class 1-specific 
antibodies recognising HLA-A,B,C (W6/32), HLA-A32 (T116-5-28) and HLA-B57 
(MA2.1) demonstrated a more than 100-fold reduction of cell surface expression for 
all MHC-class I molecules compared to normal control B-cell lines. Moreover, 
compared to B-lymphoblast lines derived from other TAP-deficient patients “BS” 
lymphoblasts expressed the lowest levels of MHC class I molecules (Figure 27).
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Figure 27. MHC class I surface expression in "BS", “NP”, “AK”, “GAB” and “NV”
Patients . 174
MHC class surface expression (W6/32)
MHC class I  surface staining o f  patients ’ and control B-lymphoblast lines with the 
pan-MHC class 1 antibody W6/32. The negative control (-C) is LG2 stained with 
secondary antibody only (PE-conjugated goat-anti-mouse IgG, i.e. no first antibody 
(i.e. no W6/32). Pink line: “B S”; orange line: “N P ”; brown line: “A K ”; green line: 
“GAB ”; blue line: “N V ”; black dotted line: LBL721.174 (TAP-deficient control); 
black line: LG2 (MHC class I  expressing control line).
Comparison of p2m surface expression on “BS” B-lymphoblasts and Daudi 
cells (p2m A) ruled out a primary p2m-deficiency in “BS” B-cells (data not shown).
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To further analyse the MHC class I pathway I immunoprecipitated the peptide loading 
complex from “BS” B-cell lysates after prior labelling with 3 5 S'methionine. The cell 
lysates had been obtained by cell lysis with either the strong ionic detergent NP40 (at 
1 % concentration) or the weak non-ionic detergent digitonin (at 1 %).
Normal TAP has a half-life in the range of 3-4 hours, while MHC class I 
molecules have half lives of 15-30 minutes. In order to obtain optimal radioactive 
signal intensities for both TAP and MHC class I molecules in the same experiment I 
radiolabelled the B-cells during a long pulse of 16 hours, followed by an additional 
short pulse of only 2 0  minutes.
Both TAPI and TAP2 bands could be detected in both digitonin as well as 
NP40-lysates (Figure 28). TAP2-bands from “BS” B-cells ran slightly higher than 
TAP2-bands of a control B cell line. Interestingly, the PLC including both TAPs,
MHC class I molecules and (32m could be co-precipitated in 1% NP40-lysates of “BS” 
cells but not normal control cells (Figure 28). These results ruled out a transcripitional 
defect of MHC class I molecules and suggested an unusually stable conformation of 
the TAP-loading complex in detergent. They also indicated the presence of functional 
tapasin, the TAP-MHC class I/p2m-bridging protein. Neither MHC class I molecules 
nor (32m were co-precipitated in detergent lysates of the tapasin-deficient line 
721.220.B44.
When “BS” B-cells were labeled with a single short 20 minutes pulse of 3 5S' 
methionine an unusually intense TAP2 band was detected, while the duration of the 
pulse was not sufficient to efficiently label TAPI. While these results were consistent 
with the known half live of normal TAPI they suggested a significantly reduced half­
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life of TAP2 in “BS” (Figure 28). Western blot experiments with antisera against the 
C-terminus of TAPI, TAP2 and tapasin confirmed that they were all expressed in 
“BS” B-cells (Figure 28). Taken together these results showed cellular expression of 
both TAPI and TAP2 in “BS” B-cells, and their association with tapasin, MHC class I 
and p2m in the peptide loading complex. However, the increased cellular turnover and 
reduced steady state level of TAP2 in “BS” B-cells suggested that TAP2 in “BS” was 
defective. Consistent with this hypothesis was the unusually stable conformation of the 
PLC in “BS” B-cells.
Figure 28. Molecular analysis of type I BLS in patient “BS”
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Figure legend on next page.
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Legend for Figure 28: Immunoprecipitation o f the peptide loading complex (PLC) in 
“B S” cell lysates and control lysates (a). Co-precipitation o f the PLC in 1% digitonin 
lysates o f cell lines “B S”, LG2 (normal control), .220 (tapasin-deficient) and ,220/tps 
(220 with restored tapasin expression) is shown on the left-hand side. “BS#” and 
control lines were pulsed for 16 hours withS35 Methionine before detergent lysis.
“BS* ” were subjected to one 16 hours pulse followed by one 20 minutes pulse and
( S35“BS## ” were pulsed only once fo r  20 minutes with Methionine.
Immunoprecipitation o f the PLC in 1% NP40 lysates (a, right-hand side) revealed that 
the PLC in “B S” cells was unusually stable. High signal intensity o f the TAP 2-band
S35was observed with single 20 minutes Methionine labelling and quantified by 
phosphoimager analysis (b). Western blotting o f TAPI, TAP2 and tapasin in “B S” and 
control lysates is shown in (c).
In order to directly study the functional integrity of the TAPl/TAP2-complex 
we compared the efficiency of TAP-dependent peptide translocation from the cytosol 
into the endoplasmic reticulum of “BS” B-cells and control B-cell lines. The results of 
these experiments demonstrated a severe impairment of TAP-dependent peptide 
transport in “BS” B-cells (Figure 29) and thereby strongly supported the suspected 
diagnosis of TAP-deficiency syndrome in “BS”.
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Figure 29. Defective peptide translocation in “BS” B-lymphoblasts
LBL721.174
Figure 29. Peptide translocation in B-lymphoblast lines “C S” (healthy), LBL721.174 
(TAP 1/2-deficient), “A K ” (TAP2-deficient) and "BS”. Peptide translocation into the 
ER corresponds to the radioactivity o f  the Concanavalin A-retrieved peptide fraction, 
containing the [1251]-labeledpeptide RRYQNSTEL ”
(Y-axis; cpm, counts per minute).
To determine which TAP subunit, TAPI or TAP2 was responsible for the 
functional TAP-defect in “BS” I generated cell fusions of “BS” B-lymphoblasts with 
TAPI - and TAP2-deficient lymphoblasts from my previously characterized TAP- 
deficient patients as well as the tapasin-deficient line 721.220.B44. Allele specific and 
pan-anti-MHC class I antibodies were used to detect restoration of specific HLA-A 
and HLA-B molecules or total HLA class 1 molecule expression on the fusion
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products (Figure 30). Fusion of “BS” B-cells with the tapasin-deficient, HLA-B44- 
expressing B-cell line 721.220.B44 restored normal surface expression of HLA-B57 
and HLA-B44, demonstrating normal tapasin function in “BS” B-cells (not shown).
As expected, surface expression of FILA-A32 was restored in fusions of “BS” with 
721.174.TAP, but not with the TAP-deficient mother line 721.174 (not shown). 
Importantly, fusions of “BS” B-cells with the TAP 1-deficient, but TAP2-competent B- 
cell line “GAB” restored surface expression of FILA-A32 and HLA-B57, while fusion 
of “BS” B-cells with the TAP2-deficient, but TAPI-competent B-cell line “AK” failed 
to restore normal MHC class I expression. These results demonstrated that the reduced 
MHC class I surface expression in patient “BS” was caused by a functional TAP2- 
deficiency.
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Figure 30. Complementation of TAP1/TAP2 function in B-cell fusions
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Fusion o f B-lymphoblast lines was carried out as described in chapter 2 (Methods). 
MHC class I  expression on fusion products was detected by the pan-MHC class I 
antibody S6/32 (BSxAK, AKxNV, AKxNP) and the anti-HLA-A32 antibody T116-5-28.
4.2.4. Genetic analysis of TAP2 in “BS” B-cells
Tissue typing of “BS” B-cells revealed that “BS” was homozygous for the TAPI allele 
TAP 1 a (TAP 1 *0101 /0 102) and the TAP2 allele TAP2E (TAP2*0102).
To characterise the underlying genetic defect in “BS” TAP2E I amplified and 
sequenced overlapping segments of TAP2E from “BS” B-cell cDNA by RT-PCR. Six 
forward primers (FP) and six reverse primers (RP) were designed on the basis of the 
published TAP2E coding sequence (CDS; Genbank; START-STOP: 77-2137) and 
used in different combinations. Both sequence analysis and agarose gel electrophoresis
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revealed that RT-PCR products amplified with primers spanning the TAP2E CDS 
region 20 -  1021 (FP1 - RP4), including exons 1 -  4, and the TAP2E CDS region 
1526 -  2203 (FP5 -  RP1), including exons 7 —11, contained single bands of expected 
size and nucleotide sequence.
In contrast, none of the RT-PCR products amplified with primer pairs spanning 
TAP2E CDS region 1021 -  1526 contained bands of the expected size. Instead, 
amplified DNA products ran either 300 base pairs below (“-300bp”) or 1200 base 
pairs above (“+1200bp”) the expected size (Figure 31). Interestingly, 4 different 
FP/RP combinations yielded two bands, one “-300bp” and one “+1200bp”, suggesting 
alternative splicing of TAP2E in “BS”.
This hypothesis was confirmed by sequence analysis, which revealed skipping 
of exons 5 and 6  in RT-PCR products from “-300bp” bands and inclusion of the first 
1184bp of intron 6  in products from “+1200bp” bands. The two splice variants of 
“BS” TAP2E were named TAP2E S (short) and TAP2E L (long).
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Figure 31. RT-PCR analysis of "BS" TAP2E
1 2 3 4 5 6
Amplification o f “B S” cDNA with primer pairs spanning the region 1021 — 1526 o f  
TAP2E revealed the presence o f two splice variants o f  the TAP2E gene in “B S”. The 
products o f  the shorter variant “TAP2E S ” ran ca. 300bp below the expectedfragment 
size (green arrows) and the products o f  the longer variant “TAP2E L ” ran ca. 1200bp 
above the expected fragment (red arrows). Sequencing o f these bands disclosed a 
single nucleotide mutation in the splice donor site o f  intron 6 with resultant exon 
skipping in “TAP2E S ” and partial inclusion o f intron 6 in “TAP2E L ”.
Sequencing of “TAP2E L” showed a single nucleotide mutation (G to C) of the 
first nucleotide in the splice donor site of intron 6  (GTGAG to CTCAG). The mutation
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was confirmed on both strands and by sequencing genomic BS TAP2E DNA (data not 
shown). On the other hand, the sequence of “TAP2E S” contained a 33 nucleotide 
sequence interposed between exon 4 and exon 7, which showed 100% homology to a 
part of the TAP2E wild type sequence in intron 6  and also to the corresponding 
retained intronic sequence in “TAP2E L”. Interestingly, closer analysis of the entire 
genomic TAP2E intron 6  sequence revealed the presence of a potential cryptic splice 
acceptor site with a characteristic polypyrimidine enhancer motif immediately 
upstream of this 33 nucleotide sequence as well as a cryptic splice donor site 
(GTGAG) immediately downstream of it (Figure 32/a). The proposed scenario for 
aberrant alternative splicing of genomic "BS" TAP2E based on the sequence analysis 
is shown in Figure 32/b.
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Figure 32. Analysis of aberrant alternative splicing of the TAP2E gene in”BS”
Mutation in TAP2E gene of patient “BS”
...Exon 61 hivon 6..
TAP2EBS : GCAG/CTGAGCG
TAP2EWT : GCAG/GTGAGCG
^mutated splice donor site^) ^cryptic splice donor site ^
In tron 6 “B S ’
r
Exon 6 CTGTAG.l.. .11111GTGTAG/AGAA.. AA G/GTGA G .j TITrGC A G Exon 7
A >
^cryptic splice acceptor site ^native splice acceptor site
b)
TAP2E Short - 294 bp
AGAA... AAG
TAP2E Long \ + 1184 bp
CTGAG... ...AAG
(a) Sequence analysis o f intron 6 o f  genomic TAP2E in “B S ” and (b) splicing scenario 
o f genomic “B S” TAP2E DNA resulting in two TAP2E mRNAs.
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Interestingly, the 33bp sequence connecting exons 4 and 7 in “TAP2E S” is in 
frame and contains no Stop codon, while “TAP2E L” contains a Stop codon at 
nucleotide position 1390, 39 codons downstream from the start of intron 6 . The splice 
variant “TAP2E S” is therefore predicted to encode a protein of slightly lower 
molecular weight than wild type TAP2E, i.e. 64 kDa compared to 76 kDa (Figure 33). 
“TAP2E S” is predicted to contain a normal COOFI-terminus including the nucleotide 
binding domain (NBD), which explains why TAP2 could be detected in 
immunoblotting experiments with antibodies against a COOH-terminal peptide of 
TAP2. Importantly, the protein encoded by “TAP2E S” lacks the putative peptide 
binding domain of TAP2, i.e. the cytosolic peptide loop linking TAP2 transmembrane 
domain (TM) 7 with TM8 , and also lacks both the putative TM8  and the major part of 
TM9 (Figure 33)117. In contrast, “TAP2E L” encodes for 5 IkDa protein with a COOFI- 
terminal truncation, which lacks the nucleotide binding domain and also a part of 
TM9, but contains the putative TAP2 peptide binding domain (Figure 33). The TAP2 
band detected in the western blot experiments could therefore not have originated from 
TAP2L.
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Figure 33. Predicted TAP2 protein sequence and domain organization in ‘
a) TAP2 encoded by wild type TAP2E
MRLPDLRPWTSLLLVDAALLWLLQGPLGTLLPQGLPGLWLEGT LRLGGLW 50 
GLLKLRGL LGFVGTL L LP LC LATP LTVS LRALVAGAS RAP PARVASAPWS 100 
WL LVGYGAAG L S WS LWAV L S PPGAQEKE QDQVNNKVLMWR L L K LSR P D LP  150 
LLVAAFF F LV LAV LGE T L I PH Y S G R V ID IL G G D F  D P H A F A S A IF F M C L F S  200 
F G SSL 3A G C R G G C FT Y T M SR IN L R IR E Q  LFSSLLRQ DL G FFQ ETK T G ELN 2 5 0  
S R L SSD T T L M SN W L PL N A N V L L R SL V K W feL Y G F M L SISP R L T L L SL L H M  300 
F'FTI AA E KVYNT R H QE VLREIQ D AVARA GQWREAVGGLQ TVRSFGAEEH 350 
EVCRYKEALEQCRQLYWRRDLERALYL LVRRVLHLGVQMLML3CGLQQMQ 400 
DGE LTQ G SL LSFM IYQ E SV GSYVQ T L\?YIYGDMLSNVGAAEKVFSYMDRQ 450 
PN L P SP G T  LAPTT L Q G W K FQ D V SF AYPNRPDRPVLKGLT FT LRPGEVT A 500 
LVGPNGSGKSTVAALLQNLYQPTGGQVLLDEKPISQYEHCYLHSQVVSVG 550 
QEPVLFSGSVRNNITYGLQSCEDDKVM AAAQAAHADDFIQEM EHGIYTDV 600 
GEKGSQLAAGQKQRLAIARALVRDPRVLILDEATSALDVQCEQALQDWNS 650 
RGDRTVLVIAHRLQTVQRAHQILVLQEGKLQKLAQL 686
b) TAP2 encoded by “TAP2E S” of patient “BS”
MRLPDLRPWT3 LLLVDAALLWLLQGPLGTLLPQGLPGLWLEGTLRLGGLW 50
GLLK LRG L LGFVGT L L LP LC LAT P LTVS LRA LVAGAS RAP PARVA3APW 3 100 
WL LVGYGAAGLSW S LWAVL S PPGAQEKEQDQVNNKVLMWR L LK LSR PD L P 150 
L L V A A F FF L V L A V L G E T L IP H Y SG R V ID IL G G D F D P H A FA SA IF FM C L FS  200 
FGSSL SA G C R GG C FTY T M SR IN LR IR EQ LF SSLLR Q D L G FF Q ETK T G ELN  2 5 0  
SRLSSDT TLM SNW L PL NANVLL RSLVK VV£L YG FM L SISPRLT LLS LLHM 300
PF T IA A E  KVYNT R H y ^ ' L R E I QDAVARAGQVVREA VGGLQ TVRSFGAEEH  
EVCR YKEALEQCRQL^^M ^ R A  LYL LVR R V LH LGV QMLM LSC G LQQM Q
350
400
' QGS L L S F M I Y Q E S V G S H W f LVYIYGDMLSNVGAAEKVFS YMDRQ 450
PNLPSPG T LAPTT LQGW KFQD VSFAYPNRPDRPVLKGLTFT LRPGEVT A 500 
LVGPNGSGKSTVAALLQNLYQPTGGQVLLDEKPISQYEHCYLHSQVVSVG 550 
QEPVLF S GSVRNNITYGLQSCE DDKVMAAAQAAHADDFIQEME HGIYTDV 600 
GEKGSQLAAGQKQRLAIARALVRDPRVLILDEATSALDVQCEQALQDWNS 650 
RGDRTVLVIAHRLQTVQRAHQILVLQEGKLQKLAQL 6 8 6
c) TAP2 encoded by “TAP2E L” of patient “BS”
MRLPDLRPWTSLLLVDAALLWLLQGPLGTLLPQGLPGLWLEGTLRLGGLW 50
GL LK LRG L LGFVGT L L LP LC LAT P LTVS LRA LVAGAS RAP PAR VAS APW S 100
WLLVGYGAAGLSWSLWAVLSPPGAQEKEQDQVNNKVLMWRLLKLSRPDLP 150
L LVAAFF F LV LAV LGET LI PH Y S G R V ID IL G G D F  D P H A FA S A IFF M C L F  S  200
F G S S  LS A G C R G G C FT Y T M SR IN L R IR E Q L FSSL L R Q D L G FFQ E T K T G E L N  2 5 0
SRLSSDT TLM SNW L PL NANVLL RSLVK VW tL Y G F M L S IS P R L T  LLS LLHM 300
P F T I A A E  KVYNTR H QEVLREIQDAVAJRAGQWREAVGGLQTVRSFGAEEH 350
EVCRYKEALEQCRQLYWRRDLERAI, Y L LVRRVLHLGVQMLMLSCGLQQMQ 400
D G E L TQ G SLL SFM IY Q ESV G S YVQA t V  IYGDMLSMVGAAEKVF S YMDRQ 
___________________________
P N L PSPG T  LAPTT L Q G W K F Q D V S F A Y S ^ f c ^ V L K G L T F T L R P G E V T A  
LVGPNGS GKS TVAAL LQNL YQPTGGQVL LDE LH S Q W S V G
QE PV LF S G 3V R N N IT  Y G LQ SC E D D K V M A A A Q A A H A D D FIynIM  iLTDM 
GEKGSQLAAGQKQRLAIARALVRDPRVLILDEATSALDVQCEQALQl  
RGDRTVLVIAHRLQTVQRAHQILVLQEGKLQKLAQL
The sequence and organization o f  the known TAP2 protein sequence (wild type) is 
shown in (a). Transmembrane regions TM1-TM9 are in red and alternate TMs are 
highlighted on yellow and light green background. The putative peptide binding 
domain is bold dark green writing and the Walker A domain, which belongs to the 
nucleotide binding domain (NBD) ofTAP2 is in bold black writing and highlighted on 
pink background. The predicted protein sequences and organization o f TAP2 encoded 
by “TAP2E S ” and “TAP2E L ” are shown in (b) and (c), respectively. Missing pieces 
o f TAP sequences are shown in grey writing on a light-grey background, and missing 
TMs are highlighted on a dark grey background. New pieces o f  sequence in these 
TAP2-variants are highlighted on a cyan background (for” TAP2E S ”) and orange 
(for “TAP2E S ”). Compare also with Figure 5 ("TAP structure and function”, p .30).
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4.3. Discussion
The two sisters presented in this chapter, “RJ” and “BS”, both suffered from 
characteristic clinical symptoms of TAP-deficiency syndrome; both patients suffered 
since early childhood from recurrent bacterial upper respiratory tract infections, and a 
chronic necrotising nodular skin disease appeared in both patients during adulthood. 
Also, the disease course in both patients worsened under immunosuppressive therapy 
and both sisters died of bilateral bacterial lung infection. However, the spectrum of 
clinical symptoms in “RJ” and “BS” extends the formerly known disease 
manifestations of TAP-deficiency. In particular, both patients suffered from 
complicated herpetic fever blisters, herpetic eye involvement and recurrent 
cerebrovascular strokes with progressive neurologic deterioration. The association of 
cerebrovascular strokes and herpetic keratitis in both “RJ” and her sister “BS” are of 
particular clinical interest. The young age of both sisters at the onset of the 
cerebrovascular complications and the lack of known atherogenic risk factors points 
towards a vasculitic process as the cause for the recurrent strokes. Consistent with this 
hypothesis echocardiographic and duplex sonographic examinations in both patients 
were normal. In light of the defective MHC class I antigen presentation pathway in 
both patients, progression of both the ophthalmic and cerebral manifestations under 
immunosuppressive therapy are very well compatible with a viral etiology. Moreover, 
Herpesviridae infections are known causes for both encephalitis and cerebral 
vasculitis in immunosuppressed patients 288.
The above studies have shown that TAP2-deficiency in “BS” was directly 
responsible for the dramatic reduction of MHC class I surface expression on B-
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lymphoblasts. The functional defect in the MHC class I antigen presentation pathway 
in “BS” B-cells was therefore equivalent to the TAP2- and TAPI-deficiencies in 
patients “AK” and “FT”, and patients “GAB”, “SAB”, “NP” and “NV”, respectively, 
whom 1 have described in the previous chapter. Similar to these patients functional 
deficiency of TAP2 in “BS” completely abrogated peptide translocation into the ER, 
and MHC class I molecules were stably bound to the PLC and retained in the ER. 
However, in contrast to all other TAP-deficient patients so far identified the single 
nucleotide defect in the TAP2 gene of “BS” did still allow for expression of a TAP2 
protein that could be detected with antibodies against the COOH-terminus of TAP2.
A previous report in a family with a TAPI-deficient patient found a splice acceptor 
site point mutation in intron 1 causing a frameshift and resulting in a premature Stop 
codon at position 228. The truncated TAPI protein or any TAPI protein variants 
resulting from alternative splicing were not detected in this patient’s B-cells using a
« ♦ 9&Qpanel of antibodies against a TAPI COOH-terminal peptide . On the other hand, 
alternative RNA splicing of TAP2, generating the splice variant TAP2iso, is a
♦ nocommon event in humans . TAP2z'so lacks exon 11 and the original 3’ untranslated 
region, but contains a new exon 12 and new 3’ untranslated region. Interestingly,
TAP2 and TAP2iso encode for TAP2 proteins with different peptide selectivities 98.
The splice donor site point mutation in TAP2E intron 6  of “BS” is unique as it 
leads to the generation of two alternatively spliced RNAs in “BS” B-cells, i.e. “TAP2E 
S” and “TAP2E L”. The predicted TAP2 protein encoded by “TAP2E L” contains 
both the pore forming complex and the peptide binding loop, but lacks the NBD. 
Conversely, the protein encoded by “TAP2E S” contains the complete NBD but lacks
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the peptide binding site. The results shown here for TAP2 in “BS” show that two 
abnormal but complementary TAP2 isoforms can not substitute for one normal TAP2 
protein. The results also show that the peptide binding and nucleotide binding domains 
of both TAPI and TAP2 need to be intact for proper TAP function. On the other hand, 
successful restoration of MHC class I expression in fusion products of “BS” and 
“GAB” B-lymphoblasts ruled out a significant dominant inhibitory effect of the 
mutant TAP2 proteins. Previous studies with GFP-TAP1 fusion proteins have 
suggested that the TAP complex contains hundreds of proteins 90. Normal TAP1/TAP2 
heterodimers in the TAP complex of “GAB”x”BS” fusions were obviously sufficiently 
effective to supply peptides to MHC class I, even in the presence of the abnormal 
TAP1/”TAP2E S” or TAP1/”TAP2E L” heterodimers. This is entirely consistent with 
the fact that TAP-deficiency is an autosomal recessive disease, and that no abnormal 
clinical phenotype has yet been described in heterozygotes 131.
4.4. Conclusions
Detection of both TAPI and TAP2 proteins in the same patient cell line by immuno- 
blotting should not be used to rule out a diagnosis of TAP-deficiency, as alternatively 
spliced mutant TAP RNA can give rise to TAP proteins with abnormal” COOH- 
terminus. Functional studies of the mutant TAP-complex in patient “BS” underpin the 
current TAP topology model and support the notion that functional NBDs from both 
TAP subunits are needed for peptide transport 290. ,
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5. Generation and Validation of human recombinant C D ld- 
tetramers made from inclusion body proteins and their use to study 
TCR V a 2 4 +  and TCR Va24- CDld-restricted T lymphocyte 
populations in humans
5.1. Introduction
Because of both their enigmatic granulomatous skin lesions and respiratory problems 
all TAP-deficient patients described in the previous two chapters were, at several time 
points, examined for suspected tuberculosis (TB). However, multiple diagnostic 
investigations, including acid fast staining, culture and PCR of tissue samples failed to 
demonstrate direct evidence for the presence of mycobacteria. On the other hand, 
purified protein derivative (PPD) based skin testing was positive in all patients, 
indicating that they had been previously exposed to mycobacteria. Furthermore, five 
TAP-deficient patients (“AK”, “FT”, “GAB”, “SAB”, “BS”) had lived for several 
years in countries with high TB prevalence rates. The apparent immune competence of 
these TAP-deficient patients against mycobacteria is still not understood to date.
1A1
Notably, TAP-deficient mice are highly susceptible to infection with Mycobacteria
104
In the mid-nineties a major breakthrough in cellular immunology was the 
discovery of T lymphocyte subsets specifically recognizing lipid antigens presented by 
the nonpolymorphic MHC class I-like CD1 molecules 146. One of the CD l isoforms, 
CDld, was found to be highly conserved in mammals. In contrast, CDla, CDlb, CDlc 
and CDle isoforms were found to be present in humans but not in mice. Intriguingly,
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the first lipid antigens shown to be presented by CD1 to human T lymphocytes were 
mycobacterial cell wall lipids 146. Hence the question arose whether TAP-deficient 
humans, but not TAP-deficient mice, could use CDla, CDlb or CDlc specific T cell 
responses in their defense against mycobacteria.
Recombinant fluorescent-conjugated MHC class I/peptide tetramers had 
already been successfully used since 1996 to sensitively detect and isolate ex vivo 
peptide-specific CD8 + T lymphocytes 2 5 7  291. At the beginning of 1999 I embarked on 
a project to generate CD 1-tetramers, as no tools to sensitively and specifically detect 
and isolate CD1 restricted lipid-specific T lymphocytes ex vivo were available at that 
time.
In this chapter I will describe the generation, validation and use of human 
CDld-tetramers. All experimental results obtained with CD Id-tetramers shown in this 
chapter were obtained with tetramers made from completely denatured and reduced 
inclusion body proteins using the ternary refolding matrix consisting of the GroEL 
minichaperone, the bacterial disulfide isomerase DsbA, and bacterial proline 
isomerase, all immobilized on a sepharose matrix. The same tetramers could also be 
produced by a second novel refolding protocol, which is discussed in the last results 
chapter of this thesis.
First, the potential of CDld-tetramers for detection of invariant NKT cells in 
peripheral blood and tissue of both human and mice will be shown. In addition, CDld- 
tetramer aided detection and isolation of a formerly unknown population of human 
CDld/lipid-specific T lymphocytes, TCR Va24-independent CDld/a-GalCer specific 
T lymphocytes, will be demonstrated.
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5.2. Results
5.2.1. Generation and validation of recombinant human CDld/a-GalCer-tetramers 
Based on primary structure disparities between human CD lb and CD Id with regard to 
hydrophobicity and number of cysteine residues I assumed that CD lb and CD Id 
molecules might have different requirements for successful refolding in vitro. In 
particular, mouse and human CDld have an odd cysteine residue at position 12156,292. 
In the first crystal structure of mouse CDld in 1997 this Cysl2 residue was shown to 
be located at the bottom of the antigen binding groove 155. Mutation of the odd 
cysteine to a serine, as had been previously shown to improve refolding of HLA- 
B27293, was therefore not considered. However, multiple different refolding protocols 
failed to yield detectable amounts of correctly folded CDld/l ipid-monomers.
The technical breakthrough, which finally allowed for the generation of 
correctly refolded CD 1 d/lipid monomers, came with the availability of the CDld 
ligand a-galactosylceramide (a-GalCer or KRN7000, provided by Yasuhiko Koezuka, 
Kirin Brewery, Japan) and a ternary refolding matrix developed by Myriam 
Altamirano and Alan Fersht at the MRC Laboratory of Molecular Biology (LMB) in 
Cambridge 249. In addition, a novel detergent-based protocol, which I had developed 
for the refolding of human CDlb could also be used for generating small amounts of 
functional CDld monomers (results obtained with this protocol will be shown in 
chapter 6 ).
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5.2.1.1. Refolding o f CD 1 d/lipid complex
When conventional-type dilution methods were used to refold CDld, all protein 
precipitated immediately. In contrast, only discrete protein precipitation was seen 
when CDld and (32m inclusion bodies and a-GalCer were refolded with the ternary 
refolding matrix. Importantly, the UV light absorption profile of the refolding 
supernatant at 280nm showed a clearly discernible peak at 160ml elution volume, 
which corresponded to the expected size of 45 kDa for monomeric CDld/p2m/a- 
GalCer -complexes and was highly similar to the elution profiles known for MHC 
class I/(32m/peptide complexes (Figure 34). The same protocol could also be 
successfully used for CDld refolding with other lipid ligands, i.e. p-GalCer, a- 
ManCer, and ganglioside GM1 (data not shown). SDS-PAGE analysis of the eluted 
155-170ml fraction, containing the putative monomeric CD ld/(32m/a-GalCer 
complex, confirmed the presence of both CDld and p2m in these soluble fractions. 
The purified CD I d/p2m/a-GalCer complexes were biotinylated, repurified and finally 
conjugated to fluorescent streptavidin to give R-Phycoerythrin (PE)- or 
allophycocyanine (APC) - conjugated CDld//p2m/a-GalCer tetramers.
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Figure 34. Purification of refolded CDld/p2m/a-GaICer monomers
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Size exclusion chromatography (SEC) and SDS-PAGE o f refolded CDld/(32m/a- 
GalCer. The UV light absorption profde at 280nm wave length showed a clearly 
discernible peak with UV280nm absorption maximum at ca. 160ml elution volume. 
SDS-PAGE Analysis o f the purified fraction containing this peak confirmed the 
presence o f both unglycosylated CD ld (at 33 kDa) and (32m (12 kDa). SEC was 
carried out using a Superdex SD75pg 26/60 column (Amersham Biosciences).
Next, the CDld-tetramers generated by this method were validated for their 
ability to bind sensitively and specifically to invariant Va24+/Vpi 1+ human NKT 
cells.
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5.2.1.2. Specificity of CDld/a-GalCer tetramers for human Va24+VB11+ iNKT cells 
In order to test the specificity of the CDld/a-GalCer tetramers, we generated human T 
cell lines enriched in TCR V a24+V pl1+ double positive invariant NKT (iNKT) cells 
by stimulation of healthy donors’ PBMC with a-GalCer. The specificity of these 
iNKT cell lines for a-GalCer was confirmed by ELISPOT assay demonstrating their 
secretion of both IFN-y and IL-4 upon addition of a-GalCer, but not upon stimulation 
with either the vehicle or a-ManCer (Figure 35).
Figure 35. ELISPOT analysis of V a24+V pll+  invariant NKT (iNKT) lines
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Va24+V(311+ human iNKT lines and Va24-depleted PBMC were tested fo r their IFNy 
and IL-4 production upon stimulation with eithe the vehicle (0.5% polysorbate 20 in 
150mMNaCl), a-ManCer or a-GalCer. Stimulation with phytohaemagglutinin (PHA) 
was used as a positive control.
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Figure 36 shows CDld/a-GalCer tetramer staining of iNKT cells from a 14 
days old a-GalCer stimulated PBMC culture with 44% Va24+Vpi 1+ iNKT cells 
(Figure 36a). Importantly, CDld/a-GalCer tetramer staining identified all Va24+ T 
cells in this culture, demonstrating the ability of CDld/a-GalCer tetramers to 
sensitively detect human V a24+/V pl1+ T cells (Figure 36b). In contrast, CDld- 
tetramers loaded with p-GalCer failed to stain any iNKT cells in this culture (Figure 
36c). Furthermore, preincubation of the iNKT line with unlabelled anti-Va24 and 
anti-Vpl 1 antibodies completely blocked CDld/a-GalCer tetramer staining of these 
lines, confirming the specificity of the CDld-tetramers (Figure 36d). Finally, CDld/a- 
GalCer tetramer+ cells expressing the co-receptor CD4 were sorted, expanded in vitro, 
and analysed for expression of both TCR Va24 and TCR V[311 chains. These 
experiments showed that iNKT cells were enriched to 96% in these in vitro expanded 
cell cultures, confirming the specificity of the CDld-tetramers by a second method 
(Figure 36e).
Taken together, these results showed that human CDld/a-GalCer tetramers 
generated from CDld and P2m inclusion bodies by in vitro refolding using a ternary 
refolding matrix specifically detect human CD ld/a-GalCer specific T cells.
147
Figure 36. CD ld/a-G alC er tetram ers specifically detect V a24+V pll+  T cells
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An in vitro generated human iNKT cell line containing 44% Va24+ V fl  1 + T cells (a) 
was used to validate the specificity o f CDld/a-GalCer tetramers. Double staining o f  
these lines with either CDld/a-GalCer tetramer and anti-TCR Va24 antibody (b) or 
CD Id/(3-GalCer tetramer and anti-TCR Va24 antibody (c) demonstrated the ligand- 
specificity o f these lines. Double staining with CDld/a-GalCer tetramer and FITC- 
conjugated anti-TCR Va24 antibody after incubation with unconjugated anti-TCR 
Va24- and anti-TCR V/311 antibodies was negative. All density plots were gated on 
the CD3+ Propidium iodide' cells; (e) CD4+ CDld/a-GalCer tetramer cells were 
expanded and then analysed for enrichment o fVa24+ Vpll+  iNKT cells.
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5.2.1.3. Sensitivity o f C D ld /a-G alC er tetram ers for human V a24+V B 11+ iNKT cells
To assess the sensitivity of the CD ld/a-GalCer tetramers for detection of human 
iNKT cells in peripheral blood and tissue we obtained PBMC and tissue samples from 
patients with liver disease. The rationale to use samples from patients with liver 
disease was based on the fact that mouse iNKT cells, which use TCR a  and p chains 
that are homologous to those used by human iNKT cells, are highly enriched in mouse 
liver 166, and on a previous study reporting high frequencies of liver infiltrating Va24+ 
T lymphocytes in human viral hepatitis294.
Ex-vivo staining of iNKT cells in PBMC samples from hepatitis patients with 
three different staining methods, including double stainings with CDld/a-GalCer- 
tetramers and anti-TCR Va24 or anti-CD3 antibody, and double staining with anti- 
TCR Va24 and anti-TCR V(311 antibodies, gave very similar results, with iNKT 
frequencies ranging from 0.06% to 2.5% (Figure 37). These results demonstrated that 
CD ld/a-GalCer tetramers could be used to sensitively detect iNKT cells in human 
PBMC samples. They also indicated that the great majority of circulating 
Va24+/Vpl 1+ cells in humans was CDld-restricted.
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Figure 37. Ex vivo detection of iNKT cells with C D ld/a-G alC er-tetram ers 
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Frequencies o f  iNKT cells in human PBMC from patients with hepatitis were 
determined by three different staining methods: Double staining with CDld/a-GalCer- 
tetramers and anti-TCR Va24 antibody (Staining 1), double staining with CDld/a- 
GalCer-tetramers and anti-CD3 antibody (Staining 2) and double staining with anti- 
TCR Va24 and anti-TCR V/311 antibody (Staining 3).
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Next, the CDld/a-GalCer tetramers were assessed for their ability to detect 
Va24/Vpl 1 iNKT cells in liver samples from patients with endstage liver cirrhosis. 
While a previous report had found up to 7% Va24+ T cells in viral hepatitis samples 
our analysis showed only very low frequencies, ranging from 0.03 % up to 0.34%, of 
intrahepatic Va24+Vpl 1 + iNKT lymphocytes in the virus-induced cirrhosis samples 
(Figure 38). Importantly, analysis of the same intrahepatic T lymphocyte samples with 
CDld/a-GalCer tetramers and anti-CD3 antibodies showed highly similar iNKT cell 
frequencies.
Figure 38. Detection of human iNKT cells in liver cirrhosis tissue samples
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lmmunostaining o f intrahepatic T lymphocytes. The two patients with the highest 
frequency ofVa24+V/311+ iNKT cells are shown.
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Further specificity analysis of the intrahepatic T lymphocytes from two 
patients with higher iNKT frequencies showed that they could not be stained with 
either CDld-tetramers loaded with the ganglioside GM1 or with HLA-A23/peptide 
tetramers (data not shown).
5.2.1.4. Cross-species reactivity of CDl d/a-GalCer tetramers for mouse iNKT cells 
Previous studies have demonstated an unusually high degree of cross-species 
reactivity of human and mouse iNKT cells for mouse and human CD ld/a-GalCer 
complex 295-297.
Moreover, insect cell-derived human CDld/a-GalCer dimers, which had been 
developed by another group, were shown to stain mouse a-GalCer specific NKT cells
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In fact, our human CD ld/a-GalCer tetramers stained mouse iNKT cells in the 
spleen thymus and liver of wild type and TAP-deficient C57BL/6 mice, but failed to 
stain any T lymphocytes in (32m-deficient mice (Figure 39).
Taken together these results validated the human CD ld/a-GalCer tetramers 
generated from inclusion body proteins for use in human peripheral blood and tissue 
samples and suggested that they might also be of value for studies in mice.
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Figure 39. Cross-species reactivity of human CDld/a-GalCer tetramers
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Thymic, intrahepatic and splenic mononuclear cells from C5 7BL/6 mice, TAP- 
deficient mice and /32m-deficient mice were stained with antibodies against mouse 
CD3, the mouse pan-NK marker NK1.1 and the human CDld/a-GalCer tetramer. 
Density plots were gated on propidium iodide negative lymphocytes and histogram 
plots were gated on CD3+CDld/a-GalCer tetramer+ propidium negative 
lymphocytes.
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5.2.2 Tetramer-aided identification and characterization o f C D ld /a-G alC er specific
V a24-Jal8 independent, non-invariant human CD8aB+ and CD4+ T lymphocytes 
In the year 2000, the only known subset of human CDld/a-GalCer specific T 
lymphocytes were the CD4+, CD8aa+ or CD4-CD8- double negative (DN) iNKT 
cells. Previous experiments in mice had indicated that CD8af3+ iNKT cells undergo 
negative selection in the thymus due to their high binding avidity to CDld expressing 
cortical thymocytes 166.
The hallmark of human iNKT cells is their usage of an invariant TCR alpha 
chain, which results from the invariant rearrangement of the TCR Variable Alpha 24 
family domain (TCR Va24 according to the Arden Nomenclature; AV10 according to 
the IMGT nomenclature) with the TCR Junctional Alpha 18 family domain (Arden, 
TCR Jal8 ; IMGT, AJ18). In addition, human iNKT T cell receptors (iNKT TCR) 
always make use of the TCR Variable Beta 11 family (Arden, TCR Vpi 1; IMGT, 
BV25-1)299.
Several lines of evidence have indicated that iNKT cells originate from 
common mainstream precursor thymocytes rather than a specific separate precursor 
cell committed to the iNKT lineage before variable gene rearrangement. For example, 
pairing of the invariant V a chain of iNKT TCRs with a particular V{3 chain is not 
forced by molecular constraint 30°. Also, the unused TCR a  and y loci of iNKT cells 
are indistinguishable from those of mainstream T cel ls 149’301. Therefore, antigen 
specificity is more likely to be the driving force for the selection of iNKT cells than is 
genetic programming. This mainstream precursor or “TCR instructive” model of
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iNKT selection has been underpinned by the observation that mouse iNKT cells go 
through a CD4+CD8+ double positive stage during thymocyte development 302.
I reasoned that, if the selection and peripheral expansion of iNKT cells was 
driven by antigen, i.e. CD ld/a-GalCer, then the repertoire of iNKT TCRs should 
contain random rearrangements of different TCR Variable Alpha and Beta segments 
with different Junctional segments, even if one of these rearrangements, i.e. Va24- 
Ja l8 , was clearly dominant over all other rearrangements.
To test this hypothesis I used the recombinant human CDld/a-GalCer 
tetramers to identify potential V a24-Jal8 independent CDld/a-GalCer specific T 
lymphocytes in a-GalCer stimulated in vitro cultures of human peripheral blood 
mononuclear cells.
5.2.2.1. Expansion of CDld/a-GalCer specific Va24-independent T cells in vitro 
from healthy donors’ PBMC
The frequency of Va24+V(311+ double positive iNKT cells in PBMC from healthy 
donors ranges from 0.01% to 1.0%. The CD ld/a-GalCer tetramers bound to a very 
small proportion of Va24-negative/CD3+ cells in fresh PBMC samples from healthy 
donors, and the signals obtained by the tetramer staining could actually not be 
distinguished from background staining with confidence (data not shown). In contrast, 
clearly distinct Va24-negative, CD ld/a-G alCer tetramer+ T cell populations were 
identified by the CDld/a-GalCer tetramers in all of a series of 14 days old, a-GalCer 
stimulated in vitro cultures from seven healthy donors. Frequencies of these Va24- 
CDld/a-GalCer tetramer+ T cells ranged from 1.0% to 5.5% of total lymphocytes
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(Figure 40) and varied with different stimulation protocols. Interestingly, efficient 
expansion of Va24- CDld/a-GalCer tetramer+ T cells required stimulation with 
a-GalCer pulsed mature autologous Mo-DC in some donors, whereas addition of 
a-GalCer to PBMC without Mo-DC was sufficient to visibly expand Va24- 
CDld/a-GalCer-tetramer+ T cells in others (Figure 40). In all donors, a greater 
expansion of Va24- CDld/a-GalCer-tetramer+ T cells was observed when mature, 
rather than immature a-GalCer pulsed Mo-DC were used for stimulation (Figure 40). 
CDld-tetramers loaded with a-mannosylceramide (a-ManCer) failed to stain both 
Va24+Vpl 1+ iNKT cells and Va24- CD ld/a-GalCer tetramer+ T cells, confirming 
the specificity of CDld/a-GalCer tetramer binding (data not shown). The lack of TCR 
Va24 expression by these Va24- CDld/a-GalCer tetramer+ cells was confirmed on 
FACS-sorted and in vitro expanded Va24- CDld/a-GalCer tetramer+ lines and clones 
(Figure 41).
These results showed that recognition of CD ld/a-G alCer in humans is not 
limited to the invariant Va24+Vpi 1+ TCR. To assess the diversity of human T cell 
receptors capable of specifically recognizing CDld/a-GalCer complex we analysed 
both the TCR usage and antigen specificity of Va24-CDld/a-GalCer tetramer+ T 
lymphocytes.
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Figure 40. In vitro expansion of Va24- CDld/a-GalCer tetramer+ T cells
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PBMC from different donors (shown are results for Donors 1, 3 and 6) were co­
cultured with lOOnM a-GalCer alone (density plots on the left-hand side), a-GalCer 
pulsed immature Mo-DC (density plots in the middle), or CD40L matured, a-GalCer 
pulsed Mo-DC (density plots on the right-hand side). Percentages ofVa24- CDld/a- 
GalCer tetramer+ cells among propidium iodide negative, CD3+ small lymphocytes 
are shown.
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Figure 41. Sorting of Va24- CDld/a-GalCer tetramer+ T cell clones and lines
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Va24-CD3+CDld/a-GalCer tetramer+ were sorted by FACSVantage (dot plot on the 
left hand side) and expanded in vitro fo r  16 days. The resulting clones and lines were 
tested again fo r expression o f TCR Va24 chain and CDld/a-GalCer tetramer binding. 
Results fo r 3 different lines and one clone are shown on the right-hand side.
522 .2 . TCR Va- and TCR VP repertoire of Va24- CD ld-a-GalCer specific T cells 
Human Va24+Vpi 1+ iNKT lymphocytes use TCR V(311 domains with polymorphic 
CDR3p regions 303. On the other hand, the murine equivalent to human Va24+Vpl 1 + 
iNKT lymphocytes, Val4-Ja281+ iNKT lymphocytes, use several different TCR Vp 
families with polyclonal CDR3p regions 304. For these reasons it has been proposed, 
that the Vp chain does not contribute to the specific recognition of CDld/a-GalCer3(b 
Interestingly, a substantial proportion of Va24- CDld/a-GalCer specific T cells 
expressed Vp 11 (Figure 42).
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Figure 42. V p il usage by Va24- CDld/a-GalCer+ T lymphocytes
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PBMC (shown here for Donor 1) were co-cultured with LPS-matured, a-GalCer 
pulsed Mo-DC. Immunostaining and FACS analysis were carried out with 
CDld/a-GalCer tetramers and either anti-Va24-specific antibodies (density plot on 
the left-hand side), or a mixture o f  anti-Va24 and anti-V/311 specific antibodies 
(density plot on the right-hand side). Percentages o f  propidium iodide negative, CD3+ 
lymphocytes are shown.
In order to determine the usage of TCR Va- and Vp-chains of Va24- 
CDld/a-GalCer specific T cells we subjected a polyclonal Va24-CDld/a-GalCer 
tetramer+ line to spectratype analysis. The spectratype analysis demonstrated that this 
Va24- CDld/a-GalCer specific line contained clones using several different TCR Va 
families, TCR Vp families, and jp  segments (Figure 43 and Table 4). Prominent 
expansions for seven different TCR Va families (Va2, 6, 8, 15, 20, 23, 26) and seven 
different TCR Vp families (V p l,3 , 9, 11, 12, 18, 23) with different CDR3 lengths, 
also within the same family (e.g. Vp3), were shown to be present in this line.
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Figure 43. Spectratype analysis of a Va24- CDld/a-GaICer-tetramer+ T cell line
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Spectratype analysis was carried out on mRNA from a pure polyclonal Va24- CDld- 
a-GalCer tetramer+ line, which had been obtained by FACS-sorting o f3000 Va24- 
CDld-a-GalCer tetramer+ T lymphocytes. Contamination o f the samples with cDNA 
from Va24+ cells was ruled out (top row, panel on right-hand side).
>98% Va24
Spectratype
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Table 4. Spectratype analysis of Va24- CDld-a-GalCer tetramer+ T cells
Va
family
CDR3a
length
vp
family
CDR3p
length
JP
family
Va2 12 BV1 8 2.7
AV6 1 BV3 10/14 2.7/2.3
AV8 10 BV9 8 2.7
AVI 5 15 BV11 14 2.3
AV20 20 BV12 10 2.7
AV23 3 BV18 10 1.4
AV26 3 BV23 8 2.7
Guided by the results of the spectratype analysis, I tested five Va24- 
CDld/a-GalCer tetramer+ oligoclonal lines and one Va24- CD ld/a-GalCer 
tetramer+ clone obtained from the same donor for binding to different anti-TCR Vp 
antibodies. Consistent with the results from the spectratype analysis, three lines 
expressed TCR V pl, and two lines and the clone were TCR Vpl 1+ (data not shown).
Pre-incubation of a pure Vpl+ Va24- CD ld/a-GalCer tetramer+ line with an 
anti-Vpl -specific monoclonal antibody significantly reduced staining by 
CDld/a-GalCer tetramers, while pre-incubation of the same line with anti-TCR Vpl 1 
antibodies had no effect on tetramer staining (Figure 44a). Similarly, pre-incubation of 
an oligoclonal Va24- CD 1 d/a-GalCer tetramer+ line containing both Vpl+ and 
Vpl 1+ expressing cells with anti-Vpi 1 antibody selectively reduced tetramer staining 
of Vpi 1+ cells (data not shown). These results formally demonstrated that staining of 
these Va24- T cell lines by CDld/a-GalCer tetramers was caused by specific binding 
of the tetramer to the TCR, but not to other receptors or non-specific binding to the T
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lymphocyte membrane. Consistently, CDld/a-GalCer tetramer staining of Va24- 
CDld/a-GalCer tetramer+ T cell lines could be partially blocked by pre-incubation of 
the cells with an excess of CDld/a-GalCer monomers (Figure 44b).
Taken together, these results demonstrated that a-GalCer not only stimulates 
Va24+Vpl 1+ iNKT lymphocytes, but can also efficiently induce a CD ld/a-GalCer 
specific polyclonal, Va24-independent T cell response. TCR Vpi 1 is over represented 
among Va24- CD ld-a-GalCer specific T cells, suggesting either an inherent affinity 
of Vpl 1 to CD Id molecules or its direct involvement in specific recognition of 
a-GalCer.
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Figure 44. Specificity of binding of CDld/a-GalCer tetramers to Va24- T cells
C D ld/a—GalCer tetramer
C D ld /a—GalCer tetramer
(a) Pre-incubation o f  a Va24- V/31+ T cell line with anti-TCR Vf3l antibody (bold 
line), but not with anti-TCR V/311 antibody (thin line) reduced the binding o f  
CDld/a-GalCer tetramers. (b) Pre-incubation o f a Va24- V/311+ line with 50x excess 
(bold line) or 25x excess (thin line) o f CDld/a-GalCer monomers partially blocked 
CDld/a-GalCer tetramer staining compared to pre-incubation o f the cells with PBS 
(grey area).
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5.2.2.3. Functional analysis of Va24- CD ld/a-GalCer specific T lymphocytes 
To assess antigen specific functions of the Va24- CDld/a-GalCer tetramer+ T 
lymphocytes, I first studied their capacity to specifically kill CD 1 d-transfected C 1R- 
cells (ClR-CDld) pulsed with different antigens, i.e. a-GalCer, a-M anCer or the 
vehicle. CD4+ and CD8ap Va24- CDld/a-GalCer tetramer+ T cells very efficiently 
lysed a-G alCer pulsed C 1R-CD1 d, but not C 1R-CD1 d pulsed with either a-M anCer 
or vehicle (Figure 45). Va24- CDld/a-GalCer tetramer+ T cells and Va24+Vpl 1 + 
iNKT were equally efficient at killing a-GalCer pulsed targets.
Figure 45. Lysis of a-G alCer pulsed CD ld+ targets by Va24- T lymphocytes 
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One Va24+Vpl 1+ iNKT line and 4 different Va24- CDld/a-GalCer tetramer+ T cell 
lines and clones were tested for their antigen specific lysis o f  CD Id-expressing C l R 
B-lmphoblasts. Specific lysis (%) is indicated on the y-axis and the effector to target 
(E:T) ratio is shown on the x-axis. Antigens used were a-GalCer, a-ManCer and the 
vehicle.
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Next I assessed antigen- and mitogen-induced cytokine secretion of two Va24- 
CDld/a-GalCer specific T cell lines compared to a Va24+Vpi 1+ iNKT line by 
intracellular cytokine staining. Either ClR-CDld lymphoblasts pulsed with 
glycolipids or a combination of phorbolmyristate acetate plus ionomycin (PMA/IM) 
were used for T cell stimulation. All tested Va24- and Va24+ lines secreted various 
cytokines, including IL-2, IFNy, IL-13 and IL-4 in response to both a-GalCer and 
PMA/IM, but not in response to a-ManCer (Figure 46). Some lines, such as the CD4+ 
Va24- T cell “line 2C” secreted IL-2 (data not shown), IFNy, IL-13 and IL-4, whereas 
other Va24- CDld/a-GalCer specific lines secreted IL-2, IFN-y and IL-13, but not 
IL-4. Interestingly, the Va24- CD ld/a-GalCer specific “clone 2A”, which 
specifically lysed a-G alCer pulsed ClR-CDld (compare Figure 45), did not secrete 
IFNy. As expected, the tested Va24+Vpl 1+ iNKT lines produced IL-13, IFNy, IL-4 
and IL-2 (data for IL-4 and IL-2 not shown). A similar cytokine secretion pattern for 
human iNKT cells has been previously reported by others 299.
Taken together these results suggested that Va24- CDld/a-GalCer specific T 
lymphocytes are similarly potent to produce cytokines as Va24+ iNKT cells.
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Figure 46. Cytokine production by a-GalCer specific Va24- and Va24+ T cells
Line ID Line 2C Va24+
a —GalCer
a—ManCer
PM A&
iononivein
Intracellular cytokine staining ofVa24- and Va24+ CDld/a-GalCer tetramer+ T 
lymphocytes after their stimulation with either a-GalCer pulsed (top row) or 
a-ManCer pulsed (middle row) C lR-CD ld lymphoblast or after nonspecific 
activation with PMA and ionomycin (bottom row). The Va24- lines 2C and ID were 
>99% pure fo r  Va24-Vfl+ and Va24-V/311+ CDld/a-GalCer-tetramer+ T cells. 
Results shown are representative o f  two experiments.
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5.2.2.4. CD4/CD8-coreceptor use and CD161-expression by Va24- CDld/a-GalCer
specific T cells
Mouse and human iNKT cells are either CD4+CD8- or CD4-CD8- (i.e. DN) 166’299. 
Interestingly, a significant proportion of Va24- CDld/a-GalCer specific CD4- T cells 
in several donors expressed the CD8a(3 heterodimer (Figure 47), while all other Va24- 
CDld/a-GalCer specific T cells were CD4+CD8- (data not shown). In contrast, CD4- 
CD8- DN Va24- CDld/a-GalCer specific T cells were not found in any of the seven 
donors included in this study (data not shown).
The great majority of a-GalCer specific mouse and human iNKT cells express 
the pan-NK marker CD 161 (NKR-P1), an NK-locus encoded C-type lectin. The 
majority of Va24+V(311+ iNKT cells expressed CD161 (Figure 47). In contrast, 
CD161 was detected only on a small proportion of CD4+ CD8ap- Va24- 
CDld/a-GalCer tetramer+ cells (data not shown) and was hardly expressed by 
CD8ocp+ Va24- CDld/a-GalCer tetramer+ cells (Figure 47).
In order to investigate the possible functional role of CD8a(3 co-receptor 
expression in Va24- CDld/a-GalCer specific T cell lines, I examined specific lysis of 
a-GalCer pulsed ClR-CDld cells by CD8a(3+ Va24- cells in the presence of a 
blocking anti-CD8 antibody 254. These experiments showed that incubation with the 
anti-CD8 blocking antibody, but not with an irrelevant isotype matched control 
antibody, significantly reduced specific lysis of a-GalCer-pulsed ClR-CDld cells 
(Figure 48).
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Figure 47. Co-receptor and CD161 expression on Va24- and Va24+ T cells
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Cells from one healthy donor were stained with CD 1 d/a-GalCer-tetramer, anti-Va24, 
and either anti-CD8(d (top row), anti-CD4, (middle row) or anti-CD161 (bottom row) 
antibodies, two weeks after in vitro stimulation with lOOng/ml a-GalCer. Histogram 
plots were gated on CDld/a-GalCer tetramer+ Va24+ and Va24- T lymphocytes 
(left and middle) and on CDld/a-GalCer tetramer- lymphocytes (right). Percentages 
o f C D 8ff, CD4+, and CD161+ cells in the gated population are shown. Propidium 
iodide staining was used to exclude dead cells from the analysis.
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Figure 48. CD8 Co-receptor dependent killing by CD8ap+ Va24- C D ld/a- 
GalCer specific T lymphocyte lines
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ClR-CDld lymphoblastoid cells pulsed with a-GalCer or the vehicle were used as 
targets for two C D 8a(f Va24- CD Id/a-GalCer tetramer + T cell lines (D5 and D6) in 
a standard 51 Cr-release assay in the presence o f either the anti-CD8 blocking antibody 
MF8 or an irrelevant isotype matched control antibody. Specific killing by the line D5 
in the presence o f either antibody is shown in (a), and MF8 antibody mediated 
inhibition o f  target cell lysis by lines D5 and D6 at a 9:1 effector: tar get (E:T) ratio is 
shown in (b).
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5.2.2.5. Differential binding o f C D ld /a-G alC er monomers to CD 8aB+ V a24- and
CD4-CD8- (DN) V a24+  CDld/a-GalCer specific T cells
Mouse V al4+  iNKT cells have previously been shown to bind CDld/a-GalCer
305monomers . Similarly, I found that CD ld/a-GalCer monomers bound to a DN 
Va24+ V|311+ line. However, CD ld/a-GalCer monomers failed to stain any of our 
CD8aP+ Va24- CDld/a-G alCer specific T cell clones or lines (Figure 49/a). Both 
CD8ap+ Va24-and DN Va24+ CDld/a-GalCer specific cells showed identical levels 
of both CD3 expression and CDld/a-GalCer tetramer staining (Figure 49/b, and data 
not shown).
Interestingly, CDld/a-GalCer monomer staining of the DN Va24+ Vpl 14- 
line disclosed two distinct populations suggesting the presence of clones with different 
binding affinities to CDld among these DN Voc24+ Vpi 1+ cells. By combining the 
monomer-staining with a chase-experiment I estimated the half-life of monomer 
binding to DN Va24+ Vpl 1+ to be in the range of approximately 50 minutes (Figure 
49, and data not shown).
These results were consistent with the hypothesis that the CD8ap+ Va24- 
CDld/a-GalCer specific T cells expressed TCRs with lower affinity for 
CDld/a-GalCer compared to DN Va24+ v p i  1+ iNKT cells.
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Figure 49. CD ld/a-G alC er M onomer binding to Va24+ and Va24- T cells 
a) Va24-/CD8ap+ Va24+/DN Chase time
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Cells were sequentially stained with CD ld/aG alC er monomers and PE- 
Extraavidin (bold lines in (a)) or with CD ld/aG alCer tetramers (bold lines in
(b)) or PE-Extraavidin only (grey area in (a,b)). In chase experiments (a) cells 
were incubated at 3 7 °C fo r  0, 15, 30, or 60 minutes after PE-Extraavidin 
staining and two washes with PBS. Percentages o f  monomer- and tetramer 
stained cells are shown fo r  each histogram plot.
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5.3. Discussion
In this chapter I have described the generation and validation of human CD 1 d/lipid- 
tetramers for detection of CD ld-restricted T lymphocytes in peripheral blood and 
tissue.
Murine CD Id-tetramers using CDld/f32m monomeric complexes secreted by 
insect cells have been generated by other research groups 298,305. However, loading of 
these complexes with endogenous lipids155 might affect their sensitivity and 
specificity. In contrast, the methods shown here, i.e. in vitro refolding of completely 
denatured and reduced recombinant bacterial inclusion body proteins in the presence 
of a specific single lipid ligand, should effectively avoid such problems.
My first refolding trials of CD lb and CD Id, using several protocols that were 
based on the classic dilution method used for refolding MHC class I/p2m/Peptide-
257 291complexes ’ , completely failed. Similarly, simple detergent-assisted dilution
additive methods were unsuccessful. On the other hand an artificial chaperone 
approach, which I had developed in parallel for the efficient refolding of 
CDlb/p2m/lipid complexes, yielded only very small amounts of CDld/a-GalCer 
monomeric complexes.
The marked hydrophobicity of all CD1 molecules was an obvious likely cause 
of hydrophobic aggregation of CD1 proteins during early refolding stages. In addition,
1 9the presence of an unpaired Cys m CD Id was also likely to further potentiate protein 
misfolding and aggregation. These problems could eventually be overcome and the 
yield of properly refolded CDld/p2m/Iipid monomers significantly increased by using 
a ternary refolding matrix, which had previously been shown to efficiently assist the
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refolding of scorpion toxin, a highly hydrophobic protein with multiple cysteines306. 
The refolding matrix consists of three components, which are immobilized on a 
sepharose matrix: The GroEL minichaperone can prevent hydrophobic interactions of 
early folding intermediates, while disulfide isomerase (DsbA) and prolyl isomerase 
catalyse the formation of native disulfide bonds and correct proline isomerization, 
respectively 249’306. Applying this refolding matrix for human CDld proteins allowed 
me to generate milligram amounts of monomeric CDld/(32m/a-GalCer complexes, 
which could be purified by size exclusion chromatography.
Fluorescent-conjugated tetramers generated from these CDld/p2m/a-GalCer 
complexes sensitively and specifically stained human Va24+V(311+ iNKT cells in 
peripheral blood and tissue. In addition, in vitro generated T lymphocyte lines, which 
had been expanded from CDld/a-GalCer tetramer+ CD3+ double positive FACS 
sorted cells, were enriched to > 95% for Va24+/V(311+ iNKT cells, confirming the 
specificity of the tetramers.
Using the CD ld/a-GalCer tetramer we measured frequencies of intrahepatic 
iNKT cells in patients with end-stage liver cirrhosis. Consistent with previous reports 
in mice, almost all CDld-tetramer+ CD3+ intrahepatic cells were either CD4 or DN T 
cells166. However, our analysis indicated that iNKT cells are not significantly enriched 
in cirrhotic human liver, which might indicate differences in tissue distribution 
between humans and mice.
Interestingly, in three patients with viral hepatitis the CDld-tetramer+ CD3+ 
tetramers stained a distinct TCR Va24-negative T cell population within the DN 
subset, representing 0.28% - 0.69% of all intrahepatic DN T cells. This suggested the
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possibility that, in addition to the known iNKT cell subset, other CD Id-restricted and 
a-GalCer specific T lymphocytes might exist in humans.
I therefore made use of the CD ld/a-GalCer tetramers to further investigate the 
hypothesis that recognition of CDld/a-GalCer complexes was not absolutely 
restricted to iNKT cells bearing the invariantly rearranged TCR V a24-Jal8 chain, but 
could also be mediated by other randomly generated TCRs. In support of this notion, 
evidence from mouse studies had previously indicated that iNKT cells branch off the 
mainstream developmental pathway because of their TCR specificity 149,300'302.
The results of these studies demonstrated the existence of distinct Va24- 
negative, CD ld/a-G alCer specific T lymphocyte populations in human peripheral 
blood. These novel CD Id-restricted T cells could only be reliably detected upon in 
vitro stimulation of PBMC with a-GalCer. a-GalCer pulsed mature Mo-DCs 
provided the strongest stimulus for in vitro expansion of these Va24-negative T cells. 
However, simple addition of a-GalCer to PBMC cultures was sufficient to expand 
Va24- CDld/a-GalCer tetramer+ cells to 5.5% in one donor, suggesting that these 
cells were already expanded in vivo, albeit at a frequency below the threshold for 
tetramer staining.
The restriction to CD Id and specificity for CDld/a-GalCer of these novel T 
cell subsets was demonstrated in several ways: Va24- CDld/a-GalCer tetramer+ 
lines and clones specifically killed a-GalCer pulsed, but not a-M anCer pulsed CD Id 
expressing target cells, demonstrating their specificity for the CD Id bound glycolipid 
ligand. Furthermore, pre-incubation of Va24- CDld/a-GalCer tetramer+ cells with
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specific anti-Vp chain antibodies or an excess of CDld/a-GalCer monomers clearly 
reduced CDld/a-GalCer tetramer staining.
Our spectratype analysis revealed that a wide variety of TCR Va and Vp 
segments can be used by Va24- CDld/a-GalCer tetramer+ cells, which supports a 
mainstream model of iNKT cell thymic selection. However, a marked bias for the use 
of Vpl 1 by Va24- CD ld/a-GalCer tetramer+ was observed in several in vitro 
cultures from different donors. Previous tetramer based studies of iNKT cells in mice 
have suggested, that the CDR3p regions are permissive, but do not specifically 
contribute to the recognition of CDld/a-GalCer complexes 305. The findings of my 
study did not exclude this possibility but they suggested the possibility that certain 
Vpl 1 regions might have an inherent affinity for CD Id, similar to the known inherent 
affinity of certain Vp regions for MHC II 307. In fact, the recently solved crystal 
structures of unbound human iNKT TCRs and of the CDld/a-GalCer/iNKT TCR 
complex have underpinned a role for the CDR2p loop of Vpi 1 in the molecular 
interaction with the a  1 helix of CD Id 187,241.
“Conventional” invariant NKT cells in humans and mice exhibit a CD4+ or a 
DN phenotype 299. In contrast, all Va24- CDld/a-GalCer specific T cells in the seven 
tested donors were either CD4+ or CD8ap+, while no DN Va24- CDld/a-GalCer 
tetramer+ could be detected. Interestingly, the cytotoxic activity of Va24- 
CDld/a-GalCer specific CD8ap+ T cells was clearly reduced by an anti-CD8 
blocking antibody, indicating that CD8ap exerts a role as a co-receptor for these cells. 
Previous studies in mice have suggested that CDld interacts with CD8 149,166)300.
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Lantz and colleagues have shown that in Val4-Joc281-transgenic mice the CD8- 
compartment is selectively depleted of V(37 and V(38, i.e. the main Vp chains used by 
mouse Val4-Ja281 iNKT cells 30°. Similarly, Val4-Ja281 iNKT are negatively 
selected in CD8 transgenic mice 149, which suggests that iNKT cells bear TCRs with a 
high inherent affinity for CD Id molecules. Consistent with this notion, I have shown 
that DN iNKT cells can bind monomeric CDl d/a-GalCer complex, whereas Va24- 
CDld/a-GalCer specific CD8aP+ T cells do not bind. Lineage decisions for 
CD1 d/lipid-specific human iNKT cells might therefore follow similar principles as 
MHC/peptide-specific T cells; higher affinities of the TCR-peptide/MHC interaction 
favor the development of a CD4+ phenotype and lower affinities rather result in a 
CD8+ phenotype 308' 309.
TCR binding kinetics might also determine the expression of CD161 (NKR- 
P l) by iNKT cells 310'312. Intriguingly, CD161 was rarely expressed on CD4+ Va24- 
CDld/a-GalCer specific T cells and not detected at all on CD8aP+ Va24- 
CDld/a-GalCer cells.
Based on the results presented in this chapter I hypothesize that in humans, a 
wide variety of CDld/a-GalCer specific TCRs are generated by random TCR 
rearrangement, and that the binding affinity of the TCR to CDld/a-GalCer complex 
determines both CD 161 expression and CD4/CD8ap/DN lineage commitment. The 
reason why one type of TCR rearrangement, i.e. the iNKT TCR, is so clearly favoured 
over other possible TCR rearrangements is unclear. The successful in vitro expansion 
of Va24- CDld/a-GalCer specific T cells upon stimulation of PBMC with a-GalCer 
could be due to lower affinity of their TCRs for CDld/a-GalCer or by their lack of
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CD161 expression. My own recent studies indicate that the former possibility may be 
less likely241.
The existence of human Va24- CDld/a-GalCer specific T cells has potential 
clinical implications in that injection of a-GalCer in vivo for therapeutic reasons 
might induce expansion of these T cells. Since the in vivo function of these cells is 
completely unknown, tetramer-based monitoring of Va24- CD ld/a-GalCer specific T 
cells as well as iNKT cells should be carried out in a-GalCer receiving patients. In 
fact, a recent paper has found Va24- CDld/a-GalCer tetramer+ T lymphocytes ex
TITvivo in the peripheral blood of patients that had been treated with a-GalCer
5.4. Conclusions
Human CDld-tetramers loaded with single lipid ligands can be generated from 
completely denatured and reduced inclusion body proteins by in vitro refolding.
These tetramers are highly sensitive and specific and allow for detailed phenotypic 
analysis and direct in vitro and ex vivo isolation of CD Id-restricted, lipid-specific T 
cells from peripheral blood or tissue. The CDld-tetramer aided identification and 
characterization of a novel lipid-specific human T lymphocyte population illustrates 
the potential of these reagents as powerful tools for the study of CD1 restricted 
immune responses.
Specific recognition of CDld/a-GalCer complex can be mediated by human 
Va24-JaQ-independent T cell subsets using diverse TCR V a and TCR Vp families. 
The existence of these novel T cells strongly suggests antigen driven selection of
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CDld/a-GalCer specific T cells and therefore underpins a TCR-instructive model of 
iNKT cell differentiation.
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6. Refolding and structure determination of recombinant lipid- 
loaded human C D lb  molecules
6.1. Introduction
The initial objective to obtain recombinant human CDl/lipid-tetramers was to use 
them for the study of mycobacterial lipid specific, CD 1-restricted T cell responses in 
TAP-deficient patients (see p .135). Human CD1 group 1 isoforms CDla, CDlb and 
C D lc146,314’315, but not CDld or CDle, had been previously shown to present 
mycobacterial lipids to T lymphocyte lines in vitro, but efficient tools to study these T 
lymphocytes ex vivo were not available.
On the other hand, it was completely unknown how individual group 1 CD1 
molecules could present Lipid ligands of greatly different fatty acid composition to T 
cell receptors. This property of CD1 molecules is most dramatically illustrated by 
human CDlb, which can present either a C32 (i.e. 32 carbon atom containing) or a 
C84 glucomonomycolate to the same CD lb-restricted T lymphocyte clone 172,196. The 
crystal structure of mouse CD ldl at a resolution of 2.7 A, published in 1997, had 
shown that the CDld antigen binding groove contained two voluminous hydrophobic 
pockets 155. However, the CDld structure could not explain how CDlb molecules 
could accommodate very long fatty acids such as mycobacterial mycolic acids on the 
one hand, and shorter glycolipids, such as sphingosines on the other hand. In addition, 
some ill-defined electrodensity was apparent inside the pockets of mouse CDld and
was thought to belong to a then unidentified (later shown to be phosphatidylcholine
1 82) endogenous lipid ligand from the insect cell derived mouse CDld molecules used
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for crystallisation. Importantly, such “contamination” of insect cell derived CD1 
molecules with endogenous ligands might greatly weaken the potential use of such 
molecules for the detection of lipid-specific T lymphocytes. Therefore, refolding in 
vitro of completely denatured and reduced recombinant CD1 and p2-microglobulin 
(p2M) inclusion body proteins, produced in E.coli, was chosen as a general approach. 
In analogy to established successful protocols for refolding of denatured and reduced
9Q1MHC class I molecules only the extracellular region of CD1 heavy chain (residues 
1-283) was used to make recombinant soluble CD1 molecules.
In 1999, at the time when I planned the first refolding trials for CD1 molecules 
the only known CD1 presented mycobacterial lipids were lipoarabinomannan (LAM), 
mycolic acid, phosphoinositomannosides PIM2 and PIM4, and glucomonomycolate. 
LAM contains a ca. 17 kDa large polar headgroup and can only be recognized by 
CD lb-specific T cells upon enzymatic processing of the headgroup in late endocytic 
compartments, i.e. after its transformation into PIMs. However, at the time it was not 
possible for us to obtain milligram amounts of either PIM2 or PIM4 for the refolding 
trials. Similarly, glucomonomycolate and mycolic acid were not available in high 
enough quantities. In addition, mycolic acid is extremely hydrophobic, and I therefore 
did not consider it as a ligand for initial refolding trials. Early reports on CD1 
molecules had suggested that CD1 was both thermostable and stable without bound
o i z:
lipid ligands . On the other hand, CDlb restricted, sphingolipid specific T cell 
responses had been reported by others177. With regard to their potential use in my 
refolding trials, several of these sphingolipids, in particular the gangliosides had two 
obvious advantages over mycobacterial lipids: they were commercially available and
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known to be soluble in aqueous solutions. Based on these facts I decided to first design 
a protocol for refolding CDlb without lipid ligands and to add sphingolipids such as 
gangliosides later, once promising results had been achieved with that protocol.
In this chapter I will report the refolding and crystallisation of two human 
CD lb/lipid complexes and describe their three-dimensional atomic structures.
6.2. Results
6.2.1. CDlb refolding and crystallisation
All known standard protocols used for refolding of MHC class I/(32m-peptide 
complexes failed when applied to human CDlb molecules. An obvious qualitative 
difference between MHC class I and CDlb is the higher content of neutral and 
hydrophobic amino acids in CDlb, which reflects its function as a lipid-binding 
molecule. Therefore I tested several detergent-assisted refolding protocols to reduce 
hydrophobic protein aggregation by protecting exposed hydrophobic surfaces of early 
refolding intermediates (see methods). A screen of 81 minirefoldings using different 
ionic, non-ionic and zwitterionic detergents at different concentrations suggested that 
the ionic detergent CTAB (CetylTriAmmonium Bromide) at 0.5mM concentration 
was effective at keeping CDlb in solution. However, ionic detergents usually form 
stable interactions with proteins, which can impede completion of the protein folding 
process. On the other hand, CTAB had previously been successfully applied to refold 
two relatively hydrophobic proteins, namely citrate synthetase and carbonic anhydrase
317 318 , by using cyclodextrins to remove the protein bound CTAB. I therefore
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incorporated P-cyclodextrin in the refolding protocol. The newly developed protocol 
was first used to refold CDlb and p2m in the absence of added lipid ligands and the 
concentrated refolding mixture was analysed by size exclusion chromatography. The 
AU280nm absorption profile of the refolding mixture showed a large aggregate peak 
followed by a distinct peak at ca. 150-170ml elution volume, i.e. in the expected 
region for CDlb/p2m monomers. SDS-PAGE analysis of this peak showed that it 
contained both CDlb and P2m, but re-purification of the same peak after only 1 day 
suggested that this protein species was not very stable (Figure 50/a, left panel). In 
subsequent trials I added potential CDlb lipid ligands, e.g. phosphatidyl-inositol, P- 
glucosylceramide or gangliosides to the refolding. Interestingly, the addition of any of 
these lipids greatly enhanced the size of the putative CD lb monomer peak and 
enhanced the stability of these CDlb/p2m complexes (Figure 50a, right panel, and 
50 b).
The presence of the lipid ligand in these “monomer peaks” was confirmed for 
CDlb re foldings with the ganglioside GM1. “Monomer peaks” were analysed for the 
presence of GM1 by ELISA using the highly GMl-specific cholera toxin p subunit 
(conjugated to horseradish-peroxidase).
These results showed that it is possible to refold CD1 molecules from completely 
denatured and reduced inclusion body proteins. Furthermore, short-chain detergents 
such as CTAB can assist the refolding of the hydrophobic CDlb proteins, but they fail 
to efficiently stabilise non-glycosylated E.coli derived CDlb molecules in the absence 
of appropriate two-alkyl chain containing lipid ligands. The comparison of “detergent-
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only” and “detergent + ligand” CDlb refolding profiles indicated that the dominant 
protein peak at 152ml contained functional complex.
Figure 50. Refolding of human C D lb with and without added lipid ligands 
a ) = U P ®  + LIPID
After 1 d a y After 1 w e e k
152 165
180  ml100 120 140  160 180  200 100 120 140 160
400
□  Detergent only 
— Detergent + GM2
300
inA U
200
100
0
220 ml120 140 160 180 200
elution volume
(a, left), Refolding o f CDlb in the absence o f added lipid ligands. Re-purification o f  
this peak after 1 day showed that it was relatively unstable (inset), (a, right), Refolding 
in the presence o f  phosphatidylinositol (PI). The resulting peaks at 152 and 165ml 
were stable.
(b) Two 250ml refoldings o f  CDlb with (bold black line) or without (grey area) the 
CDlb ligand ganglioside GM2, carried out and analysed in parallel.
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After further optimization and upscaling of the detergent-assisted refolding 
protocol I was able to generate milligram amounts of both CDlb/p2m/PI (CDlb-PI) 
and CDlb/p2m/ganglioside (CDlb-GM2). After screening of 250 different 
crystallisation conditions I succeeded in obtaining several protein crystals from both 
complexes (Figure 51). The best diffracting CDlb-PI and CDlb-GM2 crystals yielded 
data to 2.3 A and 2.8 A, respectively, which allowed the atomic structures of both 
human CD lb/ligand complexes to be determined.
Figure 51. Protein crystals of human CDlb/p2m/lipid complex
CII-20 P I-15 (PI) P I-15 (PI) P I-10
PI-12 CII-15 PI-15 CI-42
Crystals grown in conditions PI-15 and PI-10 were used fo r data acquisition.
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6.2.2. The structure o f  human C D lb  with bound ligands
Table 5 shows the statistics for data collection and refinement
6.2.2.1. Structural features of the CDlb binding groove
The CDlb heavy chain and (32m structures are identical in CDlb-PI and CDlb-GM2. In the 
following analysis I will focus on the higher resolution CDlb-PI structure. Both structures 
reveal a network of hydrophobic channels at the core of the a la 2  domain, which are 
saturated by four 11-22 hydrocarbon atoms chains (Figure 52). The binding groove 
architecture of CDlb is radically different from that of classical MHC class I and II 
molecules. The total volume (2200 A3) of the network is filled by the hydrocarbon chains. 
No buried water molecules are present. In an extension of the analogy with MHC class I 
binding pocket nomenclature introduced for mouse C D ld155, the three CDlb binding 
channels that connect directly to the surface are denoted as A', C' and F', with the fourth, a 
distinct tunnel, designated T' (Figure 52, 53, 54). Details of the key binding groove features 
are shown in Figure 53. Channels A', C! and F' interconnect via a tunnel T' (Figure 53/b). 
The sequential connection of A', T' and F’ could accommodate alkyl chains of up to 60 
carbon atoms. Channel C  leads from the T cell receptor (TCR) recognition surface between 
the a l  and a2 helices to a portal in the side of the molecule beneath the a2 helix (Figure 
53/d). The portal is surrounded by CDlb heavy chain residues 126-131 and 145-159 and is 
stabilized by a disulfide bond (C131-C145), which is unique to CDlb. This channel can 
shelter 16 carbon atom chains fully from solvent while allowing egress for longer chains. 
The PI and GM2 ligands occupy channels A' and C', whereas two detergent molecules fill 
channels F' and T' (Figure 52, 53, 54).
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Table 5. Statistics for data collection and refinement of CDlb crystal structures
Data collection CDlb/GM2 CDlb/PI
Resolution range ( A ) 100-2.8 25-2.2
Completeness (%) (outer) 88.8 (71.1) 92.3 (89.8)
Total observations 89500 334867
Unique reflections 13203 27623
Average I/a(I) (outer) 13.7(1.8) 39.1 (15.8)
Rmerge (% ) (outer) 10.3 (32.5) 5.1 (20.6)
Model refinement CDlb/GM2 CDlb/PI
Maximum resolution 2.80 2.26
Reflections (working set / test set) 12383 /535 24656/751
Rwork /  Rfree (% ) 223 121A 20.2/23.8
r.m.s.d from standard stereochemistry
Bonds ( A ) 0.012 0.008
Angles (°) 1.62 1.42
Number of atoms
Protein 3000 3005
Ligand ligands 85 90
Waters 40 232
n o 3 0 12
Ramachandran plot
Most favoured (%) 88.5 89.4
Additional (%) 11.2 9.3
Generous (%) 0.3 1.2
Disallowed (%) 0 0
Values in parentheses refer to the highest resolution 
for C D lb/PI).
w here a w
shells (2 .91-2 .80A for C D lb/G M 2 and 2.21 
is the ith measurement o f  reflection h and <
the weighted mean o f  all measurements o f  h.
/? = V  I f  - F  l/V F where F u and F , are the observed and calculated structure factorJv /  ahs 1 calc I / /  1 nbs ohs x c a lc .
amplitudes, respectively. R work and R ^  were calculated using the working and test set, respectively.
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Figure 52. Structure of two different human CDlb/p2m/ligand complexes
GM2
Human CDlb structure (a l-  a3 domains and (32m in blue-white) with bound GM2 
and CTAB (a) and bound PI and CTAB (b). Ligands are shown as Van Der Waals 
spheres: alkyl chains are in yellow and red, CTAB deep-purple and blue; GM2 
headgroup green; Phosphate blue; inositol blue, (c) Chemical structures o f CTAB, PI 
and GM2.
CHjOH
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Figure 53. Structural details of the human CDlb/PI structure
a
(a) Schematic o f the a la 2  superdomain structure o f  CDlb indicating the positions o f  
panels (b~e) (colour coding), (b) Tunnel T  traverses a path, unobstructed by bulky 
side chains, between channels A ' and F'. (c) The hinge region at bottom o f the A ' 
channel is formed by valine 12 (VI2) and phenylalamine70 (F70), which could guide 
long lipid ligands from the A ' channel into the T  tunnel, (d) A portal in the C' channel, 
stabilized by a disulfide bond Cysl31-Cysl45 (yellow), allows egress o f the lipid from  
the interior o f  the protein, (e) The F' channel with lining phenylalanine residues in 
yellow.
•Ml 55
C145
V126
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6.2.2.2. Functional recognition surfaces o fC D lb -P I and C D lb-G M 2
In the crystal structure determination, there was sufficient electron density to 
unequivocally position partial head group structures for glycolipids in the CDlb-GM2 
and CDlb-PI complexes (Figure 54). The inositol ring of PI is partially ordered in the 
CDlb-PI complex, whereas only the first of the four sugar rings that branch off the 
GM2 lipid head is visible in the CDlb-GM2 crystal structure. When compared with a 
classical MHC class I/peptide complex, the glycolipid head groups presented by CDlb 
are in a position analogous to the fourth residue (commonly designated P4) of 
nonamer or decamer peptides presented by MHC class I molecule^19.
Figure 54. Headgroups of CDlb-bound GM2 and PI
[T 157
The positioning o f the phosphoinositol (a) and the first glucosyl-head group o f GM2 
(b) are shown. Carbon atoms o f the lipid ligand are in yellow, oxygens in red, 
phosphate in lilac and nitrogen in blue. Hydrogen bonds are shown as black dotted 
lines. In both panels, the Fa - Fc omit map electron density (red mesh, contoured at 
2 .5 f was calculated after simulated annealing with the glycolipid (plus any residues 
and detergent within a distance o f 3.5 A) omitted. (Figure modified from R e f/SI).
189
The main chain topology of CDlb differs markedly from MHC class I in the 
peak height attained by the kink in the a2 helix (residues 150-154 in CDlb and 
149-152 in MHC class I, respectively). Direct substitution of CDlb into the structure 
of a MHC class I-TCR complex (by superposition of the CDlb structure onto the 
MHC class I structure) therefore results in marked steric clashes between the TCR and 
this portion of the CDlb a2 helix. The upward displacement of the TCR, which is 
necessary to provide a sterically acceptable dock onto the CDlb structure, may also 
accommodate the glycolipid head group because such head groups are much larger 
than the amino acid side chains o f a peptide antigen. Given this modification, the 
surface presented by the CDlb-glycolipid complexes appears compatible with 
standard TCR recognition, a conclusion borne out by mutagenesis studies mapping 
TCR binding to CDlb320. In contrast, key features of the a3 domain required for MHC
ITclass I binding to C D 8aa are not conserved in CDlb. In particular, the loop 
comprising residues 223-229 in the a3 domain of MHC class I, which is clamped 
between the two CD8 subunits in the recognition complex, is truncated in CDlb 
(residues 226-231). Although there is no steric hindrance for a putative complex 
between CDlb and CD8, these changes imply a reduced affinity compared to that of 
CD8 with MHC class I.
6.2.2.3. Comparison of human CDlb and mouse CD Id structures 
Comparison of the CDlb complexes with the structure of mouse CD Id, which does 
not include a specific bound ligand155, indicates broad equivalences but also marked 
differences in the architecture of the binding groove (Figure 55). Channel A' runs
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deeper in CDlb because Val63 replaces a tryptophan at the equivalent position in 
mouse CD Id. Channel T' is blocked in mCDld by the side chains of Leu 100 and 
Vail 18, equivalent to residues Gly98 and Glyl 16, respectively, in CDlb. Similarly, 
the exit portal for channel C' beneath the CDlb a2 helix is closed off in CD Id by 
Phel28 and Trpl33, replacing Vall26 and Cysl31, respectively, in CDlb (Figure 55). 
However, in addition to the structural differences resulting from the amino acid 
changes between CDlb and mouse CD Id, both molecules may share some 
conformational adaptability at residue 58 of the heavy chain. Whereas channel F' is 
partially occluded in mouse CD Id by the side chain of Leu84 (Figure 55), the side 
chain conformation selected by the equivalent residue (Phe84) in the current CDlb 
structure frees-up sufficient space for F' to accommodate a detergent molecule. 
However, in the absence of ligand, Phe84 may be expected to adopt an alternate 
conformation (analogous to that of Leu84 in mCDld) to pack against Phel44, Phe88 
and Met90. This suggests a mechanism whereby the hydrophobic binding capacity of 
the channels may be tailored to ligand requirements, a phenomenon observed for the 
binding of non-nucleoside inhibitors to HIV reverse transcriptase321 and for the groove 
closure of fatty acid binding protein322.
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Figure 55. Comparison of human CDlb and mouse CDld structures
Cysl45
Trpl33
Cysl31
Phe84
\ \ t
Leu84
Structure comparison o f  the hydrophobic antigen-binding cavity fo r  human CDlb 
(blue, transparent) and mouse CD ld (green, transparent) from top (upper panels) and 
side (lower panels). Key side chains o f  CDlb and CD ld are in blue and green. Red 
fd led arrows indicate key structural differences. The ligands present in the CD lb  PI 
structure have been superimposed onto the CD ld structure fo r  direct comparison 
(colour coding: PI is red in both A ’ and C ’, CTAB is orange in T ’ and blue in F ).
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6.2.2.4. Implications for other CD1 alleles and glycolipid ligands 
The CDlb structure helps to define the residues that confer the lipid-binding properties 
of the a la 2  domain. Sequence alignment of the CD1 family indicates that channel A' 
and the associated portion of tunnel T' are the most conserved regions of the groove 
(Figure 56). Conversely, the central portion of tunnel T' is blocked in all other CD1 
isoforms by the presence of bulky side chains of residues equivalent to Gly98 and 
Glyl 16 in CDlb. Similarly, the C' portal is occluded by tryptophan and phenylalanine 
residues that substitute for CDlb residues Cysl31 and V ail26, respectively, in all 
other CD1 family members. Residues contributing to channel F' are the least 
conserved. Overall, based on the ligand-binding architecture, CDlb appears to be 
unique among CD 1 molecules.
The arrangement of the combined detergent and lipid ligands in the CDlb-PI and 
CDlb-GM2 structures provides a general model for describing the interaction of the 
CDlb binding groove with alkyl chain-containing ligands. A model building exercise 
was carried out to explore the range of putative glycolipids that could be 
accommodated within the CDlb ligand architecture (Figure 57). Modeling of mycolic 
acid into the CDlb structure showed how the long C50-C56 meromycolate chain 
could be fully contained within a superchannel consisting of the interconnected A', T' 
and F' channels, with the shorter C22-C26 alkyl chain binding to C'. The superchannel 
has a maximum length of ca. 70 A, providing binding capacity for a single fatty acid 
chain of up to 60 carbons. Similarly modeling of a representative triacylglycerol 
showed that three acyl chains attached to a single head group could be accommodated 
within channels A', C' and F' (Figure 57).
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Figure 56. Sequence alignement of different CD1 isoforms
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Sequence alignment o f the a la 2  domains o f human CDlb with human CD la, CDlc,
CDle and C D ld and with mouse CDld. Secondary structure elements o f  CDlb, i.e. alpha 
helices and beta-pleated sheets, are indicated above the protein sequence. A colored 
background indicates those residues that confer the lipid-binding properties o f CDlb and 
are conserved at equivalent positions in other CD1 isoforms (amino acids in A ’ are in 
red, C ’ yellow, F ’pink, and T ’ blue). Hydrophobic residues guiding the ligands in CDlb 
at the bottom o f  channel A ' and between channels C' and F' are marked by green and blue 
triangles, respectively. Cysteine residues are boxed in green.
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Figure 57. Models for binding of mycolic acid and triacylglycerol to human CDlb
a
b
(a) Model fo r  binding o f  mycolic acid from M. tuberculosis to human CDlb. A pair o f  
orthogonal views with mycolic acid modeled into the CDlb structure is shown. In the 
model, the C60 long meromycolate chain (blue) is buried within the ca. 70 A long 
superchannel formed by continuous alignement o f  A V  and F'. The shorter C25 alkyl 
chain (orange) is bound to C. The end o f  the C25 chain in the mycolic acid is 
indicated by an extended chain shown as a semi-transparent surface. The chemical 
structure o f mycolic acid is shown above the CDlb model structure.
(b) Analogous model fo r  triacylglycerol (trilaurin) binding to CDlb, demonstrating 
that the three C l 1 alkyl chains (green) could separately bind to surface-linked 
channels A', C' and F'. Alkyl chains present in the CDlb-PI and CDlb-GM2 
structures but not accounted fo r by the models are overlaid in light gray.
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6.3. Discussion
In this chapter I have shown the development of a novel protocol to generate lipid- 
loaded human CDlb/p2m complexes from completely denatured and reduced 
inclusion body proteins. The validity of this refolding method could be directly 
confirmed by atomic structure analysis of two purified and crystallised monomeric 
CDlb-lipid complexes.
At first, all known standard protocols used for refolding of MHC class I/p2m- 
peptide complexes failed when applied by us to human CDlb molecules. In contrast, 
the novel detergent-assisted protocol described in this thesis enabled the production of 
soluble lipid-loaded CDlb molecules. The idea to use CTAB was to protect exposed 
hydrophobic surfaces during early refolding stages, thereby reducing hydrophobic 
protein aggregation and precipitation. While this might still have happened, crystal 
structure analysis showed two CTAB molecules bound to the T’ tunnel and F’ channel 
of the antigen binding groove, suggesting that CTAB could act as a chaperone ligand 
during CDlb in vitro refolding. Consistent with this hypothesis is the fact that 
detergent molecules only occupied the T ’tunnel and F’channel, despite a 500 fold 
molar excess of detergent over either GM2 or PI in the refolding buffer.
Similar to CTAB, short C16 chain fatty acids of the endoplasmic reticulum 
could act as chaperone ligands during refolding of CDlb in vivo until binding of 
higher affinity two-alkyl chain containing ligands. Lipids with only one available alkyl 
chain have been previously shown to bind to CDlc and CDld molecules. Binding of 
such ligands to CDld is characterised by a fast off rate. On the other hand, previous
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BiaCore study had failed to demonstrate binding o f  a C l 6 single alkyl chain lipid to
316insect cell derived human CDlb
However, four years after publication of our human CDlb structures Garcia- 
Alles and colleagues published a human CDlb structure obtained from insect cell 
derived CDlb molecules. Their structure showed the presence of both 
phosphatidylcholine and a long spacer ligand occupying the T’tunnel and 
F’channel190. Although the existence of such a long spacer in humans has not been 
shown, the Garcia-Alles structure supports the idea that chaperone ligands could play 
a role during CDlb refolding in vivo.
In both the CDlb-GM2 and CDlb-PI structure the alkyl chains were tightly 
fitted into the A' and F' channels of the CDlb crystal structures with no buried water 
molecules. This arrangement is consistent with the notion that the interaction of two- 
alkyl chain containing ligands with CDlb is stable and long-lived.
Site-directed mutagenesis studies have previously analysed the role of CDlb
T 9 Tantigen binding groove lining amino acid residues , Mutations that lie near the 
bottom of the binding groove were shown to affect both long and short alkyl chain 
glycolipid presentation, and were thought to affect the overall architecture of the 
molecule. Conversely, mutations of residues lining the A' channel and its junction with 
the T  tunnel specifically affected the presentation of long alkyl chains. The model 
shown in Figure 57 for mycolic acid binding to human CDlb is consistent with these 
mutagenesis studies.
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The two CDlb-ligand structures offer an obvious explanation how human 
CDlb can present either very large or the short mycobacterial glucomonomycolate to 
the same T cell line 172. Mycobacterial mycolates, which are crucial for mycobacterial 
growth and survival inside phagolysosomes 169, were the first known ligands for 
human C D lb146. It has long been speculated how such lipids could bind to CDlb 
without protruding from the groove. Our CDlb-ligand structures show how both fatty 
acids of mycolic acid can be fully accommodated with human CDlb. The shorter C22- 
C26 alkyl chain could bind to the C’channel, while the long C50-C56 meromycolate 
chain could be completely contained within the long, lipid binding super channel 
which is formed by connecting the A’channel, T’tunnel and F’channel. The super 
channel, which is unique to CDlb, can accommodate up to 60-65 carbons. In work 
subsequent to this thesis I was involved in determination of the first crystal structure of 
human CDlb with bound glucomonomycolate. This structure confirmed the above
1 8 Aprediction that long mycolate chains bind to the superchannel .
The arrangement of a cluster of phenylalanine residues lining the F’pocket of 
CDlb, in particular Phe 84, suggests the existence of a shutter mechanism inside the 
F’channel, which could operate in the absence of long chain fatty acid ligands. By 
choosing an alternative conformation, Phe 84 could close off the access to the 
F’channel and therefore protect the molecule from the entry of water. However, as the 
structure of insect cell derived human CDlb has shown, such a mechanism might not 
be required if a long spacer ligand was available in human myeloid cells.
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The arrangement o f the three ligand-filled channels A ’, F ’, and C’ in the two CDlb 
structures suggests the exciting possibility that lipids containing three acyl chains, 
such as endogenous triacylglycerols or mycobacterial triacyl trehalose may bind to 
human CDlb. Triacylglycerols, which are synthesised on membranes of the 
endoplasmic reticulum, are known independent risk factors for the development of
TOA TOAatherosclerosis ’ . Activated T lymphocytes are found in atherosclerotic plaques ’
325, and oxidized lipoproteins containing triacylglyerols are immunogenic for T cells 
. Interestingly, CDlb is highly expressed on foam cell macrophages in 
atheromatous lesions, but not on normal tissue macrophages328. It is therefore 
intriguing to speculate that CDlb could activate triacylglyerol specific T lymphocytes 
within atheromatous lesions.
6.4. Conclusions
The highly hydrophobic nature of both the CDlb protein and its lipidic ligands caused 
initial difficulties in refolding CD lb/lipid complexes in aqueous solutions. These 
difficulties could eventually be overcome by using detergent-assisted refolding 
techniques. Crystal structure analysis of CD lb/lipid complexes generated by this 
method demonstrated correct folding of the molecules. Whether this method will also 
allow to generate CDlb-tetramers loaded with mycobacterial lipids still needs to be 
investigated in future studies.
The first crystal structures shown in this thesis were the first ever solved 
structures of lipid-loaded CD1 molecules. They revealed a general mechanism by 
which lipids can bind to hydrophobic channels of CD1 molecules and showed the
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unexpected presence of four interconnected channels in CDlb - a real maze for alkyl 
chains.
Finally, the two structures extend the spectrum of known CDlb-ligands and 
suggest that triacyl chain ligands might be presented by CDlb to T lymphocytes.
6.5. Accession codes for human C D lb ligand structures
Coordinates and structure factors for the human CDlb/(32m/Pl and CDlb/p2m/GM2 
complexes have been deposited in the Protein Data Bank under accession codes lgzq 
and rlgzqsf (for CDlb-PI) and lgzp and rlgzpsf (for CDlb-GM2).
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7. Conclusions and future perspectives
The results shown in chapters three and four of this PhD thesis describe the clinical 
phenotype as well as the molecular and genetic defects in a group of patients with 
“TAP deficiency syndrome”. In these patients, defective peptide translocation from the 
cytosol into the endoplasmic reticulum was caused by mutations in either the TAPI or 
TAP2 genes, which encode for the two subunits of the heterodimeric peptide 
transporter TAP. In fact, MHC class I cell surfaceexpression could be experimentally 
restored in vitro in the patients’ EBV-transformed lymphoblastoid cell lines by 
reinstating TAP function.
However, current understanding of the role of MHC class I molecules for 
innate and adaptive immunity cannot sufficiently explain some of the most prominent 
symptoms in these patients, e.g. the necrotising granulomatous skin lesions and the 
frequent bacterial respiratory infections leading to bronchiectasis. Functional studies 
of NK and y5 T lymphocytes in three patients showed that these cells, after isolation 
and cytokine-aided in vitro expansion, killed autologous EBV-transformed B- 
lymphoblastoid cells. These experiments suggested that insufficient MHC class I -  
mediated inhibition of NK and y§ T cell functions via KIRs or ILTs might have been 
involved in the pathogenesis of the mutilating autoaggressive skin inflammation. 
Consistent with this hypothesis, activated NK cells expressing ILT- 2, an MHC class 
I-binding inhibitory receptor were enriched in granulomatous skin lesions of one 
patient. However, the reason why tissue destruction by these lymphocyte subsets 
should be restricted to the skin, and also the underlying cause of NK and y§ T 
lymphocyte activation in vivo remain unknown. Interestingly, chronic inflammation in
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other organs, i.e. colitis, retinal vasculitis and encephalitis, was present in some 
patients during their disease, but these tissues could not be analysed for the presence 
of NK and y8 T cells. Two affected heterozygous sisters sharing an identical 
homozygous HLA haplotype, SAB and GAB (described in chapter 3), exhibited 
significant clinical differences; necrotising granulomatous skin lesions were (and are 
still) absent in SAB, while they were present in GAB and all other patients. However, 
this thesis did not address the question whether skin involvement in TAP-deficiency 
syndrome was generally associated with activation of NK and y§ T cells in the skin or 
peripheral blood. Also, no systematic analysis of the repertoire of MHC class I- 
binding inhibitory and activating receptors was carried out. Future studies might 
address the question of whether mismatched KIR - HLA haplotypes are associated 
with autoinflammatory tissue damage in TAP-deficient patients.
Another important question that remains largely unanswered is why TAP- 
deficiency is associated with severe bacterial rather than viral infections. Neutralising 
autoantibodies against the potent antibacterial protein bactericidal permeability 
increasing protein (BPI) were present in all my patients 329. However, although these 
autoantibodies might have contributed to the susceptibility to bacterial infections they 
are unlikely to be their primary cause. Anti-BPI antibodies are often found in other 
human diseases associated with chronic bacterial infections, such as cystic fibrosis and 
inflammatory bowel diseases330. The fact that bacterial infections appear already in 
early childhood in TAP-deficiency syndrome suggests that a fully functioning MHC 
class I antigen presentation pathway is required for effective activation of the innate 
immune system during bacterial infections. It is now well established that phagocytes,
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such as neutrophilic granulocytes, have the ability to present exogenous antigens via 
MHC class I to CD8+ T lymphocytes331. This process, which is called “cross­
presentation”, requires TAP-mediated peptide translocation from the cytosol into the 
ER and should therefore be compromised in TAP-deficient patients ’ . The
occurrence of recurrent bacterial infections in TAP-deficient patients during early 
childhood might therefore indicate that “cross-presentation” to CD8+ T cells is 
particularly important in early life.
Of note, HLA-A2, the most frequent HLA class I allele family in Caucasians, 
was not contained in any of my Caucasian patients’ HLA haplotypes. The absence of 
HLA-A2 in the patients might not have been a coincidence since the spectrum of 
peptides presented by HLA-A2 contains a significant fraction of TAP independent 
peptides333. Conversely, the symptoms of TAP-deficiency syndrome as described in 
chapters 3 and 4 might only occur in patients with certain HLA-haplotypes, but not in 
others, e.g. HLA-A2 homozygous haplotypes. These questions might be answered in 
the future if additional TAP-deficient patients can be identified and studied.
The presence of necrotising granulomatous skin lesions in my patients not only 
led to extensive diagnostic testing for suspected M. tuberculosis infection, but also, in 
most patients, instigation of antituberculous drug therapy. The lack of any clinical 
effect of such treatment combined with the complete failure to demonstrate M. 
tuberculosis either by PCR, multiple acid fast staining or culture firmly ruled out the 
possibility of M. tuberculosis infection in my patients. The lack of susceptibility to 
mycobacterial infection of TAP-deficient human patients is remarkable, because TAP-
103 104 213deficient mice are highly susceptible to mycobacteria ’ ’ . This difference
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between humans and mice pointed to a possible role of CD1 group 1 molecules in the 
immune defense against mycobacteria, because mice do not possess genes encoding 
for group 1 CD1 molecules213. One of the main goals of this thesis, i.e. the 
development of CD1 group 1-tetramers to study CD 1-restricted mycobacterial lipid - 
specific T lymphocytes in TAP-deficient patients, could not be achieved. On the other 
hand, the development of recombinant CDld/lipid-tetramers, described in chapter 5 of 
this thesis, provided sensitive and specific new tools to study lipid-specific CD1 group 
2 specific, i.e. CDld-restricted invariant NKT cells. Three important factors made the 
development of the CD1 d-tetramers possible: The development of an efficient 
refolding method for CDld (chapter 5 of this thesis); availability of the previously 
identified and characterised CD 1 d-presented agonistic iNKT ligand KRN7000; and 
the relatively high affinity of iNKT TCRs for CDld/KRN7000 241.
So, why has no research group yet achieved specific staining of mycobacterial 
lipid-specific T lymphocytes with group 1 CD 1-tetramers? In chapter 6 of this thesis I 
have demonstrated that it is possible to generate correctly folded recombinant human 
CDlb/lipid-complexes. Moreover, these recombinant CDlb/lipid-complexes could be 
crystallised, which allowed for the first two atomic structures of human CDlb/lipid- 
complexes to be solved (chapter 6 of this thesis). These structures revealed a 
fascinating arrangement of four lipid-binding channels - a real maze for akyl chains -  
and provided a model of how the very long meromycolate of mycobacterial mycolic 
acid could be presented by CDlb. Later on, crystal structures of recombinant human 
CDlb/mycolic acid-complex confirmed this model186. CDlb bound mycolic acid has 
been previously demonstrated to be specifically recognised by human T lymphocyte
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lines, using assays of in vitro proliferation and cytotoxicity, but not tetramer 
staining145,146. There is no obvious reason to assume that the lack of success with 
CDlb-tetramer staining of human T lymphocytes could be caused by an “inherent” 
low TCR affinity. In fact, the affinity of CDlb-specific TCRs might actually be 
expected to be rather high, as many CD lb-restricted T cell lines lack expression of 
CD4 or CD8 co-receptors.
Whatever the reasons for the current lack of success with CDlb-tetramer 
staining might be, direct detection of human mycobacterial lipid-specific T 
lymphocytes with CD lb-tetramers ex vivo would be an important achievement in the 
field of cellular immunology, with great potential to open up new avenues for both 
diagnosis and therapy of human infectious diseases.
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